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Phosphatidylinositol 3-kinase (PtdIns3-K) signalling is a crucial survival 
pathway in multiple malignancies, and an exciting target for drug 
development. The pathway is subject to multiple regulatory mechanisms 
including ubiquitylation, a reversible process that can influence protein 
stability, localisation and activity. A family of approximately 80 
deubiquitylating enzymes (DUBs) are responsible for the cleavage of 
ubiquitin and ubiquitin chains from protein substrates. The DUBs are 
attractive drug targets and have increasingly been implicated in cellular 
processes germane to malignancy, including the PtdIns3-K pathway. The 
aim of this study was to systematically identify DUBs involved in regulating 
the pathway, with a particular view to identifying potential novel drug targets. 
 
The project employed a DUB siRNA library to perform a series of RNAi 
screens using two complementary approaches. In the first approach, the 
effects of DUB depletion on the protein level of nine PtdIns3-K pathway 
components (p110α, p110β, p110γ, p85α, p170, PDK1, PTEN, Akt, and 
mTOR) were assayed by immunoblotting. DUBs whose depletion either 
increased or decreased the protein level of these components were subject 
to further validation. Of particular interest were five DUBs (PRPF8, TNFAIP3, 
USP32, USP34 and OTUD1) whose depletion decreased the level of PDK1. 
In addition, depletion of three closely related members of the Josephin family 
of DUBs (ATXN3, ATXN3L and JOSD1) resulted in an increase in the protein 
level of the tumour suppressor PTEN. In view of the potential clinical utility of 
upregulating PTEN, the latter DUBs were prioritised for further investigation. 
Initial investigation indicates that all three DUBs alter PTEN level at a 
transcriptional rather than post-transcriptional or post-translational level. 
Initial work suggests the effects of ATXN3 may be independent of its known 
function in modulation of histone acetylation status. 
 
The second approach utilised a U2OS cell line stably transfected with EGFP 
tagged FOXO3, in which PtdIns3-K dependent FOXO3 translocation could 
be assessed by live-cell imaging. This enabled the design of a functional 
screen in which the effects of DUB depletion on downstream PtdIns3-K 
signalling were assessed. Among the DUBs identified in this screen was 
USP45, depletion of which enhanced nuclear translocation of FOXO3-EGFP 
in response to PtdIns3-K inhibition. Several DUBs regulating FOXO3-EGFP 
abundance were also identified by this assay, including USP1 and USPL1 
whose depletion respectively decreased and increased FOXO3-EGFP levels. 
This screen additionally identified three DUBs (USP8, OTUD4 and DUB4) 
whose depletion was synthetically lethal with PI-103 treatment.  
 
In summary, several novel DUB modulators of the PtdIns3-K pathway were 
identified that, subject to further mechanistic and functional studies, may 
increase the options available for targeting this vital pathway in malignancy. 
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Chapter 1 
 
Introduction 
 
1.1 Beyond kinases: Identifying novel druggable targets in the 
PtdIns3-K pathway 
 
The last few decades have seen a dramatic expansion in our understanding 
of the mechanisms by which cancer cells undergo malignant transformation, 
escape apoptosis, evade the immune system, and subsequently metastasise 
[1, 2]. An understanding of these molecular mechanisms has in turn driven 
the establishment of a new field of rational cancer drug development to 
provide targeted therapies. Much of the early work on targeted therapy in 
cancer medicine has concentrated on the phosphorylation system, and more 
specifically, the kinases; a crucial family of enzymes involved in diverse 
signalling pathways, which are commonly aberrantly activated in cancer. 
However, while inhibition of kinases has proven a very successful strategy [3, 
4], these represent only a small percentage of the druggable genome [5]. A 
large proportion of cancers are also primarily resistant to existent targeted 
therapies or develop secondary resistance after a relatively short period of 
response [6, 7] and there is thus a clear need for the identification of new 
targets for drug development. 
 
The ubiquitin system has clear parallels with phosphorylation, involving the 
reversible post-translational modification of proteins leading to diverse 
functional consequences [8]. Many of the components of the ubiquitylation 
machinery are amenable to small molecule inhibition, and are thus potential 
drug targets. These include the deubiquitylating enzymes (DUBs, 
deubiquitylases), a family of approximately 80 enzymes, which catalyse the 
removal of ubiquitin from protein substrates. The deubiquitylases have been 
shown to be involved in a wide range of pathways germane to malignancy 
[9], and are an area of intense research in our laboratory and elsewhere.  
 
  2 
In this PhD project, I set out to systematically investigate the role of DUBs in 
the phosphatidylinositol 3-kinase (PtdIns3-K) pathway, a crucial survival 
pathway, which is dysregulated in a large proportion of malignancies. 
Previous work has shown that several components of this pathway are 
ubiquitylated, and five DUBs, namely USP1, USP4, USP7, USP46 and 
UCHL1 have been implicated in its regulation. However, the full extent of 
DUB involvement in this pathway is unknown, and through the use of a 
series of siRNA screens I therefore aimed to identify further DUBs, and thus 
potential drug targets, involved in regulating the PtdIns3-K pathway. 
 
1.2 Ubiquitin and ubiquitylation 
 
Ubiquitin was originally described almost 40 years ago [10], although its 
function was initially unknown. However, in work which would later be 
recognised in the award of the 2004 Nobel Prize; Ciechanover, Hershko, and 
Rose elucidated the role of ubiquitin in the proteolytic degradation of proteins 
[11-13]. Subsequently, ubiquitylation has been shown to be the most 
versatile of post-translational modifications, with the ability to form several 
alternative chain structures, and to alter a protein’s function and localisation, 
as well as its stability [8].   
 
1.2.1 The structure of ubiquitin 
Four genes encode ubiquitin in humans; UBB, UBC, UBA52 and RB27A, 
which in all cases require processing of the precursor polypeptide to release 
free ubiquitin. UBB and UBC both encode multiple ubiquitin repeats that are 
cleaved to release free ubiquitin [14], while UBA52 and RB27A consist of a 
single ubiquitin molecule fused to the N-terminus of the L40 and S27a 
ribosomal proteins respectively [15]. Ubiquitin is a small globular protein 
made up of 76 amino acids with a molecular weight of approximately 8.5 
KDa. The crystal structure of free, unconjugated ubiquitin has been 
determined [16, 17], and is represented in fig 1.1i.  
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Fig 1.1. Ubiquitin lends itself to the formation of diverse chain 
structures. i. Representation of the crystal structure of ubiquitin, highlighting 
its secondary structure and approximate position of lysine residues (shown 
by the filled circles and designated K6 etc.). β-sheet is shown in yellow, with 
alpha-helical regions in purple and magenta. ii, iii. Space-fill models of K48 
and K63 linked diubiquitin. The position of the C-terminus of the proximal 
ubiquitin moiety (which would normally be attached to substrate by an 
isopeptide bond) is indicated by the asterisk. Structures of ubiquitin (1UBI 
[17]), K48 and K63 linked diubiquitin (3AUL [18]  and 2JF5 [19] respectively) 
were obtained from the Research Collaboratory for Structural Bioinformatics 
Protein Data Bank (http://www.rcsb.org/pdb/home/home.do), and visualised 
using Jmol version 12.2.15. 
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Ubiquitin is linked to protein substrates through an isopeptide bond formed 
between the ubiquitin C-terminal glycine residue and a lysine side-chain in 
the substrate. The modification of a substrate by the addition of a single 
ubiquitin moiety is termed monoubiquitylation (also known as 
monoubiquitination), and monoubiquitylation of multiple lysine residues is 
termed multi-monoubiquitylation.  
 
Ubiquitin itself contains seven lysine residues (K6, K11, K27, K29, K33, K48 
and K63), to which further ubiquitin moieties may be conjugated, thus 
forming polyubiquitin chains on substrates. These are each identified by the 
lysine residue involved in the linkage. The N-terminus may also be employed 
for chain propagation, leading to the formation of linear chains. In addition to 
these eight homotypic chains, further chain diversity may occur through the 
formation of heterotypic chains which contain different linkages within the 
same chain, and which may be branched [20, 21]. 
 
The structures of five ubiquitin chain linkages have been characterised to 
date, using a combination of techniques including crystallography and 
nuclear magnetic resonance spectroscopy (NMR) [22]. The structures of the 
two most studied linkages, K48 and K63, are shown in figure 1.1ii and iii 
respectively. These two linkages exhibit very different conformations. K48 
chains adopt a compact, constrained conformation in which the two ubiquitin 
moieties form an intermolecular surface (fig 1.1ii) [18, 23], whereas K63 
chains adopt an open, flexible structure in which the only point of contact 
between the two moieties is the isopeptide bond between the two (fig 1.1iii) 
[19, 24]. Linear polyubiquitin chains adopt a very similar structure to K63 
linkages [19], while K6 [25] and K11 [26] linkages result in closed structures 
more akin to K48- linked chains.  
 
The first linkages to be described were K48, which were shown to be 
involved in recognition of substrates by the proteasome [27]. This was 
followed 6 years later by the identification of K63 polyubiquitin chains, which 
were shown to result in a non-degradatory signal involved in DNA repair [28]. 
The majority of work in the ubiquitin field has focused on these chain 
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linkages, and it is only relatively recently that the diversity of the different 
chain linkages has become apparent. However, several studies employing 
mass spectroscopy have now identified all eight linkages in both yeast and 
mammalian cells [29-31].  Xu et al. used mass spectroscopy to determine the 
abundance of the different chain structures in S. cerevisiae and found that 
K48 chain linkages were the most abundant (29%) as expected [29]. 
However, the next most abundant were K11 chains comprising 28% of 
chains, followed by K63 (16%), K6 (11%), K27 (9%), K33 (4%) and K29 
(3%). This study also showed that all non-K63 linkages can target substrates 
for proteasomal degradation [29]. 
 
1.2.2 Ubiquitin binding domains 
The combination of monoubiquitylation, and homotypic or heterotypic 
polyubiquitin chains, generates an incredible diversity of substrate 
modifications. Recognition of the different conformations of ubiquitin moieties 
is essential in order for these to function as different signals. This occurs 
through ubiquitin binding domains (UBDs), which are modular elements that 
bind non-covalently to ubiquitin [32]. The first of these to be described was a 
ubiquitin interacting motif (UIM) which was involved in the recognition of 
polyubiquitylated substrate by the yeast proteasomal subunit S5a [33]. Since 
then more than 20 different UBDs have been described, which fall into five 
main families (table 1.1).  
 
Two hydrophobic patches on the surface of ubiquitin, around residues Phe4 
and Ile44, appear to be essential for the recognition of polyubiquitin chains 
[34]. Ile44 in particular is involved in binding by the majority of UBDs [32]. 
Different conformations of ubiquitin chain alter the relative orientation of 
functional surfaces, and thus hydrophobic patches [19], and influence the 
ability of different UBDs to bind. The specificity of interaction between UBD-
containing proteins and their ubiquitylated binding partners additionally relies 
on multiple other factors, which are reviewed in [32, 35].  
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UBD family and 
example 
Representative 
Proteins 
Function Ref 
α-Helix 
  UIM 
 
S5a, Vps27, 
STAM, epsins 
and RAP80 
 
Proteasomal degradation, 
endocytosis, MVB biogenesis 
and DNA repair 
 
[33, 
36-38] 
Zinc Finger (ZnF) 
  NZF 
 
NPL4, Vps36, 
TAB2 and TAB3 
 
ERAD, MVB biogenesis and 
kinase regulation 
 
[39-41] 
PH Domain 
  PRU 
 
RPN13 
 
Proteasome function 
 
[42, 43] 
Ubc-like 
  UBC 
 
UBE2D3 
 
Ubiquitin transfer 
 
[44] 
Others 
  Jab1/MPN 
 
PRPF8 
 
RNA splicing 
 
[45] 
 
Table 1.1. Ubiquitin binding domain (UBD) families. A single example is 
shown for each family. Jab1/MPN- Jun activation domain-binding protein 1/ 
Mpr1p and Pad1p N-terminus, MVB- multivesicular body, NPL4- nuclear 
protein localisation 4, NZF- nuclear protein localisation 4 ZnF, PH- pleckstrin 
homology, Prp8- pre-mRNA processing factor 8 homolog, PRU- pleckstrin 
homology receptor for ubiquitin, RAP80- receptor associated protein 80, 
RPN13- regulatory particle, non-ATPase-like 13, TAB- TAK1 binding protein, 
UBC- ubiquitin-conjugating, UBE2D3- ubiquitin-conjugating enzyme E2D 3, 
UIM- ubiquitin interacting motif, VPS-vacuolar protein sorting-associated 
protein. (adapted from [32]). 
 
1.2.3 Cellular functions of ubiquitin 
Ubiquitylation of protein substrates plays a vital role in a wide variety of 
cellular processes. Principal among these are those pertaining to protein 
degradation by the proteasome, endolysosome, or autophagosome. In each 
of these processes, ubiquitylation acts as key degradatory signal (reviewed 
in [46]). Targeting proteins for proteasomal degradation usually occurs 
through the addition of a chain of at least four ubiquitin molecules [47]. While 
initially thought to only involve K48 linkages, recent work has indicated that 
all chain linkages, with the exception of K63, may be involved [29]. 
 
Endocytosis provides a mechanism for internalisation of membrane proteins, 
which are either recycled back to the plasma membrane or degraded by the 
lysosome. Ubiquitylation of substrates plays a vital role in sorting of 
endocytosed proteins [48], with K63 polyubiquitylation in particular 
determining degradation by the lysosome [49-51]. The third degradatory 
pathway, autophagy, involves both the non-selective degradation of bulk 
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cytosol, and the selective removal of organelles, protein aggregates or 
intracellular pathogens [52]. Both polyubiquitylation and monoubiquitylation 
have been implicated in the tagging of substrates for subsequent autophagy 
[53, 54], and autophagy is also dependent on two ubiquitin-like (UBL) 
molecules Atg8 (autophagy related 8, LC3 in mammalian cells) and Atg12 
(autophagy related 12).  
 
Ubiquitylation of protein substrates is by no means exclusively a degradatory 
signal, and both monoubiquitylation and K63 polyubiquitylation may alter the 
functional status of substrates. Examples include the monoubiquitylation of 
FANCD2 (Fanconi anaemia, complementation group D2) and PCNA 
(proliferating cell nuclear antigen), both of which are involved in DNA repair 
pathways [55, 56], and NFκB (nuclear factor of kappa light chain polypeptide 
gene enhancer in B-cells) signalling where several components are K63 
polyubiquitylated (discussed in section 1.4.3).  Additionally, 
monoubiquitylation may alter the compartmentalisation of substrate; an 
example of this being monoubiquitylation of PTEN, which promotes nuclear 
localisation [57].  
 
1.2.4 Targeting the ubiquitin proteasome system (UPS) 
The involvement of ubiquitylation in multiple cellular processes with 
relevance to cancer has led to interest in the possibility of targeting the 
ubiquitylation machinery as a therapeutic strategy [58]. While research in this 
area is generally at a very early stage, the development of the proteasome 
inhibitor, bortezomib, has provided an early proof of concept. Bortezomib is 
clinically active in multiple myeloma [59] and mantle cell lymphoma [60]. 
Although bortezomib has failed thus far to demonstrate single agent efficacy 
in other tumour types, preclinical work indicates that its use in combination 
therapy may extend its clinical activity [61, 62]. In addition, several newer 
proteasome inhibitors, which may prove to have different clinical activity, are 
in development [63]. Other components of the ubiquitylation machinery are 
also under investigation in this context, including the E3 ubiquitin ligases [64] 
and the deubiquitylating enzymes (section 1.4.7). Interestingly, an inhibitor of 
the E3 ligase MDM2 (RG7112) has recently demonstrated activity in an 
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exploratory clinical study of 20 patients with liposarcoma [65]. MDM2 (mouse 
double minute 2, human homolog of) is a p53 E3 ligase, and its inhibition in 
this trial led to p53 stabilisation and a reduction in Ki67 expression in 
tumours. A partial response was observed in one patient and stable disease 
in 14 others [65]. A trial investigating RG7112 in combination with 
doxorubicin in this patient population is currently underway.  
 
1.2.5 The ubiquitin conjugating machinery 
The isopeptide bond between a ubiquitin moiety and a substrate lysine side 
chain is formed through the sequential action of a sequence of three 
enzymes, namely an E1 ubiquitin activating enzyme, an E2 ubiquitin 
conjugating enzyme and an E3 ubiquitin protein ligase ([66] and represented 
in fig 1.2). The human genome encodes two E1 enzymes, around 40 E2 
conjugating complexes and over 600 E3 ubiquitin ligases [67-70].  
 
The process commences with the ATP and Mg2+-dependent, E1-mediated 
activation of ubiquitin’s C-terminal glycine. Firstly, the E1 sequentially binds 
ATP and ubiquitin leading to the formation of an adenylate intermediate. This 
is then attacked by the catalytic cysteine residue, forming a thioester bond 
between the ubiquitin C-terminus and the E1 [71, 72]. The adenylation 
reaction is repeated with a second ubiquitin molecule, however the latter 
does not form a thioester bond. The covalently bound (activated) ubiquitin is 
then transferred to the cysteine residue on the E2, where it again forms a 
thioester bond [66].  
 
The E2 enzyme dissociates from the E1 before binding to the cognate E3 
enzyme, in turn leading to the E3 mediated conjugation of the ubiquitin’s C-
terminal glycine to a lysine side chain on the substrate. There are two main 
types of E3 enzyme and these have different mechanisms of actions. The 
HECT (homologous to E6-AP C-Terminus) ligases form a thioester linkage to 
ubiquitin before transferring the ubiquitin to its acceptor lysine side chain [73], 
while RING (really interesting new gene) ligases [74] are catalytically inert 
and act as a scaffold to bring the E2 and substrate into proximity, after which  
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Fig 1.2 Ubiquitylation of substrates involves the sequential action of 3 
enzymes. i. Ubiquitin is activated by an E1 activating enzyme in the 
presence of ATP and Mg2+, and forms a thioester bond to the catalytic 
cysteine. ii. Activated ubiquitin is transferred to an E2 conjugating enzyme. 
iii,iv. Ubiquitin is transferred to an acceptor lysine on the protein substrate. In 
the case of HECT (homologous to E6-AP C-Terminus) E3 ligases (iii), the 
ubiquitin moiety is first transferred onto the E3 ligase which catalyses 
ubiquitylation of substrate. RING (really interesting new gene) ligases (iv) are 
catalytically inactive and act as a scaffold, bringing together the E2 into 
proximity with the substrate, thus allowing E2 dependent catalysis of ubiquitin 
conjugation. v. Repeated cycles of ubiquitylation are required for the 
construction of polyubiquitin chains. 
 
 
the ubiquitin is transferred directly from the E2 to the substrate [75, 76]. In 
certain cases, the RING also activates the E2 [73]. Both families of E3 
ligases provide substrate specificity, hence their much greater diversity in 
comparison to E1s or E2s [68, 70].  
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1.2.6 Ubiquitin like molecules 
In addition to ubiquitin, almost twenty other molecules encoded by the 
genome adopt a similar structure and are conjugated to substrates in a 
manner analogous to ubiquitylation. These ubiquitin like (UBL) molecules 
include small ubiquitin like modifier (SUMO), neural precursor cell expressed, 
developmentally down-regulated 8 (NEDD8), interferon-induced 15kDa 
protein (ISG15), and autophagy related genes 8 and 12 (Atg8 and Atg12). 
Similarly to ubiquitin, UBLs are involved in a wide range of cellular functions. 
However individual UBLs may have very specialised roles. For example, 
Atg8 and Atg12 are both specifically involved in the formation of the 
autophagosome [77, 78]. While not directly the subject of this work, UBLs 
interact extensively with ubiquitylation and share some of the same 
machinery. For example, neddylation of the cullin RING E3 ligase is essential 
for its activity [79]. In addition several enzymes with the ability to cleave both 
ubiquitin and UBLs exist; these are discussed in section 1.3 below. 
 
1.3 Deubiquitylation and the deubiquitylases 
 
Protein ubiquitylation is reversible, thus enabling ubiquitin dependent 
signalling to be terminated. Deubiquitylating enzymes (DUBs, 
deubiquitylases) cleave the isopeptide bond between ubiquitin and substrate, 
and/or between ubiquitin moieties in a polyubiquitin chain [80]. The human 
genome encodes approximately 90 deubiquitylases, of which around 80 are 
catalytically active. The DUBs can be divided into five families on the basis of 
their catalytic domains; namely ubiquitin specific proteases (USPs), ubiquitin 
C-terminal hydrolases (UCHs), ovarian tumour proteases (OTUs, also known 
as otubains), Josephins, and JAB1/MPN/MOV34 (JAMMs).  
1.3.1 The DUB families 
The USP family is the largest, containing at least 56 members (fig 1.3). The 
subfamily of USP17-like genes is represented here by USP17 and DUB3. It 
consists of multiple, closely related members (several of which are annotated 
to be pseudogenes or catalytically inactive) that arose due to ancestral 
duplication and of which several exist within a tandemly repeated block on  
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Fig 1.3 The USP family of Deubiquitylases. A molecular phylogenetic 
analysis was conducted in MEGA5 (www.megasoftware.net [81]). The 
evolutionary history was inferred by using the Maximum Likelihood method 
based on the JTT matrix-based model [82]. The tree with the highest 
likelihood is shown. The tree is drawn to scale, with branch lengths 
measured in the number of substitutions per site. The analysis was 
performed using the full-length primary NCBI RefSeq 
(www.ncbi.nlm.nih.gov/RefSeq) amino acid sequences. All positions 
containing gaps and missing data were eliminated. There were a total of 46 
positions in the final dataset. Domain architecture was adapted from [80]. 
DUBs that are predicted to be catalytically inactive are indicated by an 
asterisk [80]. (DUSP: domain present in ubiquitin-specific proteases, UBL: 
Ubiquitin-like, B: B-box, TBC: domain in Tre-2, Bub2 and Cdc16, M: ZnF-
MYND [(myeloid, nervy and DEAF1)-type zinc fingers], CS: CHORD-SGT1 
domain, MATH: meprin and TRAF homology domain, CAP: CAP-Gly 
domain). 
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Fig 1.4 The OTU, JAMM, UCH and Josephin families of deubiquitylases. 
Molecular phylogenetic analyses were conducted for each DUB family as 
described in figure 1.3. The analyses were performed using the full-length 
primary NCBI RefSeq (www.ncbi.nlm.nih.gov/RefSeq) amino acid 
sequences. The trees were drawn to scale, with branch lengths measured in 
the number of substitutions per site 
 
chromosome 4 [83]. Fig 1.3 illustrates both the existence of clusters of 
closely related USPs, and the overall diversity of the family. The domain 
architecture of several examples is shown, illustrating the wide variety of 
domains that are likely to be involved in protein-protein interactions, including 
ubiquitin-like domains (UBLs) and UBDs [80, 84]. Phylogenetic trees for the 
other four families are shown in fig 1.4. 
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1.3.2 DUB catalytic activity 
Four of the five DUB families (USPs, UCHs, OTUs and Josephins) are 
cysteine proteases, while the last family (JAMMs) are metalloproteases. The 
cysteine proteases usually depend on a catalytic triad consisting of a 
histidine, a cysteine and an aspartate or asparagine residue. The histidine 
residue serves to reduce the pKa of the catalytic cysteine residue, thus 
enabling a nucleophilic attack on the isopeptide bond [80]. The aspartate or 
asparagine residue aligns and polarises the histidine residue. However, the 
latter residue is not always essential for DUB activity, as exemplified by the 
Otubain family member, TNFAIP3 (tumour necrosis factor alpha-induced 
protein 3, also known as A20) [85].  The nucleophilic attack results in the 
release of the substrate, and the formation of an acyl-intermediate involving a 
covalent bond formed between the cysteine residue and the conjugated 
(distal) ubiquitin. The intermediate is stabilised by a so-called oxyanion hole 
provided by surrounding residues. Finally the intermediate is hydrolysed by a 
water molecule, which leads to release of free ubiquitin [80, 86]. 
 
The mechanism of action of the metalloprotease DUBs (JAMMs) has been 
elucidated in a study in which the catalytic domain of STAMBPL1 (STAM 
binding protein-like 1, also known as AMSH-LP) was crystallised alone or in 
combination with K63 linked diubiquitin [87]. The catalytic domain contains a 
JAMM/MPN+ motif, which co-ordinates two zinc ions. The catalytic zinc ion 
activates a water molecule that attacks the isopeptide bond, leading to the 
formation of a charged intermediate, which is in turn collapsed to release the 
amino group of the proximal ubiquitin [80, 87].  
 
1.3.3 DUB specificity and regulation 
New DUB substrates are continually being identified, and the degree to 
which DUBs exhibit substrate specificity remains uncertain. Some DUBs 
clearly exhibit broad substrate specificity. Examples include the three DUBs 
that associate with the 19S proteasome (PSMD14, USP14 and UCHL5), and 
which deubiquitylate a wide range of proteins delivered to the proteasome 
[88]. On the other hand only a small number of substrates have been 
identified for some DUBs. An example is USP20 whose substrates include 
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type II deiodinase, the β2 adrenergic receptor, VHL (von Hippel-Lindau), 
TRAF6 (TNF receptor associated receptor 6) and TAX [89-93]. This may 
however partly reflect the immaturity of the field, and indeed several DUBs 
(such as the Josephins ATXN3L, JOSD1 and JOSD2) have no known 
substrates to date.  
 
DUB specificity is likely generated through multiple mechanisms [80]. Firstly, 
a subset of DUBs show linkage-specificity. For example, USP14 is selective 
for K48 chains [94], while another member of the USP family, CYLD 
(cylindromatosis gene), preferentially hydrolyses K63 and linear chains [95]. 
Most USP family members are however relatively promiscuous, and will 
cleave multiple chain types [19]. While the mechanisms for linkage specificity 
remain relatively unknown, a recent paper has deciphered a mechanistic 
reason for the Otubain ZRANB1’s (zinc finger, RAN-binding domain 
containing 1) specificity for K29 and K33 ubiquitin chains. This involves an 
unpredicted ankyrin repeat domain which serves as a ubiquitin-binding fold 
that orientates ubiquitin chains such that K29 or K33 linkages are 
preferentially cleaved [96].  
 
DUBs may also discriminate between cleavage from the free end of a 
ubiquitin chain, cleavage in the middle of the chain, or removal of the entire 
chain from substrate. For example, USP14 is only DUB able to cleave the 
distal ubiquitin from chains [94], while DUBs such as CYLD and TNFAIP3 
cleave between ubiquitin moieties in the chain [95, 97]. USP14 has a Fingers 
subdomain, which prevents binding to internal linkages [94], this is absent in 
CYLD for example. PSMD14 on the other hand is an example of a DUB 
which cleaves the bond between substrate and the proximal ubiquitin [88].  
 
UCH enzymes have a prominent loop that covers the active site and 
prevents the binding of large folded ubiquitin conjugates [80, 98]. This finding 
is supported by the inability of UCL1 (ubiquitin carboxyl-terminal esterase L1) 
and UCHL3 (ubiquitin carboxyl-terminal esterase L3) to cleave tetraubiquitin 
in vitro [19]. It has been suggested that UCH enzymes may therefore be 
ideally suited to the removal of monoubiquitin from non-structured protein 
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regions [80]. However, details relating to the removal of monoubiquitin from 
substrate remain scarce [80].  
 
Two DUBs (USP5 and USP13) have been shown to contain a specific ZnF-
UBD domain, which recognises the C-terminal diglycine motif in unanchored 
ubiquitin chains [99]. These DUBs act to recycle ubiquitin by cleaving 
unanchored ubiquitin chains, regardless of chain linkage, and thereby 
replenish the cellular free ubiquitin pool [80, 100, 101]. 
 
DUBs also generally exhibit specificity for ubiquitin, and do not cleave 
linkages between ubiquitin-like molecules. All DUB catalytic domains have a 
ubiquitin binding site that forms multiple interactions with the distal ubiquitin, 
principally, but not exclusively with the Ile44 patch [80, 84]. Additionally, the 
C-terminus of the distal ubiquitin, which extends from the binding site 
towards the catalytic triad and is held in place for catalysis, is distinct from 
that of ubiquitin-like molecules such as NEDD8, which prevents cleavage of 
the latter [80]. Exceptions do occur however, and include USP21, ataxin 3 
(ATXN3), UCHL1 and UCHL3, which are reported to have dual activity 
against both ubiquitin and NEDD8 [102-105], and USP18, which has activity 
against linear ISG15 chains [106]. 
 
Several other factors are likely to be involved in determining substrate 
specificity. Many DUBs contain domains that are involved in protein-protein 
interactions and which may enable substrate recognition (reviewed in [80]). 
In addition, in a recent study in which the localisation of 66 green fluorescent 
protein tagged DUBs was systematically assessed, several DUBs were 
found to be localised to distinct organelles or structures [107], which may 
serve to colocalise DUB and substrate. In certain cases, DUB specificity may 
also require binding to substrate to induce conformational changes that 
unblock the active site [98]. DUBs are also subject to multiple post-
translational modifications, including phosphorylation, which is likely to 
regulate their activity and localisation [80]. 
 
 
  16 
1.4 DUBs and cancer 
 
Since the discovery of the first deubiquitylases approximately two decades 
ago [108, 109], it has become clear that this family of enzymes is involved in 
virtually all cellular processes [110]. These encompass many processes 
germane to cancer; including signalling pathways, cell cycle regulation, DNA 
damage repair, and regulation of tumour suppressors (reviewed in [9, 111]). 
Several DUBs have also been shown to have direct tumour suppressor or 
oncogenic roles (examples of which are discussed in sections 1.4.1 and 
1.4.2.). The role of DUBs in cancer is also supported by a recent study which 
used in situ hybridisation to investigate DUB expression in cancer [112]. In 
this study, 33 DUBs were found to be expressed in one or more tissue 
samples and of these, 22 were differentially expressed in cancer samples 
[112]. 
 
1.4.1 DUBs with tumour suppressor function 
The identification of mutations in the CYLD gene as the cause for 
cylindromatosis, a rare familial disease characterised by the formation of 
multiple skin adnexal tumours (cylindromas), led to the first description of a 
DUB with tumour suppressor functions [113, 114]. Subsequently CYLD 
deletion was also shown in sporadic cylindromas and other skin adnexal 
tumours [115, 116], and more recently CYLD has also been shown to have 
tumour suppressor functions in both basal and squamous cell carcinomas of 
the skin  (reviewed in [117]). In basal cell carcinomas the CYLD gene is not 
mutated, however it is profoundly downregulated at both the mRNA and 
protein level due to recruitment of the transcriptional repressor Snail to the 
CYLD promoter [118]. Snail is an effector of Hedgehog signalling, which is 
constitutively activated in basal cell carcinoma [119-121]. The role of CYLD 
in squamous cell carcinomas is less clear, however an inactivating mutation 
has been shown to increase the malignant potential of squamous carcinomas 
in a xenograft model [122]. CYLD has also been associated with the 
pathogenesis of several other malignancies [123]. In a mouse model, CYLD 
deficiency led to increased susceptibility to induced colonic inflammation and 
colonic tumours [124]. 
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Several CYLD substrates have been described, including TNF associated 
factor 2 (TRAF2) and TRAF6, I-kappa-B kinase subunit gamma (IKKγ), 
TGFβ-activated kinase 1(TAK1) and lymphocyte specific protein tyrosine 
kinase (LCK) [125-130]. The best-studied role for CYLD is the negative 
regulation of the NFκB signalling pathway (discussed in section 1.4.3), 
however CYLD also negatively regulates JNK (c-Jun N-terminal kinase) 
signalling [128] which is likely to also contribute to CYLD’s tumour 
suppressor function [131]. CYLD is also involved in T-cell development [129] 
and function [130], which may further contribute to its role in cancer 
predisposition.  
 
TNFAIP3, a member of the OTU family of DUBs and a negative regulator of 
NFκB signalling ([132] and section 1.4.3), is also a tumour suppressor. Loss 
of TNFAIP3 expression through genetic deletion, mutation or silencing by 
promoter methylation, has been shown in a wide range of lymphoid 
malignancies [133-136]. Recently, loss of TNFAIP3 expression has also 
been reported in colorectal cancer where it is associated with poor prognosis 
[137]. 
 
A third tumour suppressor, BAP1  (BRCA1- associated protein 1), was first 
identified through a yeast two-hybrid screen for BRCA1 RING finger 
interactors [138]. The same study showed that BAP1 enhanced BRCA1 
mediated inhibition of breast cancer cell growth, and additionally showed 
rearrangements and deletions of BAP1 in lung carcinoma cell lines [138]. 
BAP1 was subsequently shown to be lost in a large proportion of 
metastasising uveal melanomas (UMs) [139]. While UM is a rare tumour 
type, BAP1 additionally appears to have tumour suppressor functions in 
other tumour types. In one study in mesothelioma, 42% of 53 tumours 
exhibited BAP1 genomic loss, mutation or both [140], while in a second 
study, biallelic BAP1 loss was reported in 16 out of 23 (60%) mesotheliomas 
[141]. Inactivating mutations in BAP1 have also been shown in 14% of 176 
renal cell carcinomas [142]. Low BAP1 expression has also been shown to 
correlate with poor prognosis in non-small cell carcinomas of the lung [143]. 
These studies have been supported by several recent reports showing that 
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germline BAP1 mutations predispose to lung adenocarcinomas and 
mesotheliomas as well as cutaneous and ocular melanomas [144-148].  
The tumour suppressor function of BAP1 has been shown to require both its 
deubiquitylating activity and nuclear localisation in a lung cancer cell line and 
in a nude mouse xenograft model [149]. BAP1 is known to reverse the 
monoubiquitylation of histone H2A [150], and its knockdown leads to the 
accumulation of monoubiquitylated H2A. In a recent study, HDAC inhibition 
appeared to reprogramme rapidly growing UM cancer cells into a low-grade 
more differentiated state. No established cell line with a BAP1 mutation was 
available, however HDAC inhibition in BAP1 mutant primary cell lines 
reversed the morphologic consequences of BAP1 loss. BAP1 had also 
previously been shown to form a complex with HCF-1, which is involved in 
regulation of gene transcription [151], indicating that its tumour suppressor 
function may be multifaceted.  
 
1.4.2 DUBs as oncogenes 
Several DUBs show increased activity in cancer through either mutation or 
upregulated expression. Translocations of USP6 (also known as TRE17) are 
found at high frequencies in aneurysmal bone cysts [152, 153], which are 
benign bone tumours, although malignant transformation has been reported 
[154]. Five translocation partners have been identified, and in each case lead 
to the placement of the USP6 coding sequence downstream of a strong 
promoter, leading to its aberrantly increased expression [152, 155]. The 
mechanism by which USP6 leads to development of aneurysmal bone cysts 
remains uncertain. However, USP6 has been shown to upregulate NFκB 
signalling, leading in turn to an induction in the expression of matrix 
metalloproteinases [156]. 
 
USP4 was originally characterised as an oncogene on the basis of its ability 
to transform NIH 3T3 cells [157], and it has subsequently been shown to be 
overexpressed in several different cancer subtypes [158, 159]. Several 
functions have been attributed to USP4, including downregulation of p53 
[159] and induction of TGFβ (transforming growth factor β) signalling [160], 
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which may help explain its oncogenic characteristics. However, USP4 is also 
known to deubiquitylate TRAF2 and TRAF6 and to downregulate NFκB 
signalling [161], indicating that it may have different effects on 
tumourigenesis in different contexts. 
 
The role of Ubiquitin C-terminal hydrolase-L1 (UCHL1) in cancer remains 
poorly understood, and both oncogenic and tumour suppressor functions 
have been described. Overexpression of UCHL1 has been reported in 
several tumour types including non-small cell lung cancer [162, 163], 
colorectal cancer [164], pancreatic cancer [165], osteosarcoma [166] and 
oesophageal squamous carcinoma [167]. In addition, overexpression has 
also been associated with tumour progression, size and invasiveness [164, 
165]. However, other reports have indicated the UCHL1 promoter may be 
hypermethylated leading to its silencing in tumours including breast cancer 
[168] nasopharyngeal carcinoma [169, 170], oesophageal squamous 
carcinoma [171] and hepatocellular carcinoma [172].  
 
The divergent findings of these sets of studies are similarly reflected in in 
vitro studies investigating UCHL1 substrates and mechanism of action. 
UCHL1 has been shown to reduce the rate of β-catenin degradation, leading 
to increased proliferation and migration in a colorectal cancer cell line [173]. 
On the other hand, ectopic expression of UCHL1 in two breast cancer cell 
lines, in which UCHL1 had been shown to be silenced by promoter 
methylation, inhibited colony formation and proliferation, and led to apoptosis 
[168]. 
 
Other DUBs which have oncogenic characteristics include USP28 which 
stabilises Myc [174] and USP2 which stabilises MDM2 [175], Cyclin A1 [176] 
and Aurora A [177]. USP2 additionally stabilises fatty acid synthase and is 
overexpressed in prostate cancer [178]. Its functional inactivation leads to 
apoptosis in prostate cancer cell lines [178, 179]. 
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1.4.3 DUBs and signalling pathways  
The deubiquitylases have been implicated in the regulation of most, if not all, 
signalling pathways relevant to cancer. Prime among these is the NFκB 
pathway, which is regulated at multiple levels by DUBs [180]. The NFκB 
pathway is a crucial regulator of immunity that is frequently dysregulated in 
cancer [181]. NFκB is normally sequestered in a complex with IκB. Upstream 
receptor stimulation leads to activation of the IκB kinase (IKK) complex, 
which phosphorylates IκB leading to its dissociation from NFκB. IκB then 
undergoes K48 polyubiquitylation and is degraded by the proteasome, 
leaving NFκB free to translocate to the nucleus where it regulates 
transcription of target genes [182]. Several proteins that promote NFκB 
signal transduction (including NFκB essential modulator [NEMO], TRAF2 and 
TRAF6) undergo activating K63 polyubiquitylation. CYLD, which as 
discussed 1.4.1 is a tumour suppressor, disassembles these K63 chains thus 
inactivating the proteins and downregulating the pathway [126, 127]. CYLD is 
transcriptionally upregulated by NFκB and acts as a negative feedback loop 
[183].  
 
TNFAIP3 is a second negative regulator of the NFκB pathway. It possesses 
both DUB and E3 ligase activity and regulates its substrates (TRAF6 and 
RIP1 [receptor interacting protein 1]) through a ubiquitin editing function in 
which K63 chains are removed and replaced with K48 linkages thus 
promoting degradation of substrate [184, 185]. Other DUBs which have been 
implicated in NFκB signalling including the Otubain OTU7B, and USP21 
which both negatively regulate the pathway [186, 187], and USP2 which 
upregulates TNFα (tumour necrosis factor α) induced NFκB signalling. 
 
Deubiquitylases have been implicated in several other signalling pathways 
including TGFβ [188-191] and Wnt [192-196] signalling. The involvement of 
DUBs in the regulation of the PtdIns3-K pathway will be discussed in section 
1.5.3. 
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1.4.4 DUBs and the regulation of tumour suppressor stability and 
function 
Loss of tumour suppressor function is a common event in oncogenesis. 
While classically described as occurring due to genomic mutations, it has 
become clear that several other mechanisms may be involved. These include 
post-translational modifications, such as ubiquitylation, which may regulate 
the stability and function of tumour suppressors [197, 198]. Such 
ubiquitylation may be reversible, and several deubiquitylases have been 
shown to play essential roles in the regulation of tumour suppressors, 
including p53, PTEN and the FOXO (Forkhead box O) family of transcription 
factors [175, 199-205].  
 
Several E3 ligases that regulate p53 ubiquitylation and thus stability have 
been identified [206]. These include MDM2 which is the best characterised 
and which is itself transcriptionally regulated by p53 [207]. A number of DUBs 
that deubiquitylate and stabilise p53 have also been described [199-201, 
204], including USP7 which additionally deubiquitylates and stabilises MDM2 
[208]. USP7 loss has been shown in certain contexts to lead to MDM2 
degradation and thus p53 stabilisation [208-210]. Interestingly, p53 
stabilisation has also been shown in cells treated with a USP7 inhibitor [211]. 
This inhibitor also induced p53-dependent apoptosis, thus supporting USP7 
inhibition as a therapeutic strategy [211]. A second DUB, USP2, has also 
been shown to stabilise MDM2 and thus promote p53 degradation [175], and 
may similarly represent a drug target in cancer. 
 
Regulation of PTEN (phosphatase and tensin homolog) and FOXO 
monoubiquitylation by USP7 will be discussed in section 1.5.4. 
 
1.4.5 Targeting DUBs as a therapeutic strategy in cancer 
The clinical activity of the proteasome inhibitor, bortezomib, in the 
management of multiple myeloma and mantle cell lymphoma (section 1.2.4) 
ignited interest in the ubiquitin proteasome system as a source of potential 
cancer drug targets. The deubiquitylases are particularly promising in this 
regard, and several large pharmaceutical companies, including Genentech 
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and Servier, have active DUB inhibitor programmes. Research in this area is 
at a relatively early stage, and to date there are no inhibitors in clinical trials.  
 
While historically cysteine proteases have proven less amenable to small 
molecule inhibition, recently early compounds with partial specificity against 
certain DUBs have been developed. Among these is a USP7 inhibitor which 
has been shown to stabilise and activate p53, and to induce apoptosis in a 
p53 dependent manner [211]. A second USP7 inhibitor has also recently 
been described which induces apoptosis in bortezomib resistant cell lines 
[62].  
 
Hybrigenics have also synthesised selective USP8 inhibitors [212], following 
their observation that USP8 silencing led to cell cycle arrest and apoptosis in 
several cell lines ([213] and section 5.4).  Recently, two partially selective 
reversible inhibitors of USP1 were identified in a high throughput screen of 
several small molecule libraries containing a total of 9525 molecules. Both 
molecules acted synergistically with cisplatin in reducing proliferation of a 
cisplatin resistant non-small cell cancer cell line [214].  
 
Additional DUB inhibitors have also been described, including a third USP7 
inhibitor [215], several UCHL3 inhibitors [216], a partially selective DUB 
inhibitor with activity against USP9X, USP5, USP14 and UCHL5 [217], and a 
USP14 inhibitor [218]. Novel platforms for DUB drug discovery have recently 
been described and are likely to facilitate the development of further 
inhibitors [215, 219]. 
 
           
  23 
1.5 The Phosphatidylinositol 3-Kinase (PtdIns3-K)/Akt pathway 
 
The PtdIns3-K/Akt cascade is a crucial signal transduction pathway, which 
links growth factor and cytokine receptors with a cascade of downstream 
effectors, and is involved in the regulation of several key cellular processes 
including survival, growth and proliferation [220]. The pathway is vital in 
many, if not most, malignancies. Several components of the pathway act as 
oncogenes (e.g. Akt), and the pathway is negatively regulated by tumour 
suppressors such as PTEN. Aberrations at all levels of the pathway are 
found in malignancies, and the pathway provides several possible targets for 
cancer drug development [221]. Inhibitors of a downstream effector of the 
pathway, mTOR (mammalian target of rapamycin), are already in the clinic 
[222, 223], while several inhibitors of p110α and Akt are in clinical 
development [224]. 
 
1.5.1 The PtdIns3-K family 
In the late 1980’s, work in Lewis Cantley’s laboratory led to the discovery of 
an enzyme which catalysed the phosphorylation of phosphatidylinositol (4,5) 
bisphosphate at position D-3 of the inositol ring [225, 226]. Since then 
several other enzymes with this activity (phosphoinositide 3-kinases) have 
been described, and these have been shown to play a vital role in many 
cellular processes including cell growth, proliferation and survival as well as 
vesicular transport (reviewed in [227]).  
 
The PtdIns3-Ks are divided into three classes on the basis of structure and 
substrate specificity (fig 1.5, [227]). Class I enzymes are heterodimeric and 
are made up of a regulatory and catalytic subunit. There are four catalytic 
isoforms, designated p110α (also known as PIK3CA), p110β (PIK3CB), 
p110δ (PIK3CD) and p110γ (PIK3CG). The first three make up the class IA 
family and bind to p85 regulatory subunits (of which there are five isoforms), 
while p110γ is the sole catalytic member of class IB, and interacts with p101 
(PIK3R5) or p84/p87 (PIK3R6) regulatory subunits. Class I PtdIns3-Ks are 
activated by receptor tyrosine kinases (RTKs) and G-protein coupled  
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Fig 1.5. Phosphatidylinositol 3-kinase classes. PtdIns3-K isoforms, that 
were specifically investigated in my PhD project are highlighted in red. BD- 
binding domain, C2- putative membrane binding domain, SH2- src homology 
2, SH3- src homology 3, iSH2- inter-src homology 2, PX- phox homology. 
(Adapted from Liu P et al [228]) 
 
receptors (GPCRs), and phosphorylate PtdIns(4,5)P2 to produce 
PtdIns(3,4,5)P3. 
 
There are three mammalian class II PtdIns3-Ks; p170 (PIK3C2A), PIK3C2B 
and PIK3C2G. Class II PtdIns3-Ks do not have regulatory subunits, and their 
activation by upstream signalling is unclear. However there is evidence to 
suggest activation by both tyrosine kinase and GPCR ligands [229, 230]. 
Class II PtdIns3-Ks are able to phosphorylate both PtdIns and PtdIns4P in 
vitro [231, 232], However current evidence suggests that, in vivo, class II 
generates PtdIns3P only [233, 234]. 
 
VPS34 (vacuolar protein sorting 34, also known as PIK3C3) is the only class 
III PtdIns3-K, and is the sole representative of the PtdIns3-K family in fungi 
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and plants. Conserved in all eukaryotes, Vps34 is the ancestral PtdIns3-K. 
Vps34 catalyses the generation of PtdIns3P only [235, 236], and functions in 
multiprotein complexes, which regulate vesicular traffic including autophagy 
[237], endocytosis [238] and phagocytosis [239]. Signalling by class I 
PtdIns3-K leads to the activation of protein kinase B (PKB also known as Akt) 
and a host of downstream effectors comprising the PtdIns3-K/PKB pathway, 
which I will describe from now on as the PtdIns3-K pathway for simplicity. 
Class IA PtdIns3-Ks are particularly associated with malignancy, and unless 
otherwise stated the following is limited to their description. 
 
1.5.2 The PtdIns3-K pathway is a phosphorylation cascade 
A wide variety of growth factors and cytokines can activate the PtdIns3-K 
pathway, including members of the human epidermal growth factor receptor 
family (such as EGFR and ErbB2), the insulin like growth factor (IGF) 
receptor and angiogenesis receptors such as vascular endothelial growth 
factor receptor (VEGFR). Signalling through the PtdIns3-K pathway is 
initiated by the binding of ligands to their cognate receptors, leading to 
phosphorylation of specific tyrosine residues (fig 1.6). These pTyr residues 
are recognised by Src Homology 2 (SH2) domain containing proteins, 
including the p85 subunits of class IA PtdIns3-K. Binding of p85 to pTyr leads 
to a change in p85 conformation, which relieves p85-dependent inhibition of 
p110 catalytic activity. Binding of p85 to pTyr also serves to localise p110 to 
the membrane thus bringing it into contact with its substrate. p85 recruitment 
may also occur through adapter proteins such as insulin receptor substrate-1 
(IRS-1) [240] or growth factor receptor bound protein 2 (Grb2) [241]. In 
addition class IA PtdIns3-K can also be activated through Ras [242], and 
recent evidence suggests that activation may also occur directly through G- 
protein coupled receptors (GPCRs) [243, 244]. 
 
Once activated, p110 catalyses the phosphorylation of position 3 of the 
inositol ring of PtdIns(4,5)P2, which is located on the inner leaflet of the 
plasma membrane (fig 1.4). PtdIns(3,4,5)P3 is the key second messenger in 
the PtdIns3-K pathway and its generation by PtdIns3-K is finely balanced by 
the tumour suppressor, PTEN [245]. PTEN was first identified in 1997 by two  
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Fig 1.6. Schematic representation of the PtdIns3-K pathway. 
Heterodimeric class I PtdIns3-K is made up of p85 and p110 subunits and is 
activated by p85 binding to receptor pTyr residues. PtdIns3-K may also be 
activated by Ras or G-protein coupled receptors (not shown). Following its 
activation p110 catalyses the phosphorylation of PtdIns(4,5)P2, and 
generates the second messenger PtdIns(3,4,5)P3, which serves to recruit 
and localise PDK1 and Akt to the membrane. PDK1 catalyses the 
phosphorylation of Akt T308, a second phosphorylation (S473) is catalysed 
by mTOR complex 2 (mTORC2). Activation of mTORC2 is dependent on 
activation of PtdIns3-K but the mechanism remains unclear. Akt 
phosphorylates a host of downstream effectors, examples of which are 
shown, along with examples of their functions. Phosphorylation of FOXO 
leads to its nuclear exclusion and thus prevents its function as a transcription 
factor. MDM2 dependent K48 ubiquitylation of p53 leads to its degradation. 
The pathway is negatively regulated by PTEN, which dephosphorylates 
PtdIns(3,4,5)P3 to PtdIns(4,5)P2. 
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research groups  who independently found PTEN to be disrupted in multiple 
sporadic tumours as well as in cancer predisposition syndromes [246, 247]. 
 
This finding was supported by the generation of PTEN knockout mice, which 
demonstrated increased susceptibility to multiple malignancies [248-250]. 
Interestingly, PTEN may function as a haploinsufficient tumour suppressor 
[251, 252], and subtle changes in PTEN protein expression can alter cancer 
susceptibility [253]. While PTEN has multiple functions which contribute to its 
role as a tumour suppressor (reviewed in [254]), its major role appears to be 
the dephosphorylation of PtdIns(3,4,5)P3 [245], and loss of PTEN leads to 
deregulated PtdIns3-K signalling which in turn increases cell survival [255, 
256].  
 
PtdIns(3,4,5)P3 engages downstream effectors in an elegant fashion, acting 
as a scaffold for the recruitment and phosphorylation of Akt by 
phosphoinositide dependent kinase 1 (PDK1). Both proteins contain 
Pleckstrin Homology (PH) domains [257]  which preferentially bind to 
PtdIns(3,4,5)P3  [258, 259]. PDK1 phosphorylates the activation loop of a 
large group of kinases which belong to the AGC family (named after three 
founder members; protein kinase A, protein kinase G, protein kinase C) and 
which include Akt [260, 261]. Binding of Akt to PtdIns(3,4,5)P3 serves two 
functions, it colocalises Akt with its kinase, PDK1, and it induces a 
conformational change in Akt which enables its phosphorylation [262]. 
Notably, although PDK1 activity requires phosphorylation of its activation 
loop, this is an autophosphorylation and PDK1 is constitutively active [263].  
 
Full activation of Akt requires phosphorylation at two sites, T308 within the 
activation loop, and S473 within the hydrophobic motif. The identity of the 
kinase responsible for the second phosphorylation event at S473 remained 
unknown until 2005, when this was shown to be due to the activity of the 
mTOR (mammalian target of rapamycin) in complex with rictor and GβL 
[264]. mTOR is a large protein kinase which exists in two distinct complexes, 
one containing raptor (mTORC1) [265-267] and the second containing rictor 
(mTORC2) [267]. Phosphorylation of Akt S473 by mTORC2 appears to be 
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dependent on activation of the PtdIns3-K pathway [268, 269] but the 
mechanism by which this is regulated remains unclear.  
 
Akt was originally discovered as the oncogene responsible for the 
transforming activity of the mouse retrovirus, AKT8 [270]. Subsequently three 
human homologues, each of which is encoded by a different gene, have 
been described; namely Akt1 [271-273], Akt2 [271, 274] and Akt3 [275]. 
Each isoform is made up of a PH, kinase and regulatory domain, and they all 
share extensive sequence homology, particularly in the catalytic domain 
[275]. Akt1 and Akt2 are widely expressed, while Akt3 is predominantly 
expressed in brain, testis, lung, heart, kidney, fat and mammary tissue [273-
275], and as discussed in section 1.5.3, all three isoforms have been 
implicated in cancer. 
 
Akt is a master kinase, with over 120 substrates reported thus far (data 
retrieved from www.phosphosite.org/homeAction.do [276]). Phosphorylation 
of these effectors serves overall to promote cell survival, growth and 
proliferation. While Akt dependent phosphorylation directly activates some 
substrates (for example the anti-apoptotic protein XIAP [277]), it also leads to 
inactivation of others (for example the pro-apoptotic protein, BAD [278]). A 
selection of effectors are discussed below. 
 
mTORC1 is a large multi-protein complex and key Akt effector, that promotes 
translation and growth, and inhibits autophagy [279]. Its activation by Akt is 
complex, and likely occurs through several mechanisms. The first of these 
involves Akt dependent phosphorylation of TSC2 (tuberous sclerosis 2), 
which leads to its dissociation from TSC1 [280, 281]. The TSC1/TSC2 
complex is a GTPase activating protein (GAP) for the small G protein Rheb 
[282]. Inhibition of TSC2 thus leads to activation of Rheb, which in turn 
activates mTORC1 [283]. Secondly, recent evidence suggests Akt may 
activate mTORC1 through phosphorylation of PRAS40 (proline rich Akt 
substrate 40kDa) [284, 285]. Additionally, Akt dependent regulation of 
cellular ATP level and AMPK (AMP activated protein kinase) may indirectly 
lead to mTORC1 activation [286] 
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MDM2 (mouse double minute 2, human homologue of) is a further Akt 
substrate. Its phosphorylation by Akt leads in turn to an increase in 
polyubiquitylation and degradation of tumour suppressor, p53 [287, 288]. Akt 
promotes proliferation through its phosphorylation of several components of 
the cell cycling machinery, including p27, p21 and cyclin D1. Akt mediated 
phosphorylation of p27 leads to its nuclear exclusion, thus antagonising cell 
cycle arrest through derepression of cyclin E/CDK2 [289-291]. Glycogen 
synthase kinase 3 (GSK3) is serine/threonine kinase with functions in a wide 
range of intracellular processes, including cellular metabolism, proliferation, 
and survival [292]. Its phosphorylation by Akt leads to inactivation, and in turn 
promotes cell cycling and survival.   
  The FOXO proteins (FOXO1, FOXO3, FOXO4 and FOXO6) are members of 
the Forkhead superfamily of transcription factors, and tumour suppressors 
[293]. The latter has been established in mouse models, in which conditional 
knockout of FOXO1, FOXO3 and FOXO4 resulted in the spontaneous 
development of tumours [294]. Interestingly, knockout of any two of the 
above did not result in an increase in tumours supporting extensive 
redundancy between the FOXO proteins [294]. FOXO proteins promote 
apoptosis and cell cycle arrest, this occurs through transcription of genes 
such as p21 [295], p27 [296], Fas ligand [297] and B-cell lymphoma 6 (BCL6) 
[298]. The FOXO proteins are regulated in part by the PtdIns3-K pathway; 
Akt dependent phosphorylation leads to their nuclear exclusion and binding 
to the chaperone 14.3.3, thus preventing their transcriptional activity [297, 
299-303].  
 
1.5.3 The PtdIns3-K pathway in cancer and therapeutics 
As discussed in section 1.5.2 above, the PtdIns3-K pathway contains both 
oncogenes and tumour suppressors. These are frequently mutated in a wide 
variety of different tumour groups, leading to constitutive activity of the 
pathway (table 1.2). In addition, upregulation of the PtdIns3-K pathway may 
also occur as a consequence of increased upstream signalling, or through 
epigenetic and post-translational mechanisms (table 1.2) Regulation of PTEN  
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Mechanism Examples of tumour groups ref 
Oncogene mutation 
  p110α 
  p85α 
  p85β 
  Akt1 
  Akt2 
  Akt3 
  PDK1 
  mTOR 
 
Breast, colon, endometrial, glioblastoma, ovarian 
Glioblastoma, ovarian, colon, endometrial 
Endometrial 
Breast, colorectal, squamous lung 
Colorectal 
Melanoma 
Colorectal 
Renal 
 
[304, 305] * 
[306, 307] 
[307] 
[308-310] 
[311] 
[312] 
[311] 
[313] 
Oncogene amplification 
  p110α 
   
  p110β 
  Akt1 
  Akt2 
 
  PDK1 
 
H and N, squamous lung, cervical, gastric, 
oesophageal 
Breast, ovarian 
Gastric 
H and N, pancreatic, ovarian, breast 
 
Breast 
 
[314-320] 
 
[321, 322] 
[271] 
[314, 323-
325] 
[326] 
Upstream activation 
  EGFR mutation 
  Her2 amplification 
 
NSCLC, glioblastoma 
Breast, gastric 
 
[327-329] 
[330-332] 
PTEN loss 
  LOF mutation/ 
  deletion 
  Epigenetic silencing       
  Post-translational 
  Mechanism unreported$ 
 
Endometrial, glioblastoma, melanoma, prostate, 
breast, bladder, ovarian, lung 
Breast, colorectal 
Bladder, lung 
Breast 
 
[246] * 
 
[333, 334] 
[335, 336] 
[337-340] 
  
Table 1.2. PtdIns3-K pathway upregulation in cancer. Examples of the 
mechanisms by which the pathway is activated, and tumour groups in which 
this occurs, are given. *COSMIC- catalogue of somatic mutations in cancer 
(www.cancer.sanger.ac.uk/cancergenome/projects/cosmic/). $These studies 
reported non-genomic loss of PTEN, but did not identify the relevant 
mechanism(s). NSCLC- non-small cell lung cancer, H and N- head and neck 
cancer. (adapted from [221, 341]). 
 
in particular, occurs at multiple levels, and loss of its function may occur 
through several mechanisms (reviewed in [197, 254]).  
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The upregulation of the PtdIns3-K pathway in virtually all tumour types has 
led to extensive interest in the potential for drugs targeting the pathway, and 
most global pharmaceutical companies have a range of inhibitors against the 
PtdIns3-K pathway in their development pipelines. These include pan-class I 
inhibitors, class I isoform specific inhibitors, Akt inhibitors, mTOR inhibitors 
and dual PtdIns3-K/mTOR inhibitors [341]. The greatest success thus far has 
been obtained with the mTOR inhibitors, two of which have now been 
licenced for clinical use (temsirolimus and everolimus) following successful 
phase III trials in kidney cancer, pancreatic neuroendocrine tumours and 
breast cancer [342-344]. Additionally, an inhibitor of p110δ is in late phase 
trials in chronic lymphocytic leukaemia [345]. The remainder of the inhibitors 
remain in early phase trials, and the full potential of this class of drugs 
remains to be seen.  
 
In view of the relatively high rates of non-genomic PTEN silencing in cancer, 
its reactivation through pharmaceutical means would be of potential clinical 
value [197]. While research in this field remains at a very early stage, 
inhibitors of x-linked inhibitor of apoptosis (XIAP), one of the E3 ligases that 
promotes PTEN degradation, are in early development [346], and PTEN 
transcription may be increased by histone deacetylase (HDAC) inhibition 
[347-349]. 
 
1.5.4. Regulation of the PtdIns3-K pathway by ubiquitylation 
The PtdIns3-K pathway is extensively regulated by ubiquitylation, which 
regulates not only the stability of components, but also their localisation and 
activation status (fig 1.7). Key among these is Akt, which undergoes both 
K48 and K63 polyubiquitylation. The former is catalysed by the E3 ligase 
TTC3 (tetratricopeptide repeat domain 3) [350]. Notably, TTC3 preferentially 
ubiquitylates phosphorylated Akt [350], suggesting its degradation may be 
coupled to its activation, thus serving as an inbuilt mechanism to switch off 
signalling after initial activation. K63 polyubiquitylation on the other hand 
enhances Akt membrane localisation, and activation through its  
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Fig 1.7. Ubiquitin dependent regulation of PtdIns3-K components.  
Deubiquitylases are identified in red text, while E3 ligases are shown in blue. 
(βTRCP: β-transducin repeat containing E3 ubiquitin protein ligase, TRAF6: 
TNF receptor associated receptor 6, Skp2: s-phase kinase-associated 
protein 2, TTC3: tetratricopeptide repeat domain 3, NEDD4.1: neural 
precursor cell expressed, developmentally downregulated 4.1, WWP2: WW 
domain containing E3 ubiquitin protein ligase 2, XIAP: x-linked inhibitor of 
apoptosis, MDM2: mouse double minute 2, human homologue of, CHIP: C-
terminus of Hsc70-interacting protein, COP1: constitutive photomorphogenic 
protein 1). 
 
phosphorylation [351]. Both TRAF6 (TNF receptor associated receptor 6) 
and Skp2 (s-phase kinase-associated protein 2) have been shown to 
catalyse Akt K63 polyubiquitylation [351, 352], however the latter study also 
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showed that different receptors appear to engage different E3 ligases, with 
IGFR utilising TRAF6, and HER family receptors utilising Skp2 [352]. 
 
The deubiquitylase, UCHL1, has been implicated in the removal of K48 
chains from Akt, leading to its rescue from proteasomal degradation [353]. 
This study specifically investigated Akt in relation to stress-induced vascular 
injury, and the findings have not yet been confirmed in an alternative model. 
However, UCHL1 has also been shown to have a separate effect on Akt, 
leading to its increased phosphorylation [354]. This was mediated through a 
reduction in the protein level of the Akt phosphatase, PHLPP1 (PH domain 
and leucine rich repeat protein phosphatase 1), although the mechanism by 
which this occurs is unknown [354]. On the other hand, the stability of 
PHLPP1 is known to be regulated by ubiquitylation, with the E3 ligase 
βTRCP (beta-transducin repeat containing E3 ubiquitin protein ligase) 
promoting its degradation [355]. In a negative feedback loop, Akt activation 
leads to stabilisation of PHLPP1, which in turn leads to the 
dephosphorylation, and thus inactivation, of Akt [355]. Two deubiquitylases 
have been shown to reverse the polyubiquitylation of PHLPP1, namely 
USP46 and USP1 [356, 357]. 
 
Recently, PDK1 has been shown to be monoubiquitylated, although the 
functional relevance of this was not determined [358]. In a screen of 70 
DUBs, only overexpression of USP4 reversed monoubiquitylation of PDK1. 
However depletion of USP4 did not alter Ub-PDK1 levels, suggesting the 
presence of other DUBs which are able to deubiquitylate PDK1 [358].  
 
PTEN may be either polyubiquitylated (K48) or monoubiquitylated, with the 
former leading to its proteasomal degradation, and the latter to nuclear 
localisation. The E3 ligases NEDD4.1 (neural precursor cell expressed, 
developmentally downregulated 4.1), XIAP (x-linked inhibitor of apoptosis) 
and WWP2 (WW domain containing E3 ubiquitin protein ligase 2) have all 
been shown to polyubiquitylate PTEN [335, 359, 360]. Notably, 
polyubiquitylation of PTEN is known to inhibit its phosphatase activity, in 
addition to promoting its degradation [361]. PTEN polyubiquitylation also has 
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an inverse relationship with its phosphorylation at the c-terminus. This 
phosphorylation prevents subsequent ubiquitylation, and stabilises PTEN, 
while on the other hand both mono and polyubiquitylation inhibit PTEN 
phosphorylation [361-364]. Monoubiquitylation of PTEN promotes its nuclear 
localisation and is essential for its full tumour suppressor function [57, 203]. 
Studies in promyelocytic leukaemia cells have shown that monoubiquitylation 
of PTEN may be reversed by USP7, which in turn is regulated by a 
PML/DAXX (promyelocytic leukaemia protein/death associated protein 6) 
network [203]. 
 
The FOXO proteins may also be either polyubiquitylated or 
monoubiquitylated. K48 polyubiquitylation is mediated by several different E3 
ligases, namely MDM2, Skp2, CHIP (C-terminus of Hsc70-interacting 
protein) and COP1 [365-368]. The recruitment of different E3 ligases may 
partly depend on phosphorylation status, with MDM2 dependent 
ubiquitylation requiring phosphorylation by ERK [365], while Skp2 dependent 
ubiquitylation requires prior phosphorylation of S256 by Akt [366]. 
Alternatively, this may represent cell type specificity with CHIP and COP1 
catalysing FOXO polyubiquitylation in smooth muscle and hepatocellular 
carcinoma cells respectively [367, 368].  
 
MDM2 has also been shown to monoubiquitylate FOXO4 following oxidative 
stress leading to nuclear localisation and increased transcriptional activity, 
but not altered stability [369]. USP7 reverses this monoubiquitylation of 
FOXO4 leading to its nuclear exclusion, and allowing its acetylation, which is 
inhibitory [205]. The study also showed that FOXO3 is similarly regulated 
[205].  
 
The above discussion illustrates the importance of reversible ubiquitylation in 
the regulation of the PtdIns3-K pathway. However, there are clearly gaps in 
our knowledge (fig 1.6), and very likely to be other, as yet undiscovered, 
components including deubiquitylases.  
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1.6 Aims and Objectives 
In this research project, I set out to investigate the role of the deubiquitylating 
enzymes in the regulation of the PtdIns3-K pathway in an unbiased manner, 
with the intention of ultimately identifying potential drug targets. For this 
purpose I utilised a series of siRNA screens and two main strategies. In the 
first I assessed the effects of DUB knockdown on the protein level of multiple 
components of the PtdIns3-K pathway, while in the second I used a 
translocation assay to assess the effects of DUB depletion on the 
downstream activation of the PtdIns3-K pathway. Candidate DUBs identified 
in the screens were subject to validation by deconvolution of the siRNA pool. 
Investigation into the mechanisms by which these DUBs regulate the 
PtdIns3-K pathway was pursued for selected candidates. 
Specifically, I aimed to: 
• Identify DUBs involved in regulating the PtdIns3-K pathway using siRNA 
screening 
• Elucidate the role of these DUBs in the pathway 
• Identify potential cancer drug targets                        
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Chapter 2 
 
Materials and methods 
 
2.1 Cell Biology  
 
2.1.1 Reagents 
Cell culture reagents, plasticware and chemicals were obtained from Gibco 
(Invitrogen, UK), Corning Inc (NY, USA) and Sigma-Aldrich (Poole, UK) 
respectively, unless otherwise stated. Recombinant human epidermal growth 
factor (EGF) was obtained from Peprotech (London, UK). Vorinostat was 
obtained from Selleck Chemicals (Houston, USA). Unless otherwise stated, 
all inhibitor stock solutions were made up in dimethyl sulphoxide (DMSO) 
(Sigma-Aldrich), aliquoted and stored at  -20oC, then thawed on the day of 
the experiment and added to the cells in warm media at the required 
concentration. The maximum final DMSO concentration used was 0.2% v/v. 
 
The DUB siRNA screens and deconvolution of hits were performed using a 
library of siRNA oligonucleotides that had previously been designed in 
collaboration with Qiagen (Crawley, UK). The library is made up of 4 siRNA 
oligonucleotides directed towards each of 92 DUB genes. Both pools and 
individual oligonucleotides were arrayed on 96 well plates for ease of use in 
screening and follow up experiments. The DUB library includes all known 
transcribed DUBs (including those predicted to be catalytically inactive), with 
the exception of OTUD3 and some members of the USP17 family. The latter 
constitute part of a tandemly repeated sequence, with multiple copies 
including pseudogenes and catalytically inactive DUBs [370]. Three 
members of the family (USP17, DUB3 and DUB4) are included in the library. 
A summary of the DUBs targeted and the sequences of each oligonucleotide, 
is provided in appendix A. The library has now been used extensively in the 
host laboratory for similar projects including screens for regulators of E-
cadherin (JiaLih Wong, PhD thesis in preparation) and TGFβ signalling 
(Monika Chojnowska-Monga, PhD thesis [371]).  
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Where necessary, siRNA oligonucleotides were repurchased from Qiagen to 
replenish the library (appendix A). Additional siRNA oligonucleotides that 
were employed in this work are summarised in Table 2.1. A subset of targets 
(UCHL3, USP20, USPL1, YOD1, USP2, ATXN3, JOSD1, OTUD4, 
STAMBPL1 and USP7) were also depleted using endoribonuclease prepared 
siRNA (esiRNA), this was generated in the host laboratory by a colleague 
(JiaLih Wong) using the technique described by R. Kittler et al [372]. esiRNA 
primer sequences were obtained from the RIDDLE database 
(bioinformatics.age.mpg.de/ bioinformatics/RiDDLE.html), with the exception 
of USP2, YOD1 and ATXN3. These DUBs were either not included in the 
RIDDLE database (ATXN3), the primers were predicted to produce a low 
proportion of efficient siRNA (USP2), or PCR was unsuccessful using the 
RIDDLE database primers (YOD1). Primers for these were designed in-
house (JiaLih Wong) and are listed in table 2.2. 
 
2.1.2 Cell culture 
A549 (human lung adenocarcinoma) and U2OS (human osteosarcoma) cells 
were obtained from the European Collection of Cell Cultures (ECAAC), while 
FKHRL1-U2OS cells were obtained from Thermo Scientific (Bioimage 
products, Lafayette, USA). The latter cell line consists of U2OS cells that 
stably express FKHRL1 (FOXO3) fused to the N-terminus of enhanced green 
fluorescent protein (EGFP). Expression of FOXO3-EGFP is controlled by a 
CMV promoter, and expression was maintained by continuous culture in 
Geneticin (G418) containing media. A wider panel of lung cancer cell lines 
was sourced and cultured as described previously [373]. 
 
A549 and U2OS cells were maintained in high glucose (4.5g/l) Dulbecco’s 
Modified Eagle Medium (DMEM) containing 2% GlutaMAX (#31966-21) 
supplemented with 10% heat-inactivated Foetal Bovine Serum (FBS), 0.1mM 
MEM non-essential amino acids, 100units/ml Penicillin and 100units/ml 
Streptomycin. FKHRL1-U2OS cells were maintained in high glucose DMEM 
(#31966-21) supplemented with 10% heat-inactivated FBS, 100units/ml  
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Protein 
Target  
siRNA 
Designation 
Sense sequence Catalogue 
number 
Company 
AllStars 
negative 
control 
Non-targeting 
(siC) 
Not provided 1027280 Qiagen 
Akt1 AKT1_10 CACGCTTGGTCCCGAGGCCAA SI02757244 Qiagen 
Akt2 AKT2_5 AACAACTTCTCCGTAGCAGAA SI00299166 Qiagen 
Akt3 AKT3_12 ACCAGAGGTGTTAGAAGATAA SI02757762 Qiagen 
PTEN PTEN_6 AAGGCGTATACAGGAACAATA SI00301504 Qiagen 
PDK1 PDPK1_5 AAGGGCATCATTCACAGGGAC SI00301140 Qiagen 
PDK1 PDPK1_8 AAGCGGTTAGGCTGTGAGGAA SI00605780 Qiagen 
ATXN3L ATXN3L_D1 CAACACTGGTTTACTATTATT D-024927-01 Dharmacon 
ATXN3L ATXN3L_D2 CAACAAGCATATTCTGTATTT D-024927-02 Dharmacon 
ATXN3L ATXN3L_D3 GGAAACACATCGCAAGATCTT D-024927-03 Dharmacon 
ATXN3L ATXN3L_D4 CCGCAGTCTATTGAGTTATT D-024927-04 Dharmacon 
 
Table 2.1. siRNA sequences. 
 
Target 
Gene 
Primers  Length of 
esiRNA  
USP2 FW.GCTAATACGACTCACTATAGGGAGAGCCAATGATGTGGTGAGCCCAT 
RV.GCTAATACGACTCACTATAGGGAGACGCAGCGACAGCATGTTGGCT 
449 bp 
YOD1 FW.GCTAATACGACTCACTATAGGGAGAGGGATCTCAGCAATGGGGATAC 
RV.GCTAATACGACTCACTATAGGGAGACGGAGGTGTATCTGGATCAGG 
405 bp 
ATXN3 FW.GCTAATACGACTCACTATAGGGAGAGGGGCATTTTTCTTGGATCTTT 
RV.GCTAATACGACTCACTATAGGGAGACCAGAGTTTAGGAACGCACCA  
552 bp 
 
Table 2.2 esiRNA primers.  FW: forward primers, RV: reverse primers. 
Bases in italics designate T7 promoter sequences, while the sequence in 
bold designates the start of the esiRNA sequence  
 
penicillin, 100units/ml streptomycin and 0.5mg/ml Geneticin. All cells were 
cultured in a humidified incubator at 37°C and 5% CO2. Cells were 
maintained in exponential growth phase by growing to confluency in 100mm 
dishes and splitting every 48 hours. Cells were washed with sterile warm 
phosphate buffered saline (PBS) and detached from the plate using 0.05% 
trypsin-EDTA. A549 and U2OS cells were split at a ratio of 1:4 to 1:5, while 
FKHRL1-U2OS cells were split at a ratio of 1:3 to 1:4. 
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2.1.3 siRNA and esiRNA transfections 
Unless otherwise stated (see sections 2.1.3.1-2 below), siRNA transfections 
were performed in 6-well plates. Cells were seeded the day before 
transfection (table 2.3) in full DMEM and allowed to attach overnight.  
 
Immediately prior to transfection, the media was replaced with 800µL of 
DMEM containing no additives, after two washes with the same. 
Transfections were performed using either Oligofectamine or Lipofectamine 
RNAiMAX transfection reagent (both from Invitrogen) as per the 
manufacturers instructions. A final siRNA concentration of 20nM 
(Oligofectamine) or 10nM (RNAiMAX) was employed, while esiRNA 
transfections were performed in RNAiMAX using a final concentration of 
150ng/ml.  
 
For Oligofectamine transfections two solutions were prepared, the first of 
which (solution A) was made up of 20pmol of siRNA diluted in 182µl 
OptiMEM I (#51985-026) while the second (solution B) consisted of 3.3µl of 
Oligofectamine reagent made up to 18µl in OptiMEM. Following a 5-minute 
incubation, the two solutions were combined and incubated for a further 20 
minutes before being added drop-wise to the cells. Two solutions were 
similarly prepared for RNAiMAX transfections, the first containing 12pmol 
siRNA or 180pg esiRNA and the second containing 2µL of RNAiMAX 
reagent, and both of which were made up to 200µL in OptiMEM. The two 
solutions were combined and incubated for 10 to 20 minutes before being 
added to the cells. For both methods of transfection, FBS was added to a 
final concentration of 10%, four hours after transfection, and the following 
day the media was replaced with fresh full media. 
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Table 2.3 Cell seeding densities for siRNA transfections (6-well plate) 
 
2.1.3.1 DUB siRNA library screen for immunoblotting 
Transfection of cells for the immunoblotting screen (chapter 3) is described 
here. A549 cells were seeded in 150mm dishes at a density of 9 x 107 cells 
per dish, and allowed to attach overnight. Transfections were performed 
using Oligofectamine in a similar manner to that described above. Prior to 
transfection, 9.5ml of no addition DMEM was added to each dish after 
washing. Solution A contained 50µl of siRNA oligonucleotide pool (10µM) 
made up to 2730µl with OptiMEM, while solution B contained 49.5µl of 
Oligofectamine made up to 270µl in OptiMEM. Incubations were performed 
as described above, and the final concentration of siRNA oligonucleotide was 
40nM. 
 
2.1.3.2 Reverse transfection (96 well plates) 
Transfections for the translocation screen (chapter 4) and synthetic lethality 
experiments (chapter 5) were performed using a reverse transfection method 
and RNAiMAX transfection reagent according to the manufacturer’s protocol. 
RNAiMAX was diluted 1 in 20 prior to transfection. A reaction mix of 3µl of 
diluted RNAiMAX and 2µl of siRNA oligonucleotide (at a concentration of 
1.2µM) made up to 20µl with OptiMEM, was dispensed in each well. An 
incubation of 10-20 minutes followed, during which time cells were harvested 
and resuspended in antibiotic free DMEM at a concentration of 3 x 104 
cells/ml. 100µl of cells were then added to each well thus obtaining a final 
siRNA concentration of 20nM, and 3000 cells per well. The rim of wells 
around the edges of each plate were not used for transfections and instead 
filled with PBS to improve humidification and minimise edge effects. The 
Cell type 48 hour transfection 
(cells per well) 
72 hour transfection 
(cells per well) 
A549 cells 1 x 105 6 x 104 
FKHRL1-U2OS 1.2 x 105 - 
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plates were then incubated overnight, and the following day the media in 
each well was replaced with 200µl of fresh, full media. 
 
2.1.4 Cycloheximide chase 
Cycloheximide (Sigma-Aldrich) was used to inhibit mRNA translation and 
thus synthesis of new protein, in order to assess the degradation half-life of 
PTEN, and other proteins (section 6.7). A549 cells were seeded in six well 
plates and transfected with ATXN3_5, USP20_2, non-targeting siRNA, or 
mock-transfected using RNAiMAX transfection reagent as described in 
section 2.1.3. The cells were incubated for a total of 72 hours after 
transfection. Prior to lysis, 100µg/ml of cycloheximide was added for the 
indicated durations (0, 1, 2, 4, 8, 20 hrs) in full media. Lysis was performed 
using NP40 buffer as described in section 2.1.8.1. Lysates were 
immunoblotted for the indicated proteins as described in sections 2.2.4-6. 
 
2.1.5 Akt depletion and EGF stimulation 
This experiment was performed to enable identification of the different bands 
detected by the Akt antibody (section 3.7). A549 cells were seeded in six well 
plates and transfected with siRNA against Akt1, Akt2, or Akt3, non-targeting 
siRNA, or mock-transfected using Oligofectamine as described in section 
2.1.3. 48 hours after transfection half of the wells were serum starved for 4 
hours, then 20ng/ml of EGF added for 15 min. All wells were then lysed using 
the hot lysis method (section 2.1.7.3), and lysates immunoblotted for Akt and 
actin (sections 2.2.4-6). 
 
2.1.6 Actinomycin D chase 
Actinomycin D (Sigma-Aldrich) was employed to inhibit transcription, and 
thus to enable assessment of the rate of transcript degradation (section 6.6). 
This was performed in either non-transfected A549 cells (seeded in 6-well 
plates at a density of 2 x105 cells per well the day before the experiment) or 
following a 48-hour transfection in A549 cells. Transfections were performed 
as described in section 2.1.3. On the day of the experiment, the cells were 
treated with actinomycin D to a final concentration of 5µg/ml for the indicated 
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times prior cell lysis and total RNA extraction, after which quantitative RT-
PCR (QPCR) was performed as described in sections 2.3.4-6. 
  
2.1.7 HDAC inhibition 
The non-selective histone deacetylase (HDAC) inhibitor, vorinostat (also 
known as suberoylanilide hydoxamic acid [SAHA]), was used to investigate a 
potential mechanism for ATXN3 dependent regulation of PTEN/PTENP1 
transcription (section 6.7). Cells were seeded at a density of 3 x 105 cells per 
well, allowed to attach, then the following day vorinostat added to the 
concentrations indicated, and the cells incubated for 16 hours. Alternatively, 
A549 cells were transfected with siRNA in 6-well plates as described in 
section 2.1.3 and incubated for 32 hours, after which 2µM vorinostat was 
added in full medium and the cells incubated for a further 16 hours. Cell lysis, 
RNA extraction and QPCR were performed as described as described in 
sections 2.3.4-6. 
 
2.1.8 Cell lysis 
2.1.8.1 NP40 lysis  
The cells were placed on ice, the medium aspirated and the cells washed 
twice with ice cold PBS. NP40 lysis buffer (0.5% NP40, 25mM Tris (pH 7.5), 
100mM NaCl, 50mM NaF) containing phosphatase and protease inhibitors 
(Complete protease inhibitor cocktail tablets and phosSTOP phosphatase 
inhibitor cocktail tablets respectively, both from Roche, Basel, Switzerland) 
was added and the cells were lysed for 15min with rocking. The lysate was 
cleared by centrifugation at 16,000g for 10 min at 4°C in a bench top 
centrifuge. Protein assays and sample preparation were performed as 
described in section 2.2.3.  
 
2.1.8.2 Cell fractionation 
The lysis method employed in the large scale library screen was adapted 
from that of Dignam et al [374], and involved the sequential use of a 0.5% 
NP40 buffer to extract predominantly cytosolic proteins, followed by a high 
salt buffer (Dignam’s buffer C) to extract nuclear proteins and finally boiling in  
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Figure 2.1. Optimisation of lysis protocol. A549 cells were grown in 15cm 
dishes and lysed when confluent. The cells were either trypsinised first, 
pelleted then NP40 added (T1 and T2), scraped off the plate into NP40 (S), 
or lysed directly on the plate with NP40 (P1 and P2), with nuclei scraped off 
subsequently. In the P2 method, after the NP40 fraction was aspirated, the 
nuclei were washed once with NP40 before being scraped off the plate. In T1 
the cells were removed in 1.5mls of PBS, while in T2 5mls of PBS was used. 
In all cases following NP40 lysis, nuclei were pelleted and subsequent lysis 
was performed in Dignam’s buffer C and Laemmli buffer. Reasonable 
fractionation was obtained in all cases, though as less tubulin was carried 
forward into the Dignam C fraction with P2, this method was subsequently 
used for the screen. 
 
Laemmli buffer to extract remaining protein from the non-solubilised pellet. 
Several variations were tested as shown in fig 2.1. A reasonable fractionation 
of proteins was obtained, as exemplified by the cytosolic protein, tubulin, the 
predominantly nuclear transcription factor REST (RE1 silencing transcription 
factor), and actin, which is found in both compartments (fig 2.1). In brief, 
NP40 lysis was performed as outlined above, nuclei were scraped off into 
PBS and spun down in a micro-centrifuge. The insoluble fraction was then 
resuspended in Dignam C buffer (20mM HEPES pH 7.9, 25% glycerol, 
420mM NaCl, 1.5mM MgCl2, 0.2mM EDTA) containing phosphatase and 
protease inhibitors, and incubated at 8oC on a vortex shaker for 40 minutes. 
Samples were then centrifuged at 16,000g for 10 min at 4°C in a bench top 
centrifuge (Eppendorf) and the supernatant recovered as the nuclear fraction. 
The pellet was resuspended in Laemmli buffer (50mM Tris pH 6.8, 2% SDS, 
10% glycerol) and incubated at 110°C for 10 mins with frequent vortexing. 
The samples were again centrifuged at 16,000g for 10 min at 4°C, and the 
supernatant recovered as the Laemmli fraction. NP40, Dignam C and 
Laemmli lysates were processed as described in section 2.2.3. 
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2.1.8.3 Hot lysis 
Cells grown in 6-well plates or 3cm dishes were rinsed twice in warm (37oC) 
PBS before lysis. The PBS was aspirated from the cells which were then 
transferred immediately onto a dry heat block at 110oC, and preheated 100-
150µl Laemmli buffer added. Working quickly to avoid evaporation, the plate 
was immediately scraped with a rubber policeman and the viscous lysate 
aspirated and placed in a preheated screw cap tube. The lysate was then 
incubated for a further 10 minutes at 110°C with frequent vortexing. After 
cooling the lysate was cleared by centrifugation and processed as described 
in section 2.2.3. 
 
2.2 Protein biochemistry 
 
2.2.1 Reagents 
ProtoGel 30% Acrylamide/Bisacrylamide solution (37.5:1 w/v ratio, #EC-890), 
ProtoGel resolving (♯EC-892) and stacking (#EC-893) buffers, were all 
obtained from National Diagnostics (Atlanta, USA). Tween-20 and 
Tetramethylethylenediamine (TEMED, #303853V) were obtained from VWR 
(Lutterworth, UK). Ammonium persulphate (APS) and Ponceau S were 
obtained from Sigma-Aldrich (Poole, UK). Perfect protein (#69079-3) and 
Rainbow markers (#RPN800E) were obtained from Merck Biosciences 
(Darmstadt, Germany) and GE healthcare (Amersham, UK) respectively. The 
latter was diluted 1 in 5 in sample loading buffer prior to use. BioTrace NT 
nitrocellulose membrane (0.2µm pore size) was obtained from VWR 
(Lutterworth, UK). Bovine serum albumin (BSA, #40-00-410) and Marvel 
skimmed milk powder were obtained from First Link (Wolverhampton, UK) 
and Premier Brands (St Albans, UK) respectively.  
 
2.2.2 Antibodies 
Lists of primary and secondary antibodies, including the conditions used for 
immunoblotting, are provided in tables 2.4 and 2.5 respectively. Secondary 
antibodies were used in the same blocking buffer as the primary. During the 
course of the project, two of the 680nm channel secondary antibodies were  
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Target 
Protein 
Species Source (Catalogue No.) Blocking 
Buffer 
Dilution 
(time) 
p110α  Rabbit Cell Signaling (4249) BSA 1:1000 (O/N) 
p110β  Rabbit Cell Signaling (3011) BSA 1:1000 (O/N) 
p110γ  Rabbit Cell Signaling (5405) Marvel 1:1000 (O/N) 
p170 Mouse BD Biosciences (611046) BSA 1:250 (O/N) 
p85α  Mouse BD Biosciences (610045) Marvel  1:2500 (O/N) 
PTEN Mouse Santa Cruz (sc-7974) *Marvel/BSA 1:250 (O/N) 
PDK1 Rabbit Cell Signaling (3062) BSA 1:1000 (O/N) 
PDK1 Rabbit Cell Signaling (5662) BSA 1:1000 (O/N) 
PDK1 Rabbit BD Biosciences (611071) BSA 1:1000 (O/N) 
PDK1 Sheep Dundee (s682) Marvel 1:1000 (O/N) 
pPDK1 Rabbit Cell Signalling (3061) BSA 1:1000 (O/N) 
Akt Rabbit Cell Signaling (9272) BSA 1:1000 (O/N) 
pAkt (S473) Rabbit Cell Signaling  (4060) BSA 1:1000 (O/N) 
pAkt (T308) Rabbit Cell Signaling (9275) BSA 1:1000 (O/N) 
FOXO1 Rabbit Bethyl (A300-397A) Marvel 
(PBST) 
1: 3000 (1hr or 
O/N) 
FOXO3 Rabbit Bethyl (A300-297A) BSA 1: 5000 (O/N) 
FOXO4 Goat Santa Cruz (sc-5221) BSA 1: 200 (O/N) 
mTOR Mouse Cell Signaling (4517) Marvel 1: 1000 (O/N) 
GFP Sheep Ian Prior, University of 
Liverpool 
Marvel 1: 1000 (1hr or 
O/N) 
YOD1 Rabbit Gift from C. Schlieker Marvel 1: 1000 (O/N) 
USP7 Rabbit Abcam (ab4080) Marvel 1: 2000 (O/N) 
USP8 Rabbit Sigma (HA004869) Marvel 1:1000 (O/N) 
USP15 Rabbit Bethyl (A300-923A) Marvel 1: 1000 (O/N) 
USP20 Rabbit Bethyl (A301-189A) BSA 1:1000 (O/N) 
USP20 Rabbit Aviva (ARP59314)  Marvel 
(PBST) 
1:750 (O/N) 
USP33 Mouse Sigma (WH0023032M1) Marvel 1: 1000 (1hr) 
USP47 Rabbit Bethyl (A301-048A) Marvel 1:2000 (O/N) 
ATXN3 Mouse BioLegend (650401) BSA 1:1000 (O/N) 
PSMD14 Rabbit Zymed (38-0200) Marvel 1: 250 (O/N) 
Actin Mouse Abcam (Ab6276) Marvel 1:10000 (1hr) 
Actin Rabbit Sigma (A2066) Marvel 1:2000 (O/N) 	  	  
Table 2.4. Primary antibodies employed in this study (continued 
overleaf).	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Target 
Protein 
Species Source (Catalogue No.) Blocking 
Buffer 
Dilution 
(time) 
α-Tubulin Rabbit  Sigma (T5168) Marvel 1:10000 (O/N) 
PARP p85 Mouse Cell Signaling (9546) Marvel 1: 2000 (O/N) 
REST Rabbit Millipore (07-579) 3% Marvel 
TBS (no 
tween) 
1: 2000 (O/N) 
	  
 
Table 2.4 Primary antibodies employed in this study. Unless otherwise 
indicated incubations were performed in 5% Bovine Serum Albumin TBS 
0.1% tween (BSA) or 5% Marvel TBS 0.1% tween (Marvel).      *PTEN blots 
were blocked in Marvel, and antibody incubations performed in BSA. PBST: 
phosphate buffered saline 0.1% tween. O/N: overnight incubations at 8oC, 
1hr: 1hour incubation at room temperature. 
 
 
Catalogue 
Number 
Antibody Dilution 
926-32213 IRDye 800CW Donkey anti-Rabbit 1:15000 
926-32212 IRDye 800CW Donkey anti-Mouse 1:15000 
926-32214 IRDye 800CW Donkey anti-Goat 1:15000 
926-32223 IRDye 680 Donkey anti-Rabbit 1:15000 
926-32222 IRDye 680 Donkey anti-Mouse 1:15000 
926-32224 IRDye 680 Donkey anti-Goat 1:15000 
926-68023 IRDye 680LT Donkey anti-Rabbit 1:20000 
926-68020 IRDye 680LT Donkey anti-Mouse 1:20000 
 
Table 2.5 Secondary antibodies employed in this study. All secondary 
antibodies were obtained from LiCor Biosciences (Nebraska, USA).  
 
replaced with a newer version (designated LT), which were used at a more 
dilute final concentration (table 2.5). 
 
2.2.3 Protein assay and sample preparation 
All protein assays were performed using a bicinchoninic acid (BCA) protein 
assay kit (#23225, Pierce, UK) according to the manufacturer’s instructions, 
using a bovine serum albumin (BSA) standard. Absorbance was read using a 
MultiSkan Spectrum plate reader (Thermo Scientific, Massachusetts, USA).  
 
Following the protein assay, samples for immunoblotting were adjusted to 
equal concentrations and loading buffer added. 5X loading buffer containing 
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15% SDS (w/v), 312.5mM Tris-HCl pH 6.8, 50% glycerol (w/v), and 16% 
βmercaptoethanol, was added to either NP40 or Dignam C lysates. A second 
loading buffer was added to Laemmli lysates. This was prepared at a 10X 
concentration and contained 1M dithiothreitol (DTT) and 1% bromophenol 
blue. Samples were then boiled for 10 minutes at 98oC prior to storage at -
20oC. 
 
2.2.4 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
SDS-PAGE was performed using either Mini Gels poured using a BioRad 
Mini-Protean® 3 system (California, USA) as per the manufacturer’s 
instructions, or larger gels for the immunoblotting screens, which were 
prepared using a FlowGen Flow200 system obtained from Scientific 
Laboratory Supplies (SLS, Nottingham, UK). The percentage concentration 
of acrylamide used was determined by the target protein molecular weight. 
Each gel was made up of a resolving (table 2.6), and a stacking (table 2.7) 
component. Quantities given here are for a single 1.5mm mini gel, quantities 
for larger gels were scaled up as required. Alternatively precast NuPAGE 
Bis-Tris 4-12% gradient gels (#NP0316BOX, Invitrogen) were used. 
 
Equal amounts of each sample were loaded, along with molecular weight 
markers (5µl each of Perfect Protein and diluted Rainbow Marker). For the 
immunoblotting screen (chapter 3), gels with 36 wells were made. Each gel 
was loaded with twenty-three sample lysates flanked by mock and non-
targeting siRNA controls. Perfect Protein and Rainbow Markers were run 
alongside the samples. Four gels were required to run all 92 samples. 
MiniGels were run at 200V for approximately 40-60 minutes, while FlowGen 
gels were run for 30 min at 90V followed by 90 min at 140V. Both types of 
gels were run in electrophoresis buffer containing 50mM TrisHCl, 01% SDS 
and 38mM glycine. NuPAGE gels were run according to manufacturers 
instructions in NuPAGE MOPS buffer containing NuPAGE antioxidant at 
200V for an hour in an CCell SureLock Mini-Cell system (Invitrogen). 
 
 
	   48	  
 Percentage Acrylamide 
Constituent 8% 10% 12% 
ProtoGel (ml) 5.3 6.7 8 
Resolving Buffer (ml) 5.2 5.2 5.2 
Water (ml) 9.2 7.9 6.6 
10% APS (µl) 150 150 150 
TEMED (µl) 15 15 15 
 
Table 2.6. Resolving Gel Constituents. 
 
ProtoGel (ml) 1.3 
Stacking Buffer (ml) 2.5 
Water (ml) 6.1 
10% APS (µl) 50 
TEMED (µl) 10 
 
Table 2.7. 4% stacking gel 
 
2.2.5 Immunoblotting protocol 
Following SDS-PAGE, protein was transferred onto nitrocellulose using a 
Genie blotter apparatus (Idea Scientific, Minneapolis, USA) with a fixed 
voltage of 25V over 1hour 15min. A 25mM tris-glycine, 20% Methanol 
transfer buffer was employed. Transfer and estimation of loading was 
assessed by Ponceau-S staining. Blots were then blocked using either 5% 
marvel or 5% BSA in TBS (20mM Tris base, 137 mM NaCl, pH 7.6) 0.1% 
Tween-20 for an hour.  Primary antibody was added in the same blocking 
buffer and the blots were incubated on a rocker for either an hour at room 
temperature or overnight at 4oC. Concentrations and conditions for each 
antibody are described in section 2.2.2. Blots were washed three times for 5 
minutes each in TBS 0.1%T before addition of appropriate secondary 
antibody (table 2.5), which was again diluted in the same blocking buffer. 
After a one-hour incubation, the blots were washed twice in TBST 0.1%T and 
once in TBS, each time for 5 minutes 
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2.2.6 Signal detection and quantification 
An Odyssey infrared scanner (LiCor, Nebraska, USA) was employed to 
detect secondary antibodies. Two-channel detection (800nm and 700nm) 
allowed the simultaneous assay of two secondary antibodies coupled to 
alternative fluorophores. Quantification was performed using Odyssey 
software. A box was drawn around each band of interest, and the integrated 
intensity of the signal within the box calculated (counts/mm2). The signal was 
normalised to background, which was determined as the median value of 
pixels immediately above and below each band. 
 
2.3 Molecular biology 
 
2.3.1 Reagents 
Reagents for reverse transcription and quantitative reverse transcription 
polymerase chain reaction (QPCR) were acquired from Promega (Madison, 
USA) and BioRad (California, USA) unless otherwise stated. All primers were 
purchased from Eurofins MWG Operon (Ebersberg, Germany). 
 
2.3.2 Agarose gel electrophoresis 
Agarose gels (between 1.2% and 2% agarose) were prepared by adding 
electrophoresis grade agarose to 0.5X TBE buffer (45mM Tris-borate, 1mM 
EDTA). The mixture was heated in a microwave until all the agarose had 
dissolved. Ethidium bromide was then added to a final concentration of 
0.5µg/ml, the gel poured and allowed to set at room temperature. DNA or 
RNA samples were made up in 6X sample buffer (30% (v/v) glycerol, 0.25% 
(w/v) bromophenol blue, 0.25 % (w/v) xylene cyanol FF), loaded onto the gel 
and resolved in a horizontal electrophoresis tank containing 0.5X TBE buffer 
run at 100V for approximately an hour. DNA or RNA bands were visualised 
using an GeneFlash UV transilluminator (Syngene, Cambridge,UK). 
 
2.3.3 Primer design and validation 
Unless otherwise stated, primers were designed in-house, aiming for the 
following: a 20mer with approximately 50% GC content, a melting 
temperature (Tm) of approximately 60oC, a GC clamp of 1-2 nucleotides at 
	   50	  
the 3’ end and an amplicon of 80-250 spanning an exon boundary. The 
primer Tm’s and the likelihood of primer dimers or secondary structure 
formation were checked using NetPrimer (www.premierbiosoft.com/netprimer 
/index.html).  
 
Initial assessment of Primer pairs was performed using an endpoint PCR. 2µl 
of cDNA (which was prepared as described in section 2.3.5), 1.5µl each of 
forward and reverse primer (both at 100µM concentration) and 15µl of 
Hotstar Taq Mastermix (Qiagen) were made up to 30µl in nuclease-free 
sterile distilled water. PCR was performed in a ThermoHybaid Px2 
thermocycler (Thermo Scientific) using an activating step (95oC for 5 
minutes) followed by 40 cycles at the following temperatures: 94oC for 30s, 
60oC for 30s, 72oC for 30s. The PCR product was assessed by 
electrophoresis on a 2% agarose gel as described in section 2.3.2. Primer 
pairs were judged satisfactory if there was a single PCR product at the 
expected molecular weight, and there were minimal primer dimers visible. 
Primer pairs were also validated by QPCR (section 2.3.6), where melt curves 
were assessed for the presence of primer dimers or secondary products. A 
list of QPCR primers is given in table 2.8. 
 
2.3.4 RNA extraction 
Cell lysis and extraction of RNA was performed using an RNeasy Mini kit and 
QIAshredder columns (Qiagen) as per the manufacturer’s instructions. An in-
column DNAse treatment step was included for samples in which QPCR for 
PTEN or PTENP1 was to be performed. Each primer pair amplifies across a 
single exon and the primers therefore also detect genomic PTEN and 
PTENP1 respectively. The DNAse step was therefore included to remove all 
genomic contamination from the RNA. The RNA concentration and purity of 
each sample was assayed using a ND-1000 NanoDrop spectrophotometer 
(Thermo Scientific, Massachusetts, USA). The ratio of absorbance at 260nm 
to that at 280nm was assessed, and a ratio of between 1.8 and 2.0 was 
considered satisfactory. RNA integrity was also assessed by electrophoresis 
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Target Primers (Tm in oC) Amplicon 
(bp) 
Actin ACTBF: CACCTTCTACAATGAGCTGCGTGTG (64.6) 
ACTBR: ATAGCACAGCCTGGATAGCAACGTAC (64.8) 
158 
PDK1 PDPK1for: AAGCAGGCTGGCGGAAACC (61.0) 
PDPK1rev: AGAACTTTGTTGACAGGATCC (57.3) 
142 
PTEN¶ PTEN_FW: GTTTACCGGCAGCATCAAAT (55.3) 
PTEN_RV: CCCCCACTTTAGTGCACAGT (59.4) 
197 
PTENP1¶ PTENP1_FW: TCAGAACATGGCATACACCAA (55.9) 
PTENP1_RV: TGATGACGTCCGATTTTTCA (53.2) 
152 
TNFAIP3 TNFAIP3FOR: TGCCCAGGAATGCTACAGATAC (60.3) 
TNFAIP3REV: TGGACGGGGATTTCTATCACC (59.8) 
227 
PRPF8 PRPF8FOR: TATGACCACCAGCCGTTGAG (59.4) 
PRPF8REV: CCATATTGAGTGCCTTGGACG (59.8) 
186 
OTUD1 OTUD1For: CCGACCATCTCGACCACTTC (61.4) 
OTUD1Rev: GTGTCCGTTACTGAGCCAACTG (62.1) 
229 
ATXN3* RT_ATXN3_F1: GTATGCAAGGTAGTTCCAGAAAC (58.9) 
RT_ATXN3_R1: TGTTGCTGCTTTTGCTGCTGT (57.9) 
126 
ATXN3L ATXN3L_FW: GAACTAAGCCGCCAAGAAACC (59.8) 
ATXN3L-RV: GCTTCTGTTCCTGCTGATGC (59.4) 
186 
JOSD1 JOSD1_FW: AAGATGCCCGAGTGGATTGG (59.4) 
JOSD1_RV: TCCTCCAACTCTGATGAGCCTC (62.1) 
126 
USP20 USP20_FW: ACCTTTGCCCTCACCTTGAC (59.4) 
USP20_RV: TGAATGGTGCTGTGGTCAGC (59.4) 
174 
SCG3 SCG3for: GATCCAGATGGTCTTCATCAAC (58.4) 
SCG3rev: CTGATTCTCAGTCCAGCTTGTG (60.3) 
266 
 
Table 2.8. QPCR primers used in this screen. All primers are oriented in 5’ 
to 3’ direction. ¶Primers designed by Poliseno et al. [375]. *ATXN3 primers 
were used at half the standard concentration, to reduce primer dimer 
formation.  
 
on a 1.2% agarose gel. This was prepared as described in section 2.3, with 
added precautions to avoid RNAse contamination. These included cleaning 
the equipment with RNaseZAP (Sigma-Aldrich) and the use of 
diethylpyrocarbonate (DEPC) treated water to prepare buffers. RNA samples 
were made up in 6X sample buffer, heated to 80oC for 2 minutes, loaded 
onto the gel and resolved as described in section 2.3. Degraded RNA was 
suggested by the presence of a low molecular weight smear, while RNA of 
good quality was indicated by the presence of two clear bands representing 
28S and 18S ribosomal RNA at a ratio of approximately 2:1. 
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2.3.5 Reverse transcription 
For each sample, a reaction mix containing 1µg RNA and 0.5µg of oligo dT 
primer made up to 11 µl with nuclease free distilled water was incubated at 
70oC for 5 minutes, following which tubes were immediately chilled on ice. To 
each reaction mix, the following was added: 4µl of 5x reverse transcription 
buffer (MBI Fermentas, NY, USA), 2µl PCR nucleotide mix (containing dATP, 
dCTP, DGTP and dTTP each at 10mM in water, Promega), 0.5µl RNasin and 
1.5µl of Nuclease free ddH2O. The reaction mix was incubated at 37oC for 5 
minutes, then held at 37oC while 1µl of M-MuLV reverse transcriptase (MBI 
Fermentas, NY, USA) was added. This was followed by incubation at 42°C 
for 1 hr for synthesis of complementary DNA (cDNA), and then denaturation 
at 70°C for 10 min. Samples (cDNA) were immediately removed to ice for 5 
minutes, then diluted to 100µl with nuclease free distilled water and stored at 
-20oC. An RT- control was included in each reverse transcription experiment. 
This was generated as described above, however the reverse transcription 
enzyme was not added to the reaction mix. 
 
2.3.6 Quantitative RT Polymerase Chain Reaction (QPCR) 
This was performed using an IQ5 real time PCR detection system and SYBR 
green supermix (BioRad). A total reaction volume of 15µl was made up for 
each sample, consisting of 1µl of cDNA (prepared as described in section 
2.3.3), 0.25µl each of forward and reverse primers (at 20µM) and 7.5µl of iQ 
SYBR green supermix (2X), made up with nuclease free distilled water. In 
the case of ATXN3, primers were used at half the above concentration to 
minimise primer dimer formation. Samples were arrayed on a 96 well PCR 
plate (Biorad #), and sealed with a plastic cover (Biorad #). Each QPCR 
experiment included blank (no template) and RT- (section 2.3.5) controls. An 
initial enzyme activation/denaturation incubation at 95°C for 3 min was 
performed followed by 40 cycles using a 2-step PCR protocol 
(denature/anneal/read) for 30 seconds at each temperature. Melt curves 
were read at 1°C intervals from approximately 55 to 95°C to check for 
amplification of a single product. Data were analysed using BioRad software, 
and a cycle threshold (Ct) set in exponential amplification phase. Ct values 
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were determined for each sample and compared to the reference gene 
(actin) using the 2-ΔΔCt method [376]. 
 
2.4 Live cell imaging and analysis 
 
2.4.1 Reagents 
Cells were cultured in standard plastic 96 well plates (Corning, #3595). 
During imaging, cells were maintained in Hanks buffered saline solution 
(HBSS). 10X HBSS (#14065-049) was obtained from Gibco, diluted to 1X 
HBSS with sterile, autoclaved water and supplemented with 10mM HEPES, 
2mM glutamine and 1mM pyruvate. DRAQ5 and DRAQ7 were obtained from 
Biostatus (Shepshed, UK). Wortmannin, LY294002, PI-103 and TGX-221 
were obtained from Calbiochem (Merck, Darmstadt, Germany). GDC-0941 
was obtained from Axon Medchem (Groningen, The Netherlands) while MK-
2206 was obtained from Selleck Chemicals (Houston, USA). HBX90,397 and 
HBX90,659 were a gift from Hybrigenics (Paris, France). Ratjadone A was 
obtained from Alexis Biochemicals (Enzo, Exeter, UK). 
 
2.4.2 Translocation screen 
2.4.2.1 Assay Development 
The translocation screen (chapter 4) employed FKHRL1-U2OS cells 
(Thermo-Fisher), which stably express FOXO3-EGFP. In these cells, 
FOXO3-EGFP subcellular localisation reflects PtdIns3-K activity. In the 
presence of PtdIns3-K signalling FOXO3-EGFP is predominantly 
cytoplasmic, while PtdIns3-K inhibition leads to its nuclear translocation. An 
initial experiment to assess the effects of different PtdIns3-K inhibitors was 
carried out. FKHRL1 cells were seeded in a 96 well plate at a density of 
5,000 cells per well, in 200µl full media containing geneticin, and allowed to 
attach overnight.  
 
The following day the cells were washed and the media replaced with phenol 
red free media containing 2.5µM DRAQ5. Following a 15 min incubation, this 
was replaced with 175µl of warm HBSS, and the cells transferred to an  
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Inhibitor Main targets (reported in vitro IC50) Concentrations used 
Wortmannin Non-specific PtdIns3-K inhibitor (2-4nM) 100nM, 200nM 
LY294002 Non-specific PtdIns3-K inhibitor (1.4µM) 10µM, 20µM 
PI-103 p110α (4nM), p110β (8nM), p110δ (>500nM), 
DNA-PK (2nM), mTORC1 (20nM), mTORC2 
(80nM) 
100nM, 200nM 
TGX-221 p110β (5nM), p110δ (100nM), p110α (5µM), 
p110γ (3.5µM) 
100nM, 1µM 
MK-2206 Akt1 (8nM), Akt2 (12nM), Akt3 (65nM) 100nM, 1µM 
 
Table 2.9. PtdIns3-K inhibitors used in this study. Inhibitor stock solutions 
were made up in DMSO, and then added to media to the final concentrations 
listed above. Final DMSO concentrations did not exceed 0.2%. The IC50 
values were obtained from the relevant datasheets. (IC50: half maximal 
inhibitory concentration) 
 
Eclipse Ti-E fluorescence microscope (Nikon, Tokyo, Japan), with heated 
chamber and automated stage. A single position was acquired per well, and 
imaged in both green (EGFP) and far-red (DRAQ5) channels. Each imaging 
position was saved, thus enabling further imaging loops of the same 
positions to be performed. Imaging was performed with the 20X objective. 
NIS Elements software was used for all image acquisition (Nikon) and 2 x 2 
binning was applied. The cells were then returned to the tissue culture hood 
where PtdIns3-K inhibitors (table 2.9) were added to the final concentrations 
indicated. The nuclear export inhibitor (Ratjadone A) was used as a control at 
a final concentration of 5nM or 10nM. The cells were then immediately 
returned to the microscope chamber. Each well was imaged 5 minutes after 
the addition of inhibitor and every 5 minutes thereafter. Focus was 
maintained over the course of the experiment using PFS (Perfect Focus 
System, Nikon). Approximately 90 minutes after addition of the inhibitor, the 
media containing inhibitor was removed and replaced with 1X HBSS. The 
cells were then imaged for a further 60 minutes. 
 
2.4.2.2 Procedure for Translocation screen and deconvolution 
FKHRL1-U2OS cells were transfected with siRNA as described in section 
2.1.3.2. 48 hours after transfection, the media was removed and the cells  
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Fig 2.2. Image segmentation using Volocity version 6. A screenshot is 
shown highlighting the protocol employed to segment images into different 
compartments for further analysis. Objects were identified using automatic 
thresholding, which was then manually adjusted to maximise discrimination. 
The perinuclear torus was defined by dilating the nuclei by 6 iterations 
(pixels), and then subtracting the nuclear compartment from the dilated 
nuclei. (FOXO3-EGFP and DRAQ5 fluorescence was detected in the green 
[FITC] and far-red [CY5] channels respectively). 
 
 
washed prior to the addition of HBSS containing 2.5µM DRAQ5, after which 
the cells were replaced in the incubator for 15 min. The media was then 
replaced with 150µl of fresh warm HBSS and the cells imaged as described 
in section 2.4.2.1. The cells were transferred to a cell culture hood, and PI-
103 added to a final concentration of 100nM, after which the plate was 
immediately replaced and further imaging performed as described in section 
2.4.2.1. 
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2.4.2.3 Image analysis 
Image analysis was performed using Volocity version 6 software 
(PerkinElmer, Massachusetts, USA). In the nuclear translocation screen, this 
allowed segmentation of images into different compartments (fig 2.2) and 
hence quantification of FOXO3-EGFP distribution. Mean FOXO3-EGFP 
fluorescence in each cellular compartment was calculated and corrected for 
background fluorescence by subtraction of the mean FOXO3-EGFP level in 
the background compartment. Accurately outlining the cytoplasm proved 
impossible in certain cases due to changes in cell morphology and low-level 
fluorescence in the cytoplasm, such as occurred following profound nuclear 
translocation (fig 4.1A). In view of this, a perinuclear torus was defined for 
each cell (fig 2.2), and fluorescence within this compartment used to reflect 
cytoplasmic FOXO3-EGFP levels. As shown in fig 4.1, this allowed the 
calculation of a nuclear/cytoplasmic ratio, which reflected FOXO3-EGFP 
translocation in response to PtdIns3-K inhibition. 
 
2.4.3 Live-cell assessment of synthetic lethality 
 
2.4.3.1 Experimental procedure 
Cell culture, transfections and imaging were generally performed as 
described in section 2.4.4, however imaging was performed every hour 
rather than every 5 minutes. While initial experiments used morphological 
changes to identify dead or dying cells, latterly DRAQ7 was used for this 
purpose. Here, the media was changed to HBSS containing 3µM DRAQ7 
and PtdIns3-K inhibitor at the desired concentration. The cells were then 
placed in the microscope chamber and imaged every hour for the duration of 
the experiment. At the end of the experiment, the media was changed to 
fresh HBSS containing 5µM DRAQ5, the cells incubated for 15-20 minutes 
and imaged a final time. 
 
Interaction between PtdIns3-K inhibition and the Hybrigenics inhibitors was 
performed as follows. A 96 well plate was seeded with 8000 cells per well in 
full media and incubated overnight. The media was then replaced with HBSS  
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Fig 2.3 Quantification of cell death using changes in morphology and 
fluorescence. Changes in cell morphology (rounding up and associated 
increase in intensity of both FOXO3-EGFP and DRAQ5 fluorescence) 
indicated probable cell death (section 5.2). Counting of these cells was 
facilitated by Volocity software. The cells were identified by thresholding in 
both channels, in each case thresholds were manually set to maximise 
discrimination between live and dead cells. Cell populations 1 and 2 were 
identified in the far-red (Cy5) and green (FITC) channels respectively. 
Population 3 was defined as the intersection between populations 1 and 2 
and contained cells which exhibited intense fluorescence in both 
compartments; these were counted and exported. Cell fragments were 
excluded by size (<50µm2). As indicated by the arrowheads, it was not 
always possible to identify all dead/dying cells by thresholding. Additionally, 
some cells that had died earlier in the experiment began to fragment leading 
to loss of fluorescence (indicated by an asterisk), and these cells were also 
difficult to identify using Volocity. Both latter cell populations were therefore 
manually counted and added to the Volocity count. 
 
 
containing 3µM DRAQ7 and replaced in the incubator. Meanwhile serial 
dilutions of PI-103 and the Hybrigenics inhibitors were prepared in warm 
HBSS. These were then added to each well such that each row had a 
different concentration of PI-103, and each column a different concentration 
of HBX90,397 or HBX90,659. The cells were then imaged as described 
above. 
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2.4.3.2 Quantification of cell death 
In section 5.2, dead or dying cells were identified as brightly fluorescent, 
rounded up cells. These were identified in Volocity using both the green 
(FITC) and far-red (Cy5) channels, using fluorescence thresholds that were 
manually adjusted to only include cells that exhibited the above changes (fig 
2.3). The number of cells identified in this manner could then be counted 
using Volocity. However, it was not possible to set thresholds that identified 
all dead/dying cells, and any such cells that were not identified by Volocity, 
were counted manually and added to the Volocity count (fig 2.3). The number 
of dead cells was then divided by the total number of cells, which was 
obtained by counting the number of nuclei (in the far-red channel), to provide 
an estimate of cell death. This method was however observer dependent, 
and also included a small population of dividing cells which underwent similar 
morphological changes. As described in sections 2.4.3.1 and 5.3, latter 
experiments used a different method to enumerate cell death. DRAQ7 is a 
far-red fluorescent dye that is only taken up by dead or dying cells. DRAQ7 
positive cells were therefore counted using Volocity and expressed as a 
percentage of the total number of cells. The latter was quantified from the 
number of cells taking up DRAQ5, which was added at the end of the 
experiment, as it emits light of a similar wavelength to DRAQ7.  
 
2.5 Data analysis 
 
Data sets were all plotted and analysed in Microsoft Excel 2008. All error 
bars reflect standard deviation. Where reported statistical tests utilised a two 
tailed student’s t-test. In the translocation screen, the rate of nuclear 
translocation was estimated using the slope of the linear regression of the 
nuclear/cytoplasmic ratio between timepoints 2 and 5. This utilised Excel’s 
slope function, and is defined as the ‘vertical distance divided by the 
horizontal distance between any two points on the line’ 	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Chapter 3 
 
Identifying DUB regulators of the abundance of PtdIns3-K pathway 
components. 
 
3.1 Introduction 
 
The phosphatidylinositol 3-kinase (PtdIns3-K) signalling pathway is subject to 
multiple regulatory mechanisms including phosphorylation, acetylation and 
ubiquitylation (sections 1.5.2 and 1.5.4). The latter is an extremely versatile 
post-translational modification, and recent work has begun to uncover the 
multiple functions that ubiquitylation plays in PtdIns3-K signalling, including 
examples of regulation of protein stability, localisation and activity (section 
1.5.4). Ubiquitin’s ability to regulate multiple aspects of protein function is 
enabled through differing chain structures [377], and through the activity of 
deubiquitylating enzymes (DUBs), which provide reversibility ([80] and 
section 1.3). However, the role of DUBs in the PtdIns3-K pathway remains 
poorly defined (section 1.5.4).  
 
The principal aim of this project was to employ a systematic approach to the 
identification of DUBs involved in the PtdIns3-K pathway. Two main 
strategies were employed, here the first of these is described; utilising 
immunoblotting to assay the protein expression levels of components of the 
PtdIns3-K pathway following a DUB siRNA screen.  
 
As discussed in section 1.5, several components of the PtdIns3-K pathway 
are known to be degraded through the ubiquitin-proteasome system (UPS), 
and it is conceivable that deubiquitylation, through the action of DUBs, may 
rescue proteins thus destined for degradation. Depletion of a DUB acting in 
this manner would lead to increased degradation of its substrate, with a 
concomitant decrease in its protein level in the cell. This in turn can be 
detected by immunoblotting, which I have therefore employed as a readout in 
these screens. Notably, in addition to directly removing ubiquitin chains  
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Fig 3.1. DUBs regulate multiple steps in protein synthesis and 
degradation. Protein abundance is determined by a balance between 
synthesis and degradation, each of which involves several steps. An 
example of a DUB involved in each step is given in parentheses and these 
are referred to in references [199, 209, 378-381]. (The green ovals depict 
K48 polyubiquitin chains, yellow and green mRNA segments respect introns 
and exons respectively.) 
 
from proteins and thus leading to their stabilisation, DUBs may also have the 
opposite effect on proteins through stabilisation of the cognate E3 ligase (fig 
3.1). The abundance of a protein is moreover dependant on several other 
factors, such as transcription and translation, which may equally be 
influenced by DUB depletion (fig 3.1). DUBs are also involved in the 
regulation of lysosomal degradation [382], and have recently been implicated 
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in autophagy [383]. Immunoblotting not only will reflect any of these 
mechanisms that affect protein levels but also has the potential advantage of 
detecting either mono- or polyubiquitylated forms of the proteins, which may 
indicate non-proteolytic regulation. Previous DUB screens have successfully 
utilised immunoblotting; an example being the identification of USP1 in the 
regulation of FANCD2, where USP1 depletion stabilised a monoubiquitylated 
form of FANCD2 [384]. 
 
3.2 DUB screening strategy and workflow 
 
In this chapter I set out to screen for DUB regulators of the abundance of 
fourteen components of the PtdIns3-K pathway, namely p110α, p110β, 
p110γ, p85α, p170, PTEN, Akt1, Akt2, Akt3, mTOR, PDK1, FOXO1, FOXO3 
and FOXO4 (fig 3.2, section 1.5.2). In order to generate sufficient protein 
lysate to immunoblot for each of these targets, a colleague (Han Liu) and I 
utilised a DUB siRNA library consisting of pools of siRNA oligonucleotides 
directed at each of 92 DUB targets (section 2.1.1 and Appendix A) to 
generate a library of lysates each derived from cells depleted of a different 
DUB (fig 3.3). Both non-targeting siRNA and mock-transfected controls were 
included. The work was performed in A549 cells grown under constant full-
serum conditions. Serial lysis buffers were employed to provide crude 
fractionation of lysate (section 2.1.4.2). The lysates from each fraction were 
arrayed in multiple storage plates, each consisting of lysates from every DUB 
depletion and control. These plates were then stored and used when 
required for this and other projects (fig 3.3).  
 
DUB RNAi libraries have previously been employed in the identification of 
DUB regulators of several different cellular processes in our laboratory and 
elsewhere [125, 192, 384-386]. This strategy has several potential 
advantages over a genome wide approach. These are partly practical, 
concerning the amount of reagents and manpower required. In addition some 
readouts would be difficult to use in a genome wide screen. For example, it 
would be impractical to perform immunoblotting for several different targets 
on all the lysates from  
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Fig 3.2. Components of the PtdIns3-K pathway selected for DUB siRNA 
screening. DUB siRNA screens were performed on a subset of components, 
which were selected on the basis of their involvement in malignancy. Where 
multiple isoforms of proteins exist, those chosen for investigation are shown 
next to the protein.	   Catalytic and regulatory PtdIns3-K subunits are shown on 
the left and right respectively. 
 
 
a genome wide screen. A focused screen also allows a greater proportion of 
hits to be validated, and harnesses local expertise and availability of 
reagents relating to a specific area of research, in this case the DUBs. 
Furthermore, this approach promotes experience relating to a specific RNAi 
library, and an appreciation of the overall knockdown efficiency and the 
likelihood of both false-positives and false negatives. A potential 
disadvantage on the other hand, relates to as yet unidentified DUBs, which 
would be covered in a whole genome screen.  
 
Off-target effects are a frequent source of false-positive results in siRNA 
screens, and may be controlled for by use of either redundancy or rescue 
experiments [387, 388]. In this study, hits from the screens were validated by 
deconvolution of the oligonucleotide pool (fig 3.3iv). This involved 
transfecting with each of the four, redundant, siRNA oligonucleotides from 
the pool separately; recapitulation of the effect observed with the pool by  
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Fig 3.3. Immunoblot screening for DUB modulators of the PtdIns3-K 
pathway. i. A549 cells were seeded in 15cm dishes and either mock-
transfected or transfected with siRNA directed at 92 DUBs or non-targeting 
siRNA (Qiagen). ii. Following a 72-hour incubation, the cells were lysed 
using a sequence of three buffers leading to crude fractionation of lysate.    
iii. For each fraction, the protein concentration of lysates was assayed, 
adjusted to a set same concentration, loading buffer added and the lysate 
boiled for 10 minutes. The lysates were arrayed on 96 well plates, with each 
plate containing extracts for the entire library in aliquots of equal volume and 
concentration.  iv. Lysates were then run on SDS-PAGE gels and 
immunoblotted for proteins of interest, and reference protein. Detection was 
performed using an infrared scanner (Odyssey, LiCor), and quantification of 
bands (integrated intensity) was performed using Odyssey software. Initial 
validation of hits was performed through deconvolution of the oligonucleotide 
pool. 
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multiple individual oligonucleotides increases the likelihood the effect is on-
target [388]. Knockdown with two or more oligonucleotides resulting in a 
change of protein level by 20% or more, in the same direction as the screen, 
was taken as confirmatory. Knockdown with the siRNA pool was usually 
performed alongside the single siRNA transfections to confirm the effect 
seen in the screen. 
 
A complementary method involved the use of endoribonuclease-prepared 
short interfering RNA (esiRNA). This is an alternate method of RNAi, which 
has been developed relatively recently and which potentially reduces off-
target effects [389]. JiaLih Wong in our laboratory has recently generated an 
esiRNA library against the majority of DUBs, a subset of which have been 
used for secondary validation in this study. 
 
 
3.3 Quality control of DUB lysate library 
 
Three main measures were employed for quality control. Firstly, examination 
of cells by light microscopy was performed prior to cell lysis. Depletion of 
most of the DUBs was associated with little visible toxicity. This was 
evidenced by an estimated confluency of between 70 and 90%, few floating 
cells in the media and healthy looking cells. Notable exceptions included 
USP1 and USP11 depletion, which both showed evidence of cellular toxicity. 
A reduced cell confluence of 40-50% with increased numbers of floating cells 
and an increased proportion of cells with granular/foamy cytoplasm was 
observed for both. Depletion of several other DUBs (USP42, YOD1, 
OTUD7B, USP51 and PRPF8) was also associated with cell toxicity, albeit to 
a lesser degree than USP1 and USP11.  
 
The microscopy findings were supported by an assay of the protein 
concentration of lysates (fig 3.4). This reflects the protein yield following cell 
lysis and is a crude surrogate measure for cell number. The median protein 
concentration was 2.6 µg/µl, with an interquartile range of 2.4 – 3.0 µg/µl  
	   65	  
 
 
Fig 3.4. Protein concentration of DUB lysate library. A549 cells were 
transfected with siRNA from a library consisting of pools of oligonucleotides 
against 92 DUB targets, incubated for 72 hours and lysed as described in Fig 
3.3. The protein concentration of each lysate was assayed; here the 
concentration of the NP40 fraction is shown ranked from low to high. The five 
top and bottom ranked DUBs or controls are indicated. DUBs whose 
depletion resulted in cellular toxicity as evidenced by light microscopic 
changes are highlighted in red. Mock controls are circled in blue. siC1 and 
siC2: technical replicates transfected with non-targeting siRNA control. The 
horizontal line represents the median, and the two dotted lines the 1st and 3rd 
quartiles. (n=1). 
 
 
indicating relatively little variability. However, the six control lysates (4 mock-
transfections and 2 with a non-targeting siRNA) are all located above the 
median (fig 3.4). This suggests that depletion of many DUBs may be 
detrimental to cell viability and/or proliferation. While this is likely to be subtle 
for the majority, depletion of a small subset of DUBs resulted in particularly 
low protein concentrations (fig 3.4).  
 
A third measure employed for quality control of the lysate library was the 
assessment of knockdown efficiency for selected DUBs (fig 3.5). USP15 
depletion resulted in an 82% reduction in USP15 protein level (fig 3.5i,ii). 
Similarly a knockdown efficiency of 72%, 94% and 79% was obtained for 
USP33, USP47 and PSMD14 respectively (fig 3.5iii,iv). Quantification of the 
USP15 blots (fig 3.5ii) also indicated extensive variability in USP15 at the 
protein level in samples depleted of other DUBs (+/- 60% from the mock). 
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This is likely to be due in part to experimental variability as well as cellular 
regulatory and compensatory mechanisms. As discussed in section 1.3.2, 
USP15 is closely related to several other members of the USP family of 
DUBs (fig 1.3). Despite these similarities, siRNA oligonucleotides against 
USP11 or USP19 did not significantly reduce USP15 protein levels (fig 
3.5Ai,ii), indicating that the oligonucleotides pools are not cross-reactive. 
While USP4 depletion appeared to increase USP15 protein level on 
quantification (fig 3.5ii), this was not visually compelling (fig 3.5i) and is likely 
to represent experimental variation. On the other hand, depletion of the 
USP33 paralogue, USP20, strongly upregulated USP33 (fig 3.5iii). This has 
previously been described in our laboratory and is likely to represent an 
example of paralogue compensation [390]. This will be discussed further in 
chapter 6. 
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Fig 3.5. Validation of knockdown efficiency in the DUB lysate library. 
Equal amounts of NP40 protein lysates from the DUB siRNA screen (fig 3.3) 
were run on SDS-PAGE gels and immunoblotted for the indicated proteins. 
Imaging and quantification was performed using an Odyssey (LiCor) infrared 
scanner and software. i. Immunoblotting for USP15; one of four blots is 
shown. ii. Quantification of USP15 screen. The USP15 signal for each DUB 
knockdown was normalised to actin then ranked relative to the mock. iii, iv, 
v. Immunoblotting for USP33, USP47 and PSMD14 respectively using 
relevant screen lysates.  The percentage knockdown compared to the mock 
is shown under each blot. Upregulation of USP33 by USP20 depletion is also 
indicated. (siC- non-targeting siRNA control) 
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3.4 PTEN abundance is regulated by several deubiquitylases. 
 
Through its function as a lipid phosphatase, PTEN inactivates 
phosphatidylinositol 3,4,5 triphosphate (PtdInsP3), thus acting as a negative 
regulator of the PtdIns3-K pathway (section 1.5.2). PTEN may be either 
polyubiquitylated or monoubiquitylated, leading to its degradation through the 
proteasome [335, 360] or nuclear localisation [57] respectively (section 
1.5.4). The latter is essential for full tumour suppressor function of PTEN [57, 
391]. The E3 ligases WWP2, NEDD4.1 and XIAP have been implicated in 
the ubiquitylation of PTEN [335, 336, 359, 360], while USP7 (also known as 
HAUSP) has been shown to cleave monoubiquitylated PTEN thus regulating 
its cellular localisation in response to oxidative stress [203]. No other DUBs 
regulating PTEN have been described thus far.  
 
Identifying DUBs involved in regulating this vital tumour suppressor would be 
of significant scientific interest, and moreover would have potential relevance 
in clinical practice, particularly as post-transcriptional modification of PTEN 
appears to be a common mechanism by which malignancies lose PTEN 
function [335, 336] (section 1.5.3). I therefore set out to identify potential 
DUB regulators of PTEN protein level using lysates from the DUB lysate 
library.  
 
Immunoblotting of NP40 lysates was performed for PTEN and blots are 
shown in fig 3.6. Marked changes in the level of PTEN can be seen for 
knockdown of several DUBs, most notably UCHL3, USP20 and YOD1 which 
decrease PTEN abundance. In contrast, OTUD4 and STAMBPL1 depletion 
increased PTEN levels. The integrated intensity of infrared fluorescence for 
each band was quantified using Odyssey (LiCor) software. For each sample, 
the PTEN signal was normalised to that of actin. A second normalization was 
applied to allow comparison of data from the four different blots. Two 
different methods were employed, firstly each band was normalised to the 
mock control from the same blot (fig 3.7i), in the second the median of the 
dataset from each blot was used for normalisation (fig 3.7ii). Normalising to a 
single value (e.g. the PTEN level in the mock control) can readily shift the  
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Fig 3.6. An immunoblot screen for DUB regulators of PTEN abundance. 
NP40 lysates from the DUB screen (fig 3.3) were run on four SDS-PAGE 
gels. Each blot included a mock-transfected and a non-targeting siRNA (siC) 
control. The blots were probed for PTEN and actin and imaged by infrared 
scanner (Odyssey, LiCor). Candidate DUBs selected for deconvolution are 
highlighted in red (upregulated) or blue (downregulated). (n=1) 
 
entire dataset up or down, if the mock is abnormally low or high. This is seen 
in fig 3.7i, and the left hand panel of fig 3.7C, where a low value for PTEN in 
the mock controls has shifted the dataset for each blot upwards. In the 
screen, the mock and non-targeting controls were run on the extreme left and 
right respectively, of each gel. The low values for the mock control in each 
case may therefore reflect an edge effect, due to uneven protein transfer. 
Normalising to the median relative PTEN level for each blot results  
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Fig 3.7. Identification of candidate DUBs from a screen for modulators 
of PTEN abundance. Immunoblotting for PTEN and actin was performed 
and is shown in fig 3.6. A. PTEN bands were quantified (Odyssey, LiCor), 
normalised to actin and then to the mock control of each blot. B. Alternatively 
the second normalisation was performed to the median PTEN/Actin of each 
blot. The four different colours indicate the different blots of origin (red- blot 1, 
green- blot 2, purple- blot 3, yellow- blot 4). C. A comparison of the data 
normalised in these two different manners is plotted separately for each blot. 
The 5 top and bottom ranked hits are highlighted in each panel. (n=1). 
 
in a more symmetrical distribution (fig 3.7ii,iii). Although this appears to be 
biased towards blot 4, subsequent deconvolution was successful for three 
candidates from this blot (fig 3.8). Normalisation to the blot median has been 
employed as the primary approach in the quantification of subsequent 
screens. 
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Fig 3.8. Deconvolution supports a role for several DUBs in the 
regulation of PTEN. i,ii. A 72-hour siRNA knockdown of DUBs identified in 
the PTEN screen was performed in A549 cells using individual 
oligonucleotides from each pool (designated A to D). Equal amounts of lysate 
for each sample were immunoblotted for PTEN and actin. siRNA 
transfections for the first set of DUBs (i) was performed using 20nM siRNA 
and oligofectamine (Invitrogen), while in the second (ii), 10nM siRNA and 
RNAiMax (Invitrogen) were employed. iii. Quantification of PTEN signal was 
performed, which was then normalised to the actin signal and compared to 
the mock. For each target, oligonucleotides A-D are depicted from left to 
right, pools (P) where included are shown in red. Targets to the left of the 
dotted line resulted in downregulation of PTEN in the screen, those on the 
right upregulated PTEN. (Detection and quantification performed on Odyssey 
infra-red scanner [LiCor]. siC- non-targeting siRNA control).  
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In all screens, the top and bottom 5 hits were picked for further validation, 
representing approximately 10% of the dataset. However, if one of the 
controls fell within the top or bottom 5 (for example in fig 3.7ii), then only four 
candidates were followed up. In this screen for DUB regulators of PTEN, the 
hits are thus STAMBPL1, OTUD4, JOSD1 (Josephin domain containing 1), 
ATXN3, and USP2 whose knockdown leads to an increase in PTEN level 
and UCHL3, USP20, USPL1, and YOD1 whose knockdown had the opposite 
effect. Deconvolution of these hits is shown in figure 3.8. USP7, which was 
9th from the top of the dataset using the median of the blot for normalisation, 
and 4th using the mock, was also included due to its known role in 
deubiquitylation of PTEN. Deconvolution of ATXN3L, which was 7th from the 
top, and which shares extensive sequence homology with ATXN3, was also 
performed.  
 
A summary of the deconvolution is provided in table 1. All candidates (with 
the exception of ATXN3L) were also depleted using esiRNA (fig 3.9). This 
was performed as a second validation step. However, while the experiment 
supported the findings of the deconvolution for ATXN3 and USP20, the 
degree of change in PTEN protein level was less marked, and esiRNA 
depletion of the other candidates did not significantly alter PTEN levels (fig 
3.9). This may partly reflect reduced knockdown efficiencies for the esiRNA, 
however this was not investigated. 
 
ATXN3, ATXN3L and JOSD1 were all successfully deconvoluted. 
Interestingly, while two siRNA oligonucleotides against USP20 resulted in 
downregulation of USP20 protein levels, the other two had the opposite 
effect. Further validation of ATXN3, ATXN3L, JOSD1 and USP20 will be 
discussed in chapter 6.  
 
Depletion of STAMBPL1 (also known as AMSHLP) by two out of the four 
siRNA oligonucleotides resulted in upregulation of PTEN. However one of 
the two oligonucleotides had a much greater effect than the other. In 
addition, depletion by a third oligonucleotide had an opposing effect and  
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DUB A B C D Deconvolution conclusion esiRNA 
UCHL3 - +  -  - No +  
USP20 ++ - + - Yes +  
USPL1 - - -  -  No - 
YOD1 - -  -  - No - 
USP2 +  - - - No - 
ATXN3 ++ ++ - - Yes ++ 
JOSD1 - ++ ++ ++ Yes - 
OTUD4 - +  - - No + 
STAMBPL1 +  -  ++ - Yes - 
USP7 - +  ++  - Yes -  
ATXN3L ++ ++ ++ ++ Yes ND 
 
Table 3.1. Summary of deconvolution for candidate DUBs from the 
PTEN screen. DUBs whose depletion decreased or increased PTEN protein 
levels in the screen are indicated in blue and red respectively. Changes in 
protein level of more than 20% are indicated by an arrow in the direction of 
change. A change in protein level of 20 - 50%  (in the same direction as the 
pool) is indicated by +, greater than 50% by ++, while less than 20% change 
(or a change in the opposite direction) is indicated by a - sign. Deconvolution 
was deemed successful if at least two siRNA oligonucleotides recapitulated 
the results of the pool. (ND- Not done). 
 
resulted in PTEN downregulation. Depletion of STAMBPL1 by esiRNA did 
not result in upregulation of PTEN (fig 3.9). Depletion of STAMBPL1 was 
also performed using 4 alternative siRNA oligonucleotides (fig 3.10). Only 
one of the four siRNA oligonucleotides upregulated PTEN protein level to any 
degree (fig 3.10). In view of these results, which show a marginal 
upregulation of PTEN at best, STAMBPL1 was not followed up further. 
 
USP7 was also successfully deconvoluted, with two out of the four 
oligonucleotides recapitulating the effect of the pool. The degree of increase 
in PTEN protein levels was however less pronounced than occurred following 
depletion of ATXN3, ATXN3L or JOSD1. As discussed above, 
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Fig 3.9. Depletion of ATXN3 and USP20 by esiRNA supports a role in 
regulating PTEN. i. A549 cells were transfected with esiRNA against the 
indicated DUBS, siRNA against PTEN, or mock transfected. Following a 72-
hour incubation the cells were lysed using NP40. Equal amounts of lysate 
were immunoblotted for PTEN and actin. ii. Quantification of PTEN signal 
was performed, which was then normalised to the actin signal and compared 
to the mock. Detection and quantification performed on Odyssey infrared 
scanner [LiCor]. 
 
 
USP7 has previously been shown to be involved in the regulation of PTEN 
localisation [203], and I therefore prioritised the other three DUBs for further 
investigation. 
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Fig 3.10. Depletion of STAMBPL1 does not significantly upregulate 
PTEN. A. A 72-hour siRNA knockdown of STAMBPL1 was performed in 
A549 cells using the indicated siRNA oligonucleotides (Dharmacon) and 
pooled oligonucleotide (P). Equal amounts of lysate were immunoblotted for 
PTEN and actin. Quantification of PTEN signal normalised to the actin signal 
and compared to the mock is shown below the blot. (Detection and 
quantification performed on Odyssey infrared scanner [LiCor]). 
 
 
3.5 Screening for DUB regulators of PtdIns3-Kinase isoforms 
 
The phosphoinositide 3-kinases are a family of lipid kinases, which regulate 
the key survival pathway bearing their name. PtdIns3-K isoforms are divided 
into three classes (I-III) on the basis of lipid substrate preference and 
structural features  (section 1.5.1).  
 
To date, there have been no reports of DUBs regulating any of the PtdIns3-K 
classes. In this section, I therefore set out to identify DUB regulators of the 
protein level of PtdIns3-K class I catalytic subunits (p110α, p110β, p110γ), 
the class I regulatory subunit, p85α, and the class II catalytic subunit, p170. 
These subunits were selected predominantly for their known association with 
cancer. Class I, and particularly p110α, is the predominant class associated 
with malignancy, although there have been reports of involvement of other 
classes, notably IB [392] and II [393], for which screens were therefore 
included. In mass spectroscopy experiments carried out in the host 
laboratory, p110β was found to be the most abundant PtdIns3-K catalytic 
subunit in A549 cells (M Clague, personal communication), and it was 
therefore also included.  
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3.5.1 Identifying DUB regulators of p110 isoform abundance 
 
I first investigated the influence of DUB knockdown on three class I catalytic 
subunits; p110α and p110β (class IA), and p110γ (class IB) using NP40 
lysates from the library described in fig 3.3. Representative immunoblots and 
signal quantification for the p110α, p110β and p110γ screens are shown in 
figs 3.11-13 respectively. Three technical replicates of the immunoblotting 
stage were performed for p110α and p110β, while two were performed for 
p110γ. In each figure the five lowest and highest ranked candidate DUBs are 
highlighted (fig 3.11-13). A comparison of the results of all three screens is 
provided in fig 3.14. 
 
All three screens showed extensive variability between immunoblotting 
replicates, with the p110α screen the most affected. This particularly affected 
identification of DUBs whose depletion resulted in upregulation of the p110 
isoforms, where the candidates identified on quantification generally did not 
appear convincing on examination of the blots. Exceptions included depletion 
of PSMD14 and/or PSMD7, which showed evidence of upregulation of all 
three isoforms (fig 3.11-13). While p110α upregulation is less obvious on 
PSMD7 or PSMD14 depletion, a higher molecular weight form of p110α 
becomes apparent (fig 3.11), that might represent polyubiquitylated p110α. 
PSMD7 and PSMD14 are integral components of the proteasome [394, 395] 
and their depletion is likely to mimic the effects of proteasome inhibition. 
These findings therefore support regulation of all three p110 isoforms by the 
proteasome (section 3.10). 
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Fig 3.11. Screening for DUB regulators of p110α. i. NP40 lysates from the 
DUB screen (fig 3.3) were run on four SDS-PAGE gels. Each blot included a 
mock-transfected and non-targeting siRNA (siC) control. The blots were 
probed for p110α and actin, and imaged by infrared scanner (Odyssey, 
LiCor). Immunoblotting of lysates was performed three times and 
representative blots from one of the three runs are shown. The red arrow 
indicates a higher molecular weight band, which is most apparent on 
knockdown of PSMD7 or PSMD14. ii. Quantification of band intensity was 
performed using Odyssey (LiCor) software and the signal in each case 
normalised to actin and the median of each blot. The five lowest and highest 
ranked candidates are indicated and also highlighted in i (in blue and red 
respectively). 
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Fig 3.12. Screening for DUB regulators of p110β. A. NP40 lysates from 
the DUB screen (fig 3.3) were run on four SDS-PAGE gels. Each blot 
included a mock-transfected and non-targeting siRNA (siC) control. The blots 
were probed for p110β and actin, and imaged by infrared scanner (Odyssey, 
LiCor). Immunoblotting of lysates was performed three times and 
representative blots from one of the three runs are shown. B. Quantification 
of band intensity was performed using Odyssey (LiCor) software and the 
signal in each case normalised to actin and the median of each blot. The five 
lowest and highest ranked candidates are indicated and also highlighted in A 
(in blue and red respectively). USP45 which was ranked 9th from the top is 
also highlighted (see text).  
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Fig 3.13. Screening for DUB regulators of p110γ. A. NP40 lysates from 
the DUB screen (fig 3.3) were run on four SDS-PAGE gels. Each blot 
included a mock-transfected and non-targeting siRNA (siC) control. The blots 
were probed for p110γ and actin, and imaged by infrared scanner (Odyssey, 
LiCor). Immunoblotting of lysates was performed twice and representative 
blots from one of the runs are shown. B. Quantification of band intensity was 
performed using Odyssey (LiCor) software and the signal in each case 
normalised to actin and the median of each blot. The five lowest and highest 
ranked candidates are indicated and also highlighted in A (in blue and red 
respectively). 
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OTUD7A depletion resulted in upregulation of both p110α and p110γ, and 
was consistent between replicates. USP45 depletion resulted in upregulation 
of p110β (fig 3.13); while this was only ranked 9th highest, it was relatively 
convincing on all immunoblot replicates. As will be discussed in chapter 4, 
USP45 was also subsequently identified in a functional screen for modulators 
of PtdIns3-K activity. 
 
Candidate DUBs whose depletion downregulated p110 isoforms appeared 
more consistent between replicates. These included USP48, USP41 and 
YOD1, which were all identified in more then one of the p110 screens (fig 
3.11-13). USP27X knockdown resulted in at least a 50% reduction in p110β 
levels in all three technical replicates (fig 3.12) and had a more modest effect 
on the other two isoforms (fig 3.11, 3.13).  
 
Comparison of the datasets for the three p110 isoforms showed generally 
good concordance in the effects of DUB depletion on the regulation of p110 
isoforms (fig 3.14) However, three DUBs were identified whose depletion 
resulted in different effects on p110α and p110β/p110γ protein levels. These 
are YOD1, USP1 and BAP1 (fig 3.14).  
 
Due to time constraints, deconvolution of the p110 isoforms has not been 
performed as yet. Our intention is to collaborate with Marco Falasca’s lab, 
who have a particular interest in p110γ (and p170, see section 3.7) for further 
investigation of p110γ targets. 
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Fig 3.14. Identification of candidate DUBs whose depletion 
concordantly regulates p110 isoforms. The quantitative results from the 
p110α, p110β and p110γ screens (fig 3.12-14) were combined and are 
shown here. For each DUB depletion, the mean of the three p110 isoform 
screens was obtained and ranked (black). The mean results of the screens 
for each p110 isoform are plotted in blue, red and green. The 5 lowest and 
highest ranked candidates are highlighted, and examples where discordance 
between the three screens was observed.  
 
3.5.2 Identifying DUB regulators of p170 abundance 
 
I also investigated the role of deubiquitylases in regulating the protein 
abundance of the class II PtdIns3-kinase catalytic subunit, p170 (PIK3C2A), 
which has been implicated in hepatocellular carcinoma [393]. Unfortunately 
only a very weak signal was obtained with this antibody (BD611046), which 
also showed extreme variability across blots and between runs. Example 
blots are shown for two immunoblotting replicates (fig 3.15). In view of the 
variability across blots and the weak signal, attempts were not made to 
quantify the bands.  
 
However, depletion of several of the DUBs showed a reproducible effect on 
p170 levels. Depletion of either PSMD7 or PSMD14 resulted in a higher 
molecular weight smear indicating probable p170 polyubiquitylation (fig 3.15), 
and thus proteasomal regulation. The most marked reduction in the p170 
protein level was observed with USP48 knockdown, however depletion of 
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YOD1, USP27X or COPS6 also resulted in a reproducible reduction in p170. 
On the other hand, depletion of either USP47 or OTUD6A led to upregulation 
of p170 protein level.  
 
Interestingly, the majority of the above candidates (USP48, YOD1, USP27X 
and USP47) were also identified in the p110 screens, which could suggest 
that the protein abundance of multiple catalytic PtdIns3-K isoforms may be 
co-regulated. An alternative explanation would be that the siRNAs against 
these DUBs (or the DUBs themselves) have generic effects on protein levels. 
However, USP48, USP27X and USP47 were only identified in screens for 
regulators of p110 or p170, which suggests that their effects may be specific 
to PtdIns3-K. YOD1 on the other hand, was additionally identified in screens 
for regulators of PDK1 (section 3.4) and mTOR (section 3.8). Candidates 
from the p170 screen are yet to be validated. 
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Fig 3.15 Depletion of either PSMD7 or PSMD14 leads to 
polyubiquitylation of p170. NP40 lysates from the DUB screen (fig 3.3) 
were run on four SDS-PAGE gels. Each blot included a mock-transfected 
and non-targeting siRNA (siC) control. The blots were probed for p170 and 
actin, and imaged by infrared scanner (Odyssey, LiCor). Immunoblotting of 
lysates was performed twice and blots from both runs are shown. The actin 
blot from the first run only is shown. A higher molecular weight smear is 
observed (red asterisk) on PSMD7 or PSMD14 knockdown.  
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3.5.3 Identifying DUB regulators of p85α abundance 
 
The class IA regulatory subunit, p85α, was the next target we investigated. 
p85α has previously been shown to be polyubiquitylated, leading to its 
degradation [396], but to date no DUBs have been associated with its 
regulation. We therefore probed NP40 lysates from our screen for p85α (fig 
3.16i), and quantified the signal as previously described (fig 3.16ii). The p85α 
signal was relatively unaffected by DUB knockdown, and no obvious 
candidates were identified visually. Subtle changes in p85α were however 
observed on quantification of the signal. Depletion of OTUD6A marginally 
increased p85α signal (by ~30%), but was also identified in the p170 screen 
where, although not quantified, its effects appeared more visually obvious. 
 
3.6 A DUB screen for regulators of PDK1 
 
PDK1 occupies a key position in the PtdIns3-K pathway, phosphorylating Akt 
in response to the generation of the second messenger PtdInsP3 (section 
1.5.2). It additionally phosphorylates and activates several other AGC 
kinases (reviewed in [260]). PDK1 auto-phosphorylates itself and is 
constitutively active [263]. A recent study has shown that PDK1 is 
monoubiquitylated in a variety of cell lines, and that this is reversed by 
overexpression of USP4 [358]. However, in this study depletion of USP4 did 
not alter monoubiquitylated PDK1, which suggests that other DUBs may be 
involved [358]. In addition, there are no known DUBs that regulate the 
stability of PDK1. I therefore set out to look at the effects of DUB depletion on 
PDK1 protein level. 
 
3.6.1 PDK1 antibody comparison and characterisation 
 
An initial PDK1 screen performed utilizing a PDK1 antibody (with an 
extensive bibliography) from Cell Signaling (3062) had to be abandoned 
when it became apparent that the principal band was non-specific. We 
therefore assessed several other antibodies including s682 (Dundee  
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Fig 3.16. A screen for DUB regulators of p85α. i. NP40 lysates from the 
DUB screen (fig 3.3) were run on four SDS-PAGE gels. Each blot included a 
mock-transfected and non-targeting siRNA (siC) control. The blots were 
probed for p85α and actin, and imaged by infra-red scanner (Odyssey, 
LiCor). ii. Quantification of p85α and actin was performed and the p85α 
signal normalised to actin, then the blot median, and ranked as shown. The 
five lowest and highest ranked candidate DUBs are highlighted. (Detection 
and quantification was performed using an Odyssey infrared scanner).  
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phosphorylation unit), a gift from Dario Alessi (data not shown), BD611071 
from BD Biosciences, a phospho-PDK1 antibody from Cell signaling (3061), 
and latterly a different production lot of 3062 from Cell Signaling (3062 lot 10) 
as well as a monoclonal antibody in development (5662). A summary of the 
antibody assessment is shown in fig 3.17i-iv. PDK1 has multiple described 
and predicted splice isoforms, principal examples of which are illustrated in 
fig 3.17v. In view of this, I felt the BD antibody most closely correlated with 
the expected band structure on immunoblots, with the principal band on 
immunoblotting correlating with isoform 1. This antibody was therefore used 
for further screens. 
 
3.6.2 PDK1 protein level is regulated by multiple deubiquitinases 
 
NP40 lysates from the DUB library  (fig 3.3) were run on four SDS-PAGE 
gels per screen and immunoblotted for PDK1. Two technical repeats of the 
immunoblotting stage were performed for PDK1 and representative blots are 
shown in figure 3.18. Both the main splice-variant and all PDK1 
immunoreactive bands detected between 50 and 70kDa were quantified. 
Intra-sample normalisation to actin and intra-blot normalisation to the median 
was performed. Results for quantification of both the main splice-variant and 
all detected variants are shown in fig 3.19. While there was significant 
variability between the two immunoblots for the screen, a number of hits 
were reproducible. Depletion of PRPF8, TNFAIP3, OTUD1, USP34, USP18 
or USP32 all reproducibly downregulated either the main PDK1 band or all of 
the detected PDK1 bands. USP6 was also selected for deconvolution as it 
was ranked 6th for both quantifications, and is a paralogue of USP32 [397]. 
Candidates upregulating PDK1 were less consistent between replicates and 
only UCHL3, JOSD1 and CYLD were selected for deconvolution. Knockdown 
of both YOD1 and JOSD2 resulted in the appearance of an extra band at 
approximately 50kDa, and both were therefore also subjected to 
deconvolution.  
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Fig 3.17. BD611071 is a specific PDK1 antibody and detects multiple 
splice variants. Comparison of the BD mouse PDK1 monoclonal antibody 
BD6111071 with a Cell Signalling antibody CS3062 (i), a phospho-PDK1 
antibody from cell signalling, CS3061 (ii), a replacement lot of CS3062 (iii) 
and a monoclonal antibody CS5662 (iv). In each case the image in the left 
hand panel was detected using the green (800) channel of the Odyssey 
scanner while that in the right hand panel was detected with the red (680) 
channel. PDK1 was knocked down with two siRNA oligos as indicated. The 
arrow indicates the predominant isoform identified by BD611071. v. The 
reference sequence transcripts and proteins for PDK1, as well as principle 
examples from the Ensembl, Uniprot and Aceview databases are shown 
here, with the predicted protein molecular weights given to the right. 
Alternative start codons account for the differences in size described in 
different databases for the first two sequences (the asterisks indicate the 
longer Aceview sequences). The kinase domain is indicated in turquoise, and 
the PH domain in orange. The green boxes indicate the positions of the two 
siRNA sequences (PDK1_5 on the left and PDK1_8 on the right). 
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Fig 3.18. A screen for DUB regulators of PDK1. i. NP40 lysates from the 
DUB screen (fig 3.3) were run on four SDS-PAGE gels. Each blot included a 
mock-transfected and non-targeting siRNA (siC) control. A 72-hour 
knockdown of PDK1, using two siRNA oligonucleotides, was performed 
separately from the screen and samples (including independent controls, 
designated siC.P and Mock.P) run alongside the screen lysates on blots 1 
and 4. The blots were probed for PDK1 and actin, and imaged by infrared 
scanner (Odyssey, LiCor). Immunoblotting of lysates was performed twice 
and representative blots are shown. Both the main band (*) and all the PDK1 
immunoreactive bands detected between approximately 50 and 70kDa (♯) 
were quantified. A prominent band (x) just above 50kDa was also seen with 
YOD1 and JOSD2 knockdowns. A very faint band of approximately 75kDa is 
indicated by an arrow and is shown also in ii, where the contrast has been 
increased.  
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Fig 3.19. Multiple DUBs are candidate regulators of PDK1. 
Immunoblotting for PDK1 and actin was performed and is shown in fig 3.19. 
i. The predominant PDK1 bands were quantified (Odyssey, LiCor), 
normalised to actin and then the median of each blot. ii. Alternatively all the 
PDK1 bands between 50 and 70kDa were quantified, normalised to actin and 
the blot median. The two replicate screens are depicted in red and green, 
with the mean in black. The six bottom, and five top ranked candidates are 
highlighted in both i and ii. 
 
 
In view of the study which showed that PDK1 may be monoubiquitylated 
[358], I also examined the blots for higher molecular weight PDK1 
immunoreactive bands. While a very faint band of approximately 75kDa was 
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seen, this was not downregulated by PDK1 depletion (fig 3.18i,ii), and 
therefore most likely represents a non-specific band. 
 
Deconvolution of the selected candidates (fig 3.20 and table 3.2) identified 
several DUBs for which more than one oligonucleotide recapitulated the 
effect of the pool. These included PRPF8, TNFAIP3, OTUD1, USP34 and 
USP32, which decreased PDK1 protein level, and UCHL3, which increased 
it. On the other hand USP18, USP6, CYLD and JOSD1 failed to validate 
through deconvolution. A combined depletion of USP6 and USP32 was also 
performed to assess whether depletion of these closely related DUBs would 
have additive effects on PDK1 protein levels. This resulted in a similar 
reduction in PDK1 protein level to USP32 depletion alone, further indicating 
that USP6 does not regulate PDK1 protein levels. The lower molecular 
weight band seen with YOD1 and JOSD2 knockdown was not recapitulated 
in deconvolution.  
 
A subset of candidates from the PDK1 screen were further investigated 
through QPCR (fig 3.21). Depletion of either PRPF8 (pre-mRNA processing 
factor 8) or TNFAIP3 using any of the individual oligonucleotides or pooled 
oligonucleotide resulted in a reduction in PDK1 transcript level. In the case of 
USP32, two of the individual USP32 oligonucleotides, and the pool, led to a 
reduction in PDK1 transcripts. There was a good correlation between the 
effects of USP32 oligonucleotides on PDK1 mRNA and protein level (fig 
3.21ii), suggesting that USP32’s effects on PDK1 may similarly be mediated 
through transcription. However, in the case of OTUD1, there was no 
correlation between PDK1 mRNA and protein suggesting that its effects on 
PDK1 are post-transcriptional, with alterations in mRNA occurring through 
compensatory mechanisms. 
 
 
	   91	  
 
Fig 3.20. Deconvolution reveals multiple DUB regulators of PDK1 
protein level. i. Target DUBs were knocked down separately with each of 
the four individual oligonucleotides from the pool (designated A-D in each 
case) as well the pool (P), cells were incubated for 72 hours, lysed with 
NP40, and lysates immunoblotted for PDK1. ii. The predominant PDK1 
isoform was quantified, normalised to actin. Change in PDK1 level is shown 
here as a percentage of the mock control. For each DUB, the four oligos are 
shown from left to right with the pools shown in red. Knockdown of DUBs to 
the left of the line resulted in decreased PDK1 stability in the screen, while 
those to the right increased PDK1 levels. The data represent the means of 
two experiments (siC- non-targeting siRNA control, USP6/32_P- combined 
depletion of USP6 and USP32 using oligonucleotide pools for both). 
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DUB A B C D Deconvolution conclusion 
PRPF8 +  ++  ++  ++  Yes 
TNFAIP3 +  +  +  ++  Yes 
OTUD1 -  - +  ++  Yes 
USP34 ++  - +  +  Yes 
USP18 -   ++  -  - No 
USP6 -   -   - +  No 
USP32 +  ++  - +  Yes 
CYLD -   -   -   -   No 
JOSD1 - - - - No 
UCHL3 ++  +  +  ++  Yes 
 
Table 3.2. Deconvolution of hits from PDK1 screen. DUBs whose 
depletion decreased or increased PDK1 protein levels in the screen are 
indicated in blue and red respectively. Changes in protein level of more than 
20% are indicated by an arrow in the direction of change. A change in protein 
level of 20 - 50%  (in the same direction as the pool in the original screen) is 
indicated by +, greater than 50% by ++, while less than 20% change (or a 
change in the opposite direction) is indicated by a - sign. Deconvolution was 
deemed successful if at least two siRNA oligonucleotides recapitulated the 
results of the pool.  
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Fig 3.21. PRPF8, TNFAIP3 and USP32 depletion decreases PDK1 
transcript levels. i. A549 cells were transfected with siRNA oligonucleotides 
against the indicated targets and incubated for 72 hours after which total 
RNA was extracted. cDNA was prepared by reverse transcription, after which 
QPCR was performed using an iQ5 Real-Time PCR detection system  and 
SYBER green mastermix (BioRad) using actin as the reference gene.  The 
knockdowns were performed in two separate experiments, respectively 
shown to the left and right of the dotted line, with independent controls. In 
each case mRNA level was calculated with reference to the mock control. 
For each target, oligonucleotides A-D are shown from left to right and the 
pools in red. The controls are in green. ii,iii. Correlation between relative 
mRNA level as assayed by QPCR and protein level assayed previously by 
immunoblotting (fig 3.20) for USP32 and OTUD1 respectively. (siC- non-
targeting siRNA control) 
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3.7 Screening for modulators of Akt protein level 
 
The next component of the pathway to be investigated was Akt. Activation of 
Akt requires two phosphorylation events (section 1.5.2). The first site (T308) 
is phosphorylated by PDK1 [261], while phosphorylation of the second 
(S473) is mediated by mTORC2 [264]. Akt in turn is a master kinase, with a 
host of downstream effectors (section 1.5.2).  
 
Akt is known to be polyubiquitylated through both K48 and K63 linkages 
(section 1.5.4) with the latter modification leading to membrane localisation 
and activation of Akt [351]. Depletion of the DUB UCHL1 has been shown to 
increase proteasomal degradation of Akt ([353] and section 1.5.4). However 
no attempts have been made to my knowledge to systematically identify 
DUBs that may be involved in Akt regulation. 
 
3.7.1 Akt antibody characterisation 
 
Three isoforms of Akt are encoded by separate genes, all of which have 
been implicated in malignancy (reviewed in [398]). In this study, I used an 
antibody from Cell Signalling (CS9272), which detects all three isoforms; 
Akt1, Akt2 and Akt3. Although the three isoforms are of very similar 
molecular weight (~56kDa), it is possible to distinguish them to an extent by 
immunoblotting (fig 3.22, left). However it is feasible that phosphorylation of 
Akt isoforms may shift the apparent molecular weight, making analysis of the 
band structure less clear (fig 3.22, right). The Akt3 band in particular is less 
clear after treatment with EGF.  
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Fig 3.22. Antibody CS9272 detects, and discriminates between, the 
three Akt isoforms. Knockdown of individual isoforms was performed, and 
A549 cells were either directly lysed in hot SDS-buffer, or pre-treated with 
EGF for 15min prior to harvesting. Lysates were run on 8% SDS-PAGE and 
immunoblotted for Akt and actin. (siC- non-targeting siRNA control). 
 
 
 
3.7.2 Akt screen 
 
NP40 lysates from the DUB screen were immunoblotted for Akt (fig 3.23). 
Three runs (technical replicate gels) were performed and blots from a single 
replicate are shown in Fig 3.23. It proved impossible to quantify the individual 
Akt isoforms separately, and although there were visual indications that 
certain DUB knockdowns affected specific bands disproportionately, these 
were not consistent between runs and have not been pursued further.  
 
Partly due to the complex band structure, there was extensive variability 
between runs (fig 3.24i) and the data was therefore also plotted in an 
alternative fashion to allow comparison (fig 3.24ii) of each datapoint with its 
neighbours. This allowed an assessment of both the reproducibility between 
replicates and any gel bias. The five lowest ranked candidates were relatively 
reproducible between replicates (fig 3.24ii). However, the highest ranked 
candidates were biased by replicate run 3. USP44, USP46 and USP47 are 
all from a contiguous section of blot, and there was little correlation with the 
other blots. Akt quantification for USP15 depletion was similarly biased by 
one of the three runs, while in the case of OTUD6B depletion, Akt was only 
marginally elevated in a second screen. Only DUBs whose depletion 
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Fig 3.23. An siRNA screen for DUB regulators of Akt level. NP40 lysates 
from the DUB screen (fig 3.3) were run on four SDS-PAGE gels. Each blot 
included a mock-transfected and non-targeting siRNA (siC) control. The blots 
were probed for Akt and actin, and imaged by infrared scanner (Odyssey, 
LiCor). Immunoblotting of lysates was performed three times and blots from 
one of the three replicates are shown. Candidate DUBs to be considered for 
validation are highlighted in blue.  
 
downregulated Akt will be considered for validation, these are: PRPF8, 
USP54, OTUD4, ZRANB1 and USP11. Depletion of UCHL1 has been 
reported to reduce Akt stability and thus abundance [353]. In the screen 
UCHL1 depletion did affect Akt protein level in the expected direction. 
However UCHL1 was only ranked 14th for the downregulation of Akt protein 
level, and with limited reproducibility between screens (fig 3.24). Due to the 
lack of reproducibility between replicates, deconvolution of the Akt screen 
was not prioritised and has not yet been performed. 
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Fig 3.24. Quantification of Akt blots identifies several candidate DUBs 
whose knockdown decreases Akt protein level. Immunoblotting for Akt 
and actin was performed and is shown in fig 3.23. i. Akt bands were 
quantified (Odyssey, LiCor), normalised to actin and then the median of each 
blot. The mean of 3 immunoblotting replicates was ranked from low to high. 
The 5 top and bottom ranked candidates are highlighted. UCHL1, ranked 14th 
from the bottom, is highlighted. ii.  Here the data are not ranked on 
quantification, but are plotted according to their position on the gel, enabling 
each data point to be compared with its neighbours.  
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3.8 Identifying DUB modulators of mTOR 
 
The mammalian target of rapamycin (mTOR) is a key component of two 
multiprotein complexes in PtdIns3-K signalling (section 1.5.2). The first of 
these (mTORC1) is a key effector of the pathway [399], while the second 
(mTORC2) is responsible for the second phosphorylation event leading to full 
activation of Akt [264]. The recent introduction of mTOR inhibitors into clinical 
practice has generated further interest in the regulation of this key protein, 
particularly as mTOR inhibition drives activation of the PtdIns3-K pathway 
through a feedback loop [400, 401]. Ubiquitylation by the E3 ligase and 
tumour suppressor FBXW7 has been shown to promote degradation of 
mTOR and cell lines harbouring mutations in FBXW7 have been shown to be 
particularly sensitive to mTOR inhibitors [402]. However, no DUBs have been 
shown to regulate mTOR function.  
 
NP40 lysates from the DUB library were immunoblotted for mTOR. Three 
technical replicates of the immunoblotting were performed. Unfortunately the 
signal was very variable across blots and inconsistent between replicates 
such that quantification was not informative. However, a striking reduction in 
the protein level of mTOR following YOD1 knockdown was observed in all 
replicate runs, and an example of one of these blots is shown in fig 3.25i. 
This effect of YOD1 depletion on mTOR was however only recapitulated by 
one of the four oligonucleotides from the original siRNA pool (fig 3.25ii). This 
does not appear to be due to differences in YOD1 depletion efficiency 
between oligonucleotides, as all generated satisfactory depletion of YOD1 as 
shown in fig 3.25iii.  
 
Depletion of two other DUBs, namely OTUD5 and TNFAIP3, also had 
reproducible effects on mTOR in the three technical repeats, increasing the 
mTOR protein level in all cases (fig 3.25i). Deconvolution of these two 
candidates has not yet been performed. 
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Fig 3.25. Knockdown of YOD1 reduces mTOR protein level through a 
potential off target effect. NP40 lysates from the DUB screen (fig 3.3) were 
run on four SDS-PAGE gels. Each blot included a mock-transfected and non-
targeting siRNA (siC) transfected control. The blots were probed for mTOR 
and actin, and imaged by infrared scanner (Odyssey, LiCor). Immunoblotting 
of lysates was performed three times. i. Example of one of the blots showing 
effects of depletion of several DUBs on mTOR protein level. ii,iii. A 72-hour 
knockdown of YOD1 was performed with each of the four oligonucleotides 
from the original pool (designated A-D) and the pool (P), the cells were lysed 
with NP40, and lysates immunoblotted for mTOR (ii) or YOD1 (iii). 
 
3.9 A549 cells express low levels of FOXO1, FOXO3 and FOXO4 protein 
 
The FOXO family of transcription factors are key effectors of the PtdIns3-K 
pathway, and are known to be subject to both poly- and monoubiquitylation 
(section 1.5.4). In the case of FOXO4 (and FOXO3), monoubiquitylation has 
been shown to be reversed through the action of USP7 [205]. I had intended 
to systematically investigate the role of DUBs in the regulation of the FOXO 
family members in both cytosolic (NP40) and nuclear (Dignam C) fractions. 
However, the signal obtained with several different antibodies (against 
FOXO1, 3 and 4) using either fraction or the whole cell lysate was extremely 
low, indicating low expression levels and thus precluding an immunoblotting-
based screen in this cell line.  
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Fig 3.26. Low FOXO1 protein expression in lung cancer cell lines. A 
panel of cell lines were maintained under normal, basal culture condition. 
Whole cell lysis of cells was performed with hot SDS buffer. Equal amounts 
of lysate were immunoblotted for FOXO1 (i) or FOXO3 (ii) and actin. The first 
three ‘normal’ cell lines were derived from bronchial epithelium, while the 
other three normal cell lines were derived from lung fibroblasts. (asterisk 
indicates non-specific bands, SCLC- small cell lung cancer, NSCLC- non-
small cell lung cancer, C- carcinoid). 
 
FOXO protein expression was also assessed in a panel of cell lines derived 
from small cell lung cancer (SCLC), non-small cell lung cancer (NSCLC) and 
normal lung fibroblasts or epithelial cells (Fig 3.26), to identify alternative cell 
lines which may be used in future screens for modulators of FOXO 
abundance. Lysates from these cell lines had been prepared previously by J. 
Coulson and M. Faronato. FOXO1 expression was virtually undetectable in 
all of the SCLC and NSCLC lines (fig 3.26i). Interestingly, 3 cell lines derived 
from lung epithelium (non-malignant) showed higher FOXO1 expression, 
while three cell lines derived from normal lung fibroblasts did not (fig 3.26i). 
FOXO3 expression was more variable across the panel, with a proportion of 
both SCLC and NSCLC cell lines expressing higher protein levels (fig 3.26ii), 
and it may therefore be feasible to perform a screen for DUB regulators of 
FOXO3 abundance in one of these cell lines in future.  
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In chapter 4, I will describe a second screening approach to identifying DUB 
regulators of the PtdIns3-K pathway, in which translocation of stably 
expressed FOXO3-EGFP was employed as a read out. This also provided 
the opportunity to identify DUBs that regulated the abundance of 
overexpressed EGFP-tagged FOXO3, which will be discussed in section 4.4. 
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3.10 Discussion 
 
In this chapter I have described a systematic approach to investigating the 
role of DUBs in the regulation of the protein level of nine components of the 
PtdIns3-K pathway (fig 3.27). This led to the identification and initial 
validation of several novel regulators of two core components, PTEN and 
PDK1 (fig 3.27), and in addition has identified lead candidates for the 
regulation of other components of the pathway (listed in table 3.3). 
 
 
 
 
Fig 3.27. Graphical summary of a systematic investigation into the role 
of DUBs in the regulation of the PtdIns3-K pathway. Ticks denote 
components of the pathway that were successfully investigated through 
immunoblotting, while those marked with a cross were not. Isoforms of 
PtdIns3-K, Akt and FOXO included in this study are listed. Assessment of the 
individual Akt isoforms was not feasible, and a combined quantification of all 
three isoforms was therefore performed. The boxes highlight candidate 
DUBs which were successfully validated through deconvolution. (red and 
blue indicate DUBs whose depletion respectively leads to upregulation or 
downregulation of the target protein).  
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DUB PTEN p110α p110β p110γ p170 p85α PDK1 Akt mTOR 
UCHL3 D1      U1   
USP20 D2     U4    
USPL1 D3         
YOD1 D4  D3 D4 D    D 
STAMBPL1 U1         
OTUD4 U2       D3  
JOSD1 U3      U2   
ATXN3 U4         
USP2 U5         
ATXN3L U7         
USP7 U9         
OTUD1  D1     D3   
BAP1  D2        
USP48  D3  D1 D     
USP41  D4 D5       
UCHL5  D5        
USP37  U1        
USP2  U2        
USP30  U3 U3       
OTUD7A  U4  U1      
USP42  U5        
USP27X   D1  D     
USP18   D2    D4   
JOSD2   D4   U1    
PSMD14  * U1 U2 ¶     
MPND   U2       
USP9Y   U4   D4    
USP24   U5       
USP19    D2      
USP21    D3      
USP11    D5    D5  
PDMD7  *  U3 ¶     
USP47    U4 U     
USP46    U5 U     
OTUD6A     U U5    
EIF3F      D1    
PRPF8      D2 D1 D1  
VCPIP1      D3    
USP54      D5  D2  
USP4      U2    
USP3      U3    
TNFAIP3       D2  U 
USP34       D3   
USP6       D4   
USP32       D5   
CYLD       U3   
ZRANB1        D4  
OTUD5         U 
 
Table 3.3 Summary of candidate DUBs affecting the stability of selected 
PtdIns3-K components. DUBs identified in each screen are listed. D and U 
indicate down and up-regulation respectively, and the number in each case 
represents the ranking. For example D1 represents the candidate DUB 
whose depletion most strongly downregulated the abundance of the 
respective PtdIns3-K component.  The p170 and mTOR screens were not 
quantified for technical reasons, and so candidates are not ranked. 
Candidate DUBs which were successfully deconvoluted are highlighted in 
green, while those which were not are in orange. The remainder have not 
been deconvoluted. The two proteasomal components (PSMD14 and 
PSMD7) are highlighted in bold. The asterisk refers to upregulation of a 
higher molecular weight species of p110α on depletion of either PSMD14 or 
PSMD7. The ¶ refers to a higher molecular weight smear of p170 observed 
on depletion of the same DUBs. 
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The siRNA transfections and lysate production were performed on a large 
scale, thus allowing assessment of protein stability for multiple targets within 
the PtdIns3-K pathway, and providing a valuable resource for other projects 
in the laboratory. Knockdown efficiency has only been determined for a 
selection of targets, but where assessed appears satisfactory (fig 3.5).  
 
Notably, RNAi screening methodology is subject to both false positive 
negative discovery rates ([387, 388] section 3.2). In the screens I performed 
in this work, several steps were taken to minimise both false positives and 
negatives. Firstly, the library I employed utilised pools of four siRNA 
oligonucleotides against each DUB target rather than single oligonucleotides. 
This would be expected to compensate for potential poor knockdown 
efficiencies of individual oligonucleotides, and thus reduce false negative 
results [403]. Interestingly, recent work suggests that increasing pool 
complexity may also reduce off-target effects (and thus false positives), at 
least at the mRNA level [389]. Although increasing the number of siRNA 
oligonucleotides would likely increase the number of other transcripts 
affected, the concentration of each siRNA oligonucleotide in the pool is 
decreased thus reducing the magnitude of its off-target effects [389].  
 
Both false positive and negative results may be reduced by experimental 
repeats and technical replication [404]. However, due to time and practical 
constraints, the initial generation of a library of DUB knockdown lysates was 
performed only once. Multiple technical replicates of the immunoblotting step 
were however performed for the majority of screens. While immunoblotting is 
an extremely well established methodology, and the only feasible method for 
studies such as this, it is subject to several limitations which may cause 
variability between replicate immunoblotting of the same sample [405]. 
Additionally, due to the number of samples in the lysate library, several large 
blots were run per screen, which increased the likelihood of variability across 
screens, and introduced a further step (and thus source of error) to enable 
comparison across blots. The use of multi-strip immunoblotting has been 
proposed as an alternative strategy, to minimise such variability [406] and 
may be an option for further work. 
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A relatively large proportion of the hits (approximately 10%) were selected for 
further investigation, in order to reduce the likelihood of false negatives. In 
two of the screens, these candidates have been refined by deconvolution. 
This was deemed successful if at least two of the individual oligonucleotides 
making up the pool recapitulated the effects seen in the screen. 
Approximately half of the candidates subjected to deconvolution met the 
criteria set. The remainder of the screens have not been subject to 
deconvolution experiments to date, due to time constraints. 
 
Five DUB regulators of PTEN protein level were identified, and validated by 
deconvolution. They include USP7, which has been shown to reverse 
monoubiquitylation of PTEN, and thus promote its nuclear exclusion [203]. 
While the study did not address the effects of USP7 on PTEN stability, PTEN 
nuclear localisation has been shown elsewhere to result in its protection from 
polyubiquitylation and thus degradation [57]. It is thus possible that USP7 
depletion would lead to increased monoubiquitylation of PTEN, its nuclear 
localisation and hence stabilisation, which would fit with the results seen in 
my screen. Nuclear localisation of PTEN following USP7 depletion has not 
been assessed. However in other experiments, PTEN was almost entirely 
extracted in the NP40 fraction (see fig 6.7). While this may reflect a true 
cytosolic localisation of PTEN, it may alternatively be due to extraction of 
nuclear PTEN in the NP40 fraction. This has not been investigated further, 
and USP7 was not prioritised for further study. 
 
Depletion of ATXN3, ATXN3L or JOSD1 also increased PTEN protein level, 
and this was confirmed in each case by more than one siRNA 
oligonucleotide. The effects of USP20 depletion were less clear. Depletion by 
two out of four siRNA oligonucleotides resulted in a decrease in PTEN 
protein level, thus recapitulating the effect of the pool. However, the other 
two oligonucleotides had the opposite effect and led to an increase in PTEN 
level. Regulation of PTEN by any of these four DUBs has not been described 
previously. 
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ATXN3 was first identified due to its role in Machado-Joseph disease. 
Subsequently it has been shown to have multiple functions, including 
regulation of retrotranslocation of substrate in endoplasmic reticulum 
associated protein degradation (ERAD) [407] and transcriptional repression 
[378]. Recently, increased longevity was described in C. elegans worms 
deficient in ATXN3 and p97 [408]. Interestingly this appears to be mediated 
through IGF signalling [408].  Another potential link between ATXN3 and 
PtdIns3-K signalling is suggested by a proteomic study of the EGF induced 
ubiquitin network, which included ATXN3 and JOSD1 [409]. No functions 
have been ascribed to JOSD1. 
 
The host laboratory has previously shown a role for ATXN3L in hepatocyte 
growth factor-induced scattering of epithelial cells [385], but no other 
functions have been described to date. USP20 on the other hand stabilises 
HIF-1α [92], regulates β2-adrenergic receptor recycling [91] and is a negative 
regulator of NFκB signalling [93].  
 
Six candidates DUBs were identified that regulate PDK1 (fig 3.27). Four of 
these were assessed by QPCR, which showed that depletion of PRPF8, 
TNFAIP3 or USP32 decreased PDK1 mRNA levels, suggesting that their 
effects on PDK1 are manifested through regulation of transcript levels. The 
effects of OTUD1 on PDK1 protein level on the other hand appeared to be 
independent of transcript level. 
 
PRPF8 is a member of the JAMM/MPN+ family of DUBs, although it is 
catalytically inactive [410]. It is however a core component of the 
spliceosome [411], suggesting that its effects on PDK1 may be mediated 
through defects in splicing. This is supported by the finding that PRPF8 
depletion reduced PDK1 mRNA levels. PRPF8 depletion also reduced p85α 
and Akt levels, however neither of these findings has been validated. 
 
TNFAIP3 is a well-established negative regulator of the NFκB pathway. It has 
both DUB and E3 ligase activity allowing it to act through a ‘ubiquitin-editing‘ 
mechanism whereby K63 ubiquitin chains are removed from key mediators of 
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the pathway, and replaced with K48 chains leading to their degradation [185]. 
There is extensive cross talk between NFκB and PtdIns3-K signalling [412, 
413]. Moreover RIP1 (a TNFAIP3 substrate) has been shown to 
downregulate PTEN and mTOR at a transcriptional level [414]. Similar 
indirect mechanisms may explain the effects that I observed of TNFAIP3 on 
PDK1 mRNA level. 
 
No functions have been ascribed to OTUD1 in the literature as yet. OTUD1 
has however been shown to interact with USP11 [415], another DUB that has 
been shown to be involved in NFκB signalling [416]. Intriguingly CYLD, which 
was also identified in this screen (although it did not validate through 
deconvolution), is a further DUB classically associated with NFκB signalling 
[126, 127].  
 
The other two DUBs whose depletion led to decreased protein levels of 
PDK1 were USP32 and USP34. USP32 has been shown to be 
overexpressed in breast cancers [417], but no substrates have been 
described. USP34 on the other hand regulates the stability of axin, and thus 
wnt/β-catenin signalling [195]. Depletion of the final candidate, UCHL3, led to 
increased PDK1 protein levels. Significantly, UCHL3 has previously been 
implicated in insulin signalling and adipogenesis [418]. In that study, 
decreased activation of the PtdIns3-K pathway was observed in response to 
insulin signalling in mouse embryonic fibroblasts derived from UCHL3 
knockout mice [418]. While these results appear contrary to the results in my 
screen, this may indicate cell type dependence, or represent a feedback 
mechanism. 
 
Interestingly, depletion of one or other of two proteasomal DUBs, PSMD14 
and PSMD7, altered protein levels all four PtdIns3-K catalytic subunits (table 
3.3). Both are integral components of the proteasome [394, 395] and their 
depletion would be expected to phenocopy proteasomal inhibition, leading to 
protein stabilisation and the accumulation of polyubiquitylated species. 
Protein levels of p110β and p110γ were both increased by PSMD14 and/or 
PSMD7 depletion, while higher molecular weight species are seen in the 
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p110α and p170 screens. These findings suggest that turnover may be 
relatively rapid for these proteins, and supports further investigation into the 
role of DUBs in their regulation. Confirmation by proteasomal inhibition has 
yet to be performed. 
 
In this chapter, I identified several novel DUB regulators of PTEN and PDK1, 
which are both core components of the PtdIns3-K pathway. Further 
investigation into the PTEN regulators, USP20, ATXN3, ATXN3L and 
JOSD1, will be described in chapter 6.  Additionally several interesting 
candidate DUBs were identified for other components of the PtdIns3-K 
pathway and the study also provided evidence of proteasomal regulation of 
PtdIns3-K catalytic subunits. Due to time constraints, these latter findings 
have not been followed up as yet.                              
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Chapter 4 
 
A functional RNAi screen for DUB regulators of the PtdIns3-K 
pathway 
 
4.1 Introduction 
 
The FOXO group of transcription factors regulate a variety of cellular 
processes including differentiation, stress response, cell cycling and 
apoptosis [419]. Activation of the PtdIns3-K pathway leads to Akt-dependent 
phosphorylation of FOXO resulting in transcriptional inactivation, 
translocation to the cytoplasm and binding to 14.3.3 ([297, 302, 420], section 
1.5.2). Subcellular localization of FOXO is thus dependent on activity of the 
PtdIns3-K pathway, and provides a readout that has previously been 
employed in screens for small molecule inhibitors of this pathway [421, 422].  
 
Ubiquitylation is a versatile post-translational modification, involved not only 
in the regulation of protein stability, but also in the subcellular localization 
and activity of substrates, including components of the PtdIns3-K pathway 
(discussed in section 1.6). In chapter 3, immunoblotting was employed to 
identify deubiquitylases involved in regulating the protein level of several 
components of the PtdIns3-K pathway. Here I describe an alternative, and 
complementary approach, in which subcellular localization of FOXO3-EGFP 
is employed as a marker of downstream activation of the PtdIns3-K pathway. 
Live cell imaging enabled the design of a dynamic screen, in which the 
effects of DUB knockdown on the rate and extent of FOXO3-EGFP 
translocation in response to PtdIns3-K inhibition were followed. Regulation of 
FOXO3-EGFP abundance by DUBs was also assessed in this screen as a 
secondary output. 
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4.2 FOXO3-EGFP screen development and workflow 
 
To facilitate the assessment of nuclear to cytoplasmic shuttling of FOXO, I 
obtained a human osteosarcoma cell line stably expressing a FOXO3 
(FKHRL1)-EGFP construct (FKHRL1-U2OS, Fisher). FOXO3-EGFP is 
predominantly cytoplasmic under normal cell culture conditions, and as 
expected translocates to the nucleus on PtdIns3-K inhibition using either a 
non-selective (LY294002) or selective class IA (PI-103) inhibitor (fig 4.1i). 
Under basal conditions, FOXO3-EGFP constantly shuttles between the 
cytoplasmic and nuclear compartments, as indicated by accumulation in the 
nucleus when export is blocked using Ratjadone A (fig 4.1i). The use of a live 
cell nuclear counterstain enables FOXO3-EGFP localization to be assayed 
through image segmentation and analysis (fig 4.1ii). As described in section 
2.4, cytoplasmic fluorescence was measured in a perinuclear torus defined 
by dilating the nuclei. This was used in preference to measuring the whole 
cytoplasm, which was difficult to define in certain cases due to changes in 
cell morphology and low-level fluorescence in the cytoplasm, such as 
occurred following profound nuclear translocation (section 2.4 and fig 4.1ii). 
The ratio of nuclear to cytoplasmic FOXO3-EGFP was utilised as a single 
quantitative measure of subcellular localisation (Box 1, Fig 4.1iii).  
 
Live cell imaging of FOXO3-EGFP in FKHRL1-U2OS cells where nuclei were 
counterstained with a vital dye enables translocation of FOXO3-EGFP to be 
followed in real time, as shown in fig 4.1iii-v. Treatment of cells with either 
LY294002 or PI-103 led to a dose-dependant nuclear translocation of 
FOXO3-EGFP (fig 4.1iv). This is reflected by the ratio of nuclear to 
cytoplasmic FOXO3-EGFP, which started to increase from about 5 minutes 
after addition of inhibitor. From 10-25 minutes the increase in ratio was 
essentially linear after which the rate of change decreased and the ratio 
reached a plateau at approximately 50 minutes (fig 4.1iv). Both LY294002 
and PI-103 are reversible inhibitors of PtdIns3-K, and FOXO3-EGFP rapidly 
translocates back to the cytoplasm on washout of the inhibitor (fig 4.1iii,iv).  
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Fig 4.1 FOXO3-EGFP subcellular localization is responsive to 
inhibition of the PtdIns3-K pathway. FKHRL1-U2OS cells were 
seeded in a 96 well plate and incubated overnight. The cells were stained 
with 2.5µM DRAQ5 in phenol red free DMEM for 15 min, after which the 
media was removed and replaced with HBSS. Fluorescence imaging of each 
well was performed using a Nikon Ti-E automated microscope. 
Approximately 20-30 cells were imaged per well. The plate was removed, 
inhibitors added at the described concentration in Hank’s Buffered Saline 
Solution and imaging performed every 5 minutes for 90 minutes, after which 
the inhibitors were removed and replaced with fresh HBSS. Cells were then 
imaged for a further hour. i. Representative images taken at baseline (left-
hand panel) or 60 minutes after addition of inhibitors. (scale bar: 50µm) . ii. 
Image segmentation and quantification was performed using Volocity 
(PerkinElmer) software. Nuclei are outlined in a thick red line, the perinuclear 
torus in a thin red line and the cytoplasm in yellow. (scale bar 20µm). iii. 
Timecourse of mean nuclear and cytoplasmic GFP fluorescence, and 
nuclear/cytoplasmic ratio following addition of 100nM PI-103. iv,v. 
Timecourse of FOXO3-EGFP translocation in response to indicated 
inhibitors. Following 1µM TGX-221 treatment, the cells were washed off 
when the inhibitor was removed. (LY: LY294002, PI: PI-103, TGX: TGX-221, 
RJA: Ratjadone A, MK: MK-2206, N/C nuclear/cytoplasmic). 
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Treatment with TGX-221, which is a selective p110β inhibitor with ~1,000 
fold selectivity over p110α [423], resulted in minimal translocation (fig 4.1iv) 
even at a concentration well in excess of the IC50 (5nM against the purified 
kinase). This suggests p110β is not involved in PtdIns3-K signalling under 
these conditions, and supports instead a role for p110α and/or p110δ, which 
are inhibited by PI-103 with an IC50 of 8nM and 48nM respectively. Inhibition 
of signalling downstream of PtdIns3-K, using the allosteric Akt inhibitor, MK-
2206 [424] on the other hand, also resulted in nuclear translocation of 
FOXO3-EGFP (fig 4.1v), thus demonstrating that FOXO3-EGFP 
translocation is responsive to perturbation of the PtdIns3-K/Akt signalling 
axis at multiple levels. 
 
The above findings confirm that the localisation of FOXO3-EGFP in 
FKHRL1-U2OS cells is responsive to alterations in PtdIns3-K signalling, and 
provides a readout of activation status of the pathway. Moreover, live cell 
imaging provides the ability to follow FOXO3-EGFP translocation in response 
to PtdIns3-K inhibition. This in turn allowed the design of a dynamic RNAi 
screen to identify DUB regulators of the pathway, not only under basal 
conditions, but also following its perturbation by the addition of a PtdIns3-K 
inhibitor (fig 4.2). This has potential benefits as follows. Firstly, depletion of 
proteins by siRNA (over a period of 48 hours here) may allow cellular 
adaptation, through upregulation of redundant proteins for example. 
However in the presence of stress, a partially compensated functional deficit 
may then be unmasked. Secondly, this approach would favour discovery of  
Box1. FOXO3-EGFP nuclear/cytoplasmic ratio 
The FOXO3-EGFP nuclear/cytoplasmic ratio was the primary output for 
the screen described in this chapter. The mean intensity of GFP 
fluorescence in the nuclear (n) and cytoplasmic (c) compartments was 
measured as described in section 2.4. Subtraction of mean background 
GFP intensity (b) was performed to obtain corrected nuclear (N) and 
cytoplasmic (C) fluorescence. The ratio of corrected nuclear to cytoplasmic 
(N/C) FOXO3-EGFP is thus a measure that integrates changes in 
fluorescence in both compartments, and acts as a robust indicator of 
translocation. 
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Fig 4.2. Schematic of an siRNA screen for DUB modulators of 
the PtdIn3-K pathway. FKHRL1-U2OS cells were transfected with siRNA 
directed at 92 DUBs in 96 well plates. Targets were split equally between 2 
plates. 2 mock controls and a non-targeting siRNA control were included on 
each plate (red). The outermost wells were not utilised for cell culture, and 
instead filled with PBS to minimise edge effects. After a 48 hour incubation, 
the cells were counterstained with 2.5µM DRAQ5 and imaged using a Nikon 
automated microscope as outlined. A single position was selected for each 
well, and the same position imaged at each timepoint. Image segmentation 
and quantification of fluorescence was performed using Volocity (Perkin 
Elmer) software. Three main parameters were analysed, the first two are 
discussed in this chapter, while the third is discussed in chapter 5. 
 
regulators of the PtdIns3-K pathway, over those of other pathways known to 
affect FOXO translocation (such as oxidative stress [425]). Additionally, 
FOXO3-EGFP was predominantly cytoplasmic at baseline suggesting 
constitutive activation of the PtdIns3-K pathway in these cells, thus reducing 
the chances of identifying DUBs whose depletion increases PtdIns3-K 
activity. However, following PtdIns3-K inhibition, FOXO3-EGFP localisation 
becomes predominantly nuclear, and it would be expected that DUB 
depletion leading to increased activity of the PtdIns3-K pathway would 
antagonise this translocation. In the screen, PI-103 was employed at a 
concentration of 100nM (fig 4.2). At this concentration, PI-103 had been 
shown to result in sub-maximal translocation of FOXO3-EGFP (fig 4.1iv), 
thus allowing for measurement of both potentiation or inhibition of the 
response with each DUB siRNA. 
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Notably, the predominantly cytoplasmic localisation of FOXO3-EGFP under 
basal conditions also precluded the reverse approach to a dynamic screen, 
in which cytoplasmic translocation of FOXO3-EGFP is assayed following 
stimulation of the PtdIns3-K pathway. 
 
4.3 Identifying DUBs that modulate FOXO3-EGFP localisation  
 
4.3.1 Nuclear translocation screen 
Three independent screens were performed for assessment of translocation 
as outlined in fig 4.2. In each, the ratio of nuclear/cytoplasmic FOXO3-EGFP 
was assayed for every well once every 5 minutes following the addition, and 
then washout of 100nM PI-103, using live cell imaging and subsequent 
quantitative image analysis. Due to the time taken to image all the wells on a 
96-well screen plate (approximately 4 minutes), there were slight differences 
in the timing of imaging between wells after the addition of inhibitor, although 
each well was imaged at exactly 5-minute intervals. The timepoint for each 
imaging loop was therefore reported, rather than the absolute time from the 
addition of the inhibitor. 
 
Trajectories of response to PI-103 treatment (fig 4.3) predominantly followed 
a similar pattern to that seen in preliminary experiments (fig 4.1), with an 
initial linear increase in the nuclear/cytoplasmic ratio, followed by a plateau 
phase and a rapid reduction in the nuclear/cytoplasmic ratio following 
washout of the inhibitor.  
 
To determine the effects of DUB knockdown, data were analysed at several 
timepoints; namely at baseline, on reaching plateau, and then pre- and post-
washout of inhibitor. The rate of nuclear translocation was estimated by the 
slope of the linear regression of the ratio between timepoints 2 and 5 (fig 
4.3). In each case, data were normalized to the mean of the dataset, then 
results from the three screens averaged and ranked as shown in fig 4.4i-v.  
 
Alterations to the mean nuclear/cytoplasmic ratio following DUB depletion 
were modest. At baseline a maximum increase of 39%, and decrease of 14%  
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Fig 4.3. Effects of DUB depletion on the timecourse of FOXO3-
EGFP nuclear translocation following PI-103 treatment. Three 
screens were performed, data from one of which are represented here. 48 
hours after transfection with a DUB siRNA library, the cells were stained with 
2.5µM DRAQ5 in phenol red free DMEM for 15 min, after which the media 
was removed and replaced with HBSS. A single position in each well was 
imaged at baseline and then at 5-minute intervals (timepoints) following 
treatment with 100nM PI-103, and then washout of inhibitor as indicated. 
Imaging was performed using a Nikon Ti-E automated microscope, and a 
median of 137 cells were imaged per well (range 49-137). Image analysis 
was performed for each timepoint using Volocity software (PerkinElmer) and 
the nuclear/cytoplasmic (N/C) ratio calculated as described in Box 1. The 
arrows beneath the plot indicate timepoints (baseline [A], plateau [B] and 
pre- [C] and post [D] washout) at which data from the three experiments 
were collated for further analysis. The rate of change in nuclear/cytoplasmic 
ratio between timepoints 2 and 5 (E) was similarly estimated.  
 
were observed following knockdown of USP1 and UCHL3 respectively, while 
at plateau the maximum increase and decrease (for OTUD1 and USPL1) 
were 26% and 35% respectively. However, depletion of several candidate 
DUBs resulted in changes to the nuclear/cytoplasmic ratio that were 
maintained over multiple timepoints (fig 4.4i-iv) thus shifting the entire curve 
upwards or downwards (fig 4.4vi). Examples include OTUD1 whose 
knockdown increased the nuclear/cytoplasmic ratio, and UCHL3 and USP32 
whose knockdown decreased it (fig 4.4vi). This is also illustrated in  
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Fig 4.4. Identification of candidate DUBs whose knockdown 
modulates FOXO3-EGFP translocation in response to PtdIns3-K 
inhibition. Three independent screens were performed as described in 
figure 4.3. The first two screens were imaged at 20X and the final screen at 
10X magnification. Median (range) of cells imaged per condition were 29 (11-
56), 40 (20-71), and 137 (49-238) for screens 1, 2 and 3 respectively. The 
nuclear/cytoplasmic ratio at baseline (i), plateau (ii) and pre- (iii) and post 
(iv) washout (see fig 4.3) for each screen (blue, red and green respectively) 
was normalised to the median. The mean of the three screens (black) was 
ranked as shown. The rate of change in the nuclear/cytoplasmic ratio 
following treatment with PI-103 (fig 4.3) is similarly ranked in v. In each case, 
the 5 highest and lowest ranked candidates are highlighted. vi. Trajectories 
for OTUD1 (red), UCHL3 (blue), USP45 (green) and USP32 (orange) are 
overlaid on the dataset from the third screen. 
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Fig 4.5. Depletion of OTUD1 or USP45 increases nuclear 
translocation of FOXO3-EGFP. Three independent screens were 
performed as described in fig 4.4. Changes to the FOXO3-EGFP 
nuclear/cytoplasmic (N/C) ratio following treatment with PI-103 in cells 
depleted of OTUD1 (i), USP45 (ii), UCHL3 (iii) or USP32 (iv) are shown in 
comparison to mock-transfected cells. Similar results were seen on 
comparison with the non-targeting siRNA control (data not shown). Error 
bars represent the standard deviation. n=3 with the exception of (iv) where 
n=2. A student’s t-test was used to compare each siRNA depletion with the 
mock control, the asterisk indicates p <0.05. 
 
fig 4.5, which contrasts the trajectories of selected DUB depletions with the 
mock controls. Depletion of some of the DUBs altered the rate of nuclear 
translocation following treatment with PI-103. For example, USP45 depletion 
increased the rate of nuclear translocation (fig 4.5ii), while depletion of either 
UCHL3 and USP32 flattened the response (fig 4,5iii,iv).  
 
Unfortunately, several technical factors led to a loss of datapoints, 
particularly at later time points. These included; focus slippage, poor nuclear 
staining leading to difficulties segmenting images, and loss of cells during 
media change. In certain cases there was also evidence of cell death, and  
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Fig 4.6. Selection of targets for deconvolution. The 5 top and bottom 
ranked targets from three screens for DUB modulators of the PtdIns3-K 
pathway (figure 4.4) are shown here in more detail. Candidates altering 
baseline or plateau nuclear/cytoplasmic ratio, and rate of nuclear 
translocation are shown from left to right. (Black bar indicates the mean of 
the three screens, error bars the standard deviation. n=3 with the exception 
of DUB knockdowns marked with an *, where n=2). 
 
this is discussed further in chapter 5. Due to these factors, deconvolution 
was limited to candidates identified in the early timepoints only (baseline and  
plateau nuclear/cytoplasmic ratio, rate of nuclear translocation) for which 
data were available from at least 2 screens. Exceptions were USP1 and 
USP43, where data were available from only one experiment for plateau ratio 
and rate of translocation. 
 
The top and bottom ranked candidates from these timepoints are shown in 
more detail in figure 4.6. USP47, USP43 and USP46 were not selected for 
deconvolution, as their effects were very small (less than 10% mean 
reduction in baseline nuclear/cytoplasmic ratio). OTUD7B was also excluded, 
as it had minimal effects in two of the three screens. The rest of the 
candidates were deconvoluted as described below. 
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4.3.2 Deconvolution of nuclear translocation screen 
Deconvolution was performed in triplicate in a similar manner to the original 
screen (fig 4.2). However the washout step was not performed and cells 
were only imaged for 55 minutes (11 timepoints) after addition of PI-103. For 
each candidate DUB, knockdown was performed using the four individual 
siRNA oligonucleotides that constituted the original pool, which was also 
used for comparison. Results from the deconvolution experiments are shown 
in figure 4.7. Deconvolution was deemed successful if two or more single 
oligonucleotides recapitulated the effects of the siRNA pool. This was 
defined as a minimum change of 20% from the negative controls. Out of 16 
candidate DUBs, 8 (50%) were successfully deconvoluted for at least one 
parameter (table 4.1). 
 
4.3.3 USP45 and USP32 depletion respectively increase and 
decrease the nuclear translocation of FOXO3-EGFP in response 
to PI-103 treatment 
USP45 depletion increased both the rate of nuclear translocation and the 
nuclear/cytoplasmic ratio at plateau in the FOXO3-EGFP translocation 
screen (fig 4.6). These findings were recapitulated in deconvolution (fig 4.7 
ii,iii), which also showed a modest increase in the nuclear/cytoplasmic ratio 
at baseline following USP45 depletion by two of the siRNA oligonucleotides 
(and the pool) (fig 4.8i). A timecourse of the nuclear/cytoplasmic ratio 
following PI-103 treatment is shown in fig 4.8ii. The increase in nuclear 
accumulation of FOXO3-EGFP is clearly visible 50 minutes after addition of 
100nM PI-103 in USP45 depleted cells (fig 4.8iii).  
 
The findings for USP32 depletion in the screen (fig 4.6) were also 
recapitulated on deconvolution of the siRNA pool, where depletion of USP32 
by three out of four oligonucleotides resulted in a reduced rate of 
translocation (fig 4.7iii). Examination of the timecourse (fig 4.9i) shows that 
two of the four siRNA oligonucleotides (A and D), had the most marked effect 
with a persistently reduced gradient of the curve compared with the controls. 
Following depletion of USP32 using either of these oligonucleotides, a large  
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Fig 4.7. Deconvolution of the nuclear translocation screen 
candidates. FKHRL1-U2OS cells were transfected with four independent 
siRNA oligonucleotides (A-D) and pooled (P) oligonucleotide against each 
target. 48 hours after transfection, each well was imaged at baseline and 
then at 5-minute intervals (timepoints) for 55 minutes following addition of 
100nM PI-103 using a Nikon Ti-E automated microscope. A median (and 
range) of 126 (28-292) cells were imaged per well. Image analysis was 
performed using Volocity (PerkinElmer) software, and the 
nuclear/cytoplasmic ratio at baseline and time 10 (plateau) calculated as 
described in Box 1. The rate of translocation between timepoints 2 and 5 was 
estimated by the slope of the linear regression. Each datapoint was 
normalised to the mean of the controls. Deconvolution for baseline and 
plateau N/C ratio, and rate of increase in N/C ratio are shown in (i-iii) 
respectively. For each oligonucleotide and parameter the mean +/-SD is 
shown. Horizontal dotted lines indicate +/- 20% change compared to 
controls. Candidates to the left of the vertical dotted line were downregulated 
in the screen, while those on the right were upregulated. 
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Table 4.1 Summary of deconvolution of DUB candidates from the 
translocation screen. Candidate DUBs selected for deconvolution are 
shown here with numbers indicating ranking in the original screen (fig 4.4). 
Deconvolution of candidate DUBs was considered to have been successful 
where two or more single oligonucleotides recapitulated the effects of the 
siRNA pool. This was defined as a minimum change of 20% from the 
negative controls. Deconvolution results are shown in parentheses (Y- Yes, 
N- No), and successfully deconvoluted candidates are shown in blue (down 
regulation) or red (up regulation). (N/C- nuclear/cytoplasmic) 
 
 
proportion of cells showed a persistent cytoplasmic localisation of FOXO3-
EGFP  despite PI-103 treatment (fig 4.9ii). 
 
OTUD1 was also deconvoluted according to the criteria set, with two of the 
four siRNA oligonucleotides increasing the nuclear/cytoplasmic ratio at both 
baseline and plateau. However, only one of the siRNA oligonucleotides 
resulted in a reproducible increase in all three experiments, and the 
phenotype was marginal (fig 4.7). Similarly, while three siRNA  
 
DUBs whose 
knockdown: 
      
Baseline N/C Ratio Plateau N/C Ratio Rate of Translocation 
UCHL3 1 (N)  3 (N)  3 (N)  
USP1  1 (Y)     
OTUD1  2 (Y)  1 (Y)   
PSMD14  3 (Y)     
CYLD  4 (N)   1 (N)  
PSMD7  5 (Y)     
USPL1   1 (N)  5 (Y)  
OTUD6A   2 (N)  2 (N)  
BRCC3   4 (N)    
DUB3   5 (N)    
USP45    2 (Y)  3 (Y) 
USP38    3 (N)  1 (N) 
ATXN3L    5 (N)  5 (Y) 
USP32     4 (Y)  
USP27X      2 (N) 
USP41      4 (N) 
  122 
 
 
Fig 4.8 USP45 knockdown increases nuclear translocation of 
FOXO3-EGFP in response to PI-103 treatment. Data for USP45 
knockdown from three deconvolution experiments (fig 4.6) are highlighted 
here. (i). Baseline nuclear/cytoplasmic (N/C) ratio following knockdown with 
4 individual siRNA oligonucleotides (A-D) and pooled oligonucleotides. The 
ratio in each case was normalised to the mean of 4 negative controls (2 
mock and 2 non-targeting siRNA [siC]). The black bars show the mean of 
three experiments, and the error bars show the standard deviation. (ii) 
Timecourse of nuclear/cytoplasmic ratio following addition of 100nM PI-103. 
The data represent the mean of three experiments for each timepoint (iii). 
Representative greyscale FOXO3-EGFP fluorescence images from timepoint 
10 (50 minutes). (scale bar represents 100µm) 
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Fig 4.9. USP32 depletion decreases the nuclear translocation 
rate of FOXO3-EGFP in response to PI-103 treatment. Data for 
USP32 knockdown from three deconvolution experiments (fig 4.6) are 
highlighted here. In each experiment knockdown of USP32 was performed 
with 4 individual siRNA oligonucleotides (A-D) and pooled oligonucleotides. 
The nuclear/cytoplasmic ratio for each timepoint was calculated as described 
in Box 1. The ratio in each case was normalised to the mean of 4 negative 
controls (2 mock and 2 non-targeting siRNA [siC]). i. A timecourse of the 
nuclear/cytoplasmic ratio following addition of 100nM PI-103 is shown here. 
The data represent the mean of three experiments for each timepoint. ii. 
Representative greyscale FOXO3-EGFP images. Scale bar represents 
100µm.  
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oligonucleotides against ATXN3L increased the rate of translocation, only 
one did so convincingly (fig 4.7C). 
 
In the original screen, UCHL3 depletion reduced the nuclear/cytoplasmic 
ratio at baseline and at plateau, as well as reducing the rate of translocation 
(fig 4.6). These effects were not deconvoluted with individual 
oligonucleotides, and the effect of the pool was also not reproduced (fig 4.6).  
 
USP1, USPL1, and the proteasomal subunits PSMD7 and PSMD14, were 
also successfully deconvoluted. However, depletion of these DUBs also 
affected the overall abundance of FOXO3-EGFP (see section 4.4), making it 
difficult to interpret their effects on nuclear-translocation of FOXO3-EGFP, 
and this has not been pursued further at present. 
 
4.4 Screening for DUB regulators of FOXO3-EGFP abundance 
 
4.4.1 FOXO3-EGFP fluorescence 
A secondary output from the screen was a measure of the total cellular level 
of FOXO3-EGFP fluorescence indicating changes to the abundance of 
FOXO3-EGFP. Here, mean total cellular fluorescence was determined at 
baseline (i.e. in the absence of PtdIns3-K inhibition), corrected for 
background, normalized to the mean of the dataset and ranked (fig 4.10i). 
Knockdown of the five top ranked DUB candidates increased FOXO3-EGFP 
abundance by between 1.5 and 2-fold while depletion of the bottom ranked 
five candidates decreased FOXO3-EGFP abundance by about half on 
average (fig 4.10ii). The effects of depletion of those candidates (particularly 
those reducing FOXO3-EGFP fluorescence) was relatively consistent 
between experiments (fig4.10ii).  
 
Several DUBs whose depletion affected FOXO3-EGFP abundance, also 
altered its translocation (USP1, PSMD7, PSMD14 and OTUD6A) and were 
therefore deconvoluted as described in fig 4.7. In view of the potential utility 
of stabilizing FOXO3 in cancer therapy, I additionally selected the remainder 
of the five candidates which upregulated FOXO3-EGFP in the screen for  
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Fig 4.10. Screening for DUB regulators of total cellular FOXO3-
EGFP fluorescence. Three independent screens were performed as 
described in figs 4.3 and 4.4. Here analysis of the mean intensity of FOXO3-
EGFP fluorescence at baseline is shown. The periphery of the cells were 
outlined, and mean intensity of GFP fluorescence within cells determined and 
corrected to background. Results from each screen were normalised to the 
median. i. For each DUB knockdown, the mean of the three screens was 
ranked and plotted as shown. The top and bottom 5 candidates are 
highlighted, and shown with error bars in ii. Median (range) of cells imaged 
per condition were 29 (11-56), 40 (20-71), and 137 (49-238) for screens 1, 2 
and 3 respectively). Error bars represent standard deviation. 
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Fig 4.11. Deconvolution of candidate DUBs from the FOXO3-
EGFP abundance screen. Candidate DUBs were deconvoluted as 
described in fig 4.6, and here data for whole cell FOXO3-EGFP fluorescence 
at baseline (prior to addition of PI-103) are shown, which was calculated as 
described in fig 4.9. For each candidate DUB, knockdown was performed 
using 4 individual siRNA oligonucleotides (A-D) and pooled oligonucleotides. 
Results for each DUB knockdown were normalised to the mean of four 
negative controls (2 mock and 2 non-targeting siRNA). A median (and range) 
of 105 (35-246), 98 (28-234), 126 (28-292) cells were imaged per condition in 
the first, second and third experiments respectively Candidates up and down 
regulating FOXO3-EGFP in the screen are separated by the vertical dotted 
line. (Horizontal dotted lines indicate +/- 20%, error bars show SD. n=3) 
 
deconvolution. USPL1, which had also been identified in the translocation 
screen, was ranked seventh in the abundance screen and was therefore also 
included in the deconvolution, the results of which are summarised in fig 
4.11. 
 
Similarly to the translocation screen, deconvolution was deemed successful if 
at least two single oligonucleotides recapitulated the effects of the siRNA 
pool. This was defined as a minimum change of 20% from the negative 
controls, and all candidate DUBs were deconvoluted successfully by these 
criteria (fig 4.11).  
 
Both PSMD7 and PSMD14 are integral components of the 19s proteasome, 
and as discussed in section 3.11, their depletion would be expected to 
interfere with the proteasomal degradation of proteins thus potentially leading  
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to their stabilisation. This is supported by the findings here, with depletion of 
either PSDM7 or PSMD14 resulting in an increase in FOXO3-EGFP 
fluorescence in the screen, an effect that was recapitulated by 4 and 3 
individual siRNA oligonucleotides respectively.  
 
Depletion of USPL1 similarly increased FOXO3-EGFP fluorescence in the 
screen. This was supported by deconvolution experiments in which depletion 
of USPL1 by each of the four individual oligonucleotides, or the pool, resulted 
in an increase in fluorescence, ranging from approximately 50 to 150% (fig 
4.11). Representative images for two of the oligonucleotides and two controls 
are shown in fig 4.12i. This increase in FOXO3-EGFP abundance was further 
investigated in an independent experiment, in which FOXO3-EGFP was 
assayed by immunoblotting for either FOXO3 or EGFP (fig 4.12ii). Both the 
FOXO3 and EGFP antibodies detected the same fusion protein species, and 
showed similar upregulation following USPL1 depletion (fig 4.12ii). In 
addition, the results of immunoblotting assay for FOXO3-EGFP abundance 
were similar to those of the fluorescence experiment (fig 4.12iii). 
 
USP15, OTUD6A or USP49 depletion also resulted in an increase in 
FOXO3-EGFP fluorescence. All three DUBs were successfully deconvoluted 
according to the criteria set, however confirmation by immunoblotting has not 
been performed for these candidates. 
 
Depletion of USP1, on the other hand, resulted in a decrease in FOXO3-
EGFP fluorescence. On deconvolution, all four of the oligonucleotides 
reduced FOXO3-EGFP fluorescence, although this was most appreciable for 
two of the four (fig 4.11, 4.13i). Confirmation of the effects of USP1 depletion 
on FOXO3-EGFP abundance was performed by immunoblotting for EGFP 
and FOXO3 (fig 4.12ii) for which results were very similar to fluorescence 
microscopy (fig 4.12iii).  
 
Interestingly, USP1 knockdown was also quite toxic, and resulted in a 
noticeable reduction in cell number at 48 hours post transfection (fig 4.12i). In 
the three deconvolution experiments, a mean of 47, 63, 69, 126 and 63 cells  
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Fig 4.12. Depletion of USPL1 increases FOXO3-EGFP 
abundance. i. Representative images from the deconvolution experiments 
described in fig 4.10. ii. A 72-hour knockdown of USPL1 was performed 
using the indicated oligonucleotides, cells were lysed with NP40 and 
immunoblotted for the indicated proteins. Imaging was performed using an 
infrared scanner (Odyssey [LiCor]). FOXO3 and EGFP were detected using 
the green and red channels respectively, and a merge of the results from the 
two is shown in the third panel from the top. iii. Comparison of fluorescence 
imaging and immunoblotting for EGFP. In each method normalised EGFP 
signal was compared to the mock control. (A-D: individual siRNA 
oligonucleotides, P: pool, siC: non targeting siRNA control, FM: fluorescence 
microscopy, IB: immunoblotting, scale bar represents 100µm, n=1) 
 
were counted per microscopy field following USP1 knockdown using 
oligonucleotides A-D and the pool respectively, compared to a mean of 163 
cells for the negative controls.  
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Fig 4.13. Depletion of USP1 decreases FOXO3-EGFP 
abundance. i. Representative images from the deconvolution experiment 
described in fig 4.10. ii. A 72-hour knockdown of USP1 was performed using 
the indicated siRNA oligonucleotides, cells were lysed with NP40 and 
immunoblotted for FOXO3 and EGFP as indicated. Imaging was performed 
using an infrared scanner (Odyssey [LiCor]). FOXO3 and EGFP were 
detected using the green and red channels respectively, and a merge of the 
results from the two is shown in the third panel from the top. iii. Comparison 
of fluorescence imaging and immunoblotting for EGFP. In each method 
normalised EGFP signal was compared to the mock. (A-D: individual siRNA 
oligonucleotides, P: pool, siC: non targeting siRNA control, FM: fluorescence 
microscopy, IB: immunoblotting, scale bar represents 100µm, n=1) 
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4.4.2 Immunoblotting for FOXO3-EGFP 
As described in section 4.4.1 above, quantification of the effects of USP1 and 
USPL1 depletion on FOXO3-EGFP abundance using immunoblotting for 
either FOXO3 or EGFP gave very similar results to its determination by 
quantification of fluorescence imaging. This therefore provided an alternative 
assay for an siRNA screen seeking to identify DUBs whose depletion altered 
FOXO3-EGFP abundance (fig 4.14). 
 
A simplified version of the screening strategy described in chapter 3 was 
employed here, in which the cells were grown in 96 well plates, lysed in situ, 
then prepared directly for immunoblotting, without prior normalisation of 
protein concentration. This led to considerable variability in protein loading 
between lanes as demonstrated by immunoblotting for actin (fig 4.14i). 
However, normalisation to actin allowed comparison of samples, as shown in 
fig 4.14ii. Three of the five candidates whose depletion downregulated 
FOXO3-EGFP, were similarly among the candidates identified using 
fluorescence microscopy.  
 
However, correlation between the two screens was less good for DUBs 
whose depletion increased FOXO3-EGFP, with only one of the top 5 
candidates by immunoblotting (USP15) also identified in the fluorescence 
screen. The coefficient of correlation for the whole dataset was 0.403 (fig 
4.14iii). Interestingly, USP7, which has been shown to be involved in nuclear 
localisation of FOXO4 [205], was identified as one of the candidates 
upregulating FOXO3-EGFP levels. However, USP7, and other candidates 
identified in this screen, have not been subject to further validation thus far. 
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Fig 4.14 An immunoblotting screen for DUB regulators of 
FOXO3-EGFP. A 48-hour knockdown with pooled oligonucleotides 
directed at 92 DUBs was performed in U2OS-FKHL1 cells grown in two 96 
well plates. Mock and non-targeting siRNA (siC) controls were also included. 
Lysis was performed directly on the plates using NP40 buffer. Loading buffer 
was then added to each well, following which the lysate was transferred to a 
new 96 well plate, which was sealed, and the lysate boiled. Samples were 
then directly run out on four SDS-PAGE gels and immunoblotted for FOXO3 
and actin. i. Representative blot. ii. The FOXO3 signal was normalised to 
actin and the median of each blot, then ranked as shown. iii. Plot of the 
results of the immunoblotting screen compared to the fluorescence screen 
described in section 4.4.1. (Imaging and analysis of blots was performed on 
an odyssey [LiCor] infrared scanner, n=1). 
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4.5 Discussion 
 
In this chapter I have described an siRNA screen for DUB modulators of 
downstream PtdIns3-K activity which utilised PtdIns3-K dependent 
translocation of FOXO3-EGFP as a readout for pathway activity. The screen 
used live cell imaging to follow the effects of DUB depletion on FOXO3-
EGFP translocation following PtdIns3-K inhibition, thus increasing both the 
scope and dynamic range of the screen as discussed in section 4.2.   
 
The effects of DUB depletion on FOXO3-EGFP localisation in cells under 
normal growth conditions and following PI-103 treatment, as well as the rate 
of nuclear translocation after PI-103 treatment were assessed. In general, 
depletion of single DUBs only resulted in modest changes to each of these 
parameters. Interpretation of the data from this screening strategy was also 
complicated by marked variability between the three replicate screens. 
However, of the five top and five bottom ranked candidate DUBs, half were 
successfully validated for at least one parameter (table 4.2) by deconvolution 
of the original oligonucleotide pool. 
 
As described in section 3.9, low endogenous expression of the FOXO family 
precluded immunoblot screening for DUBs affecting endogenous FOXO 
protein level in A549 cells. In the current screen, using cells in which FOXO3-
EGFP was stably overexpressed, I observed significant variations in overall 
fluorescence (reflecting FOXO3-EGFP abundance) following knockdown of 
several DUBs, and therefore utilized fluorescence intensity as a secondary 
output from the screen. Seven DUB candidates whose depletion upregulated 
or downregulated FOXO3-EGFP fluorescence were subject to deconvolution, 
which was successful in all cases (table 4.2). For two of the candidates 
(USP1 and USPL1), the effects on FOXO3-EGFP abundance have been 
further validated by immunoblotting. 
 
Depletion of several DUBs identified in the screen resulted in particularly 
compelling phenotypes, and these are further discussed here. USP45 
knockdown resulted in an increased rate of translocation of FOXO3-EGFP  
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Table 4.2 Summary of successfully deconvoluted DUB 
candidates. The first two columns include DUBs affecting either baseline or 
plateau nuclear/cytoplasmic ratio or rate of translocation. Deconvolution was 
deemed successful if two or more single oligonucleotides recapitulated the 
effects of the siRNA pool, which was defined as a minimum change of 20% 
from the negative controls. 
 
into the nucleus, and an increased degree of nuclear localization as the 
response plateaued. No substrates or functions have been ascribed to 
USP45 to date. However, several USP45 interactors have been described in 
a mass spectroscopy based screen [415]. Interestingly, these include 
PIK3CG (PtdIns3-K p110γ). In my (previously described) screen for DUB 
regulators of the protein level of PtdIns3-Kinases (section 3.4), USP45 
knockdown resulted in a small reduction (~10%) in the protein level of p110γ. 
On the other hand, USP45 knockdown upregulated the protein level of both 
p110β and p110α and was ranked 9th and 13th respectively for these two 
screens. While the changes in protein level were modest, the increase in 
p110β and p110α, may represent compensatory changes in response to 
alterations in p110γ level or activity. 
 
DUB whose 
knockdown: 
Decreases 
nuclear 
localisation 
Increases 
nuclear  
localisation 
Decreases total 
cellular 
fluorescence 
Increases total 
cellular 
fluorescence 
USPL1 ✓   ✓ 
USP32 ✓    
USP1  ✓ ✓  
OTUD1  ✓   
PSMD7  ✓  ✓ 
PSMD14  ✓  ✓ 
USP45  ✓   
ATXN3L  ✓   
OTUD6A    ✓ 
USP15    ✓ 
USP49    ✓ 
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Knockdown of USP32 led to reduced nuclear accumulation of FOXO3-EGFP 
in response to PtdIns3-K inhibition. This was only apparent for two out of the 
four individual siRNA oligonucleotides, which may reflect differential 
knockdown efficiency or alternatively different effects on USP32 splice 
variants, and will require further investigation.  
 
USP32 is closely related to the human proto-oncogene USP6 [397], and in 
one study was found to be overexpressed in 50% of breast cancer cell lines 
(9/18) and 22% (9/41) of primary breast cancers [417]. As previously 
discussed, USP32 knockdown results in a decrease in the protein level of 
PDK1 (section 3.4). However, this is unlikely to explain the data seen here, 
as loss of PDK1 would be expected to decrease activation of Akt, and thus 
favour nuclear accumulation of FOXO3. This suggests that USP32 regulates 
other components of the PtdIns3-K pathway. Several USP32 interactors 
have described [415], but none of these is directly related to PtdIns3-K 
signalling. 
 
As demonstrated by Ratjadone A treatment (fig 4.1), nuclear export inhibition 
results in rapid and profound nuclear accumulation of FOXO3-EGFP 
suggesting it is continuously shuttling between the cytoplasm and nucleus. 
While USP45 and USP32 were successfully deconvoluted, further validation 
will be required to prove that the effects on nuclear translocation were due to 
modulation of PtdIns3-K downstream activity, and not due to general effects 
on nuclear import or export. This may include the use of a cell line 
expressing a GFP labelled protein with a strong nuclear export signal, such 
as is described by Zanella et al [426]. Their study employed a GFP tagged 
Rev protein which is almost exclusively cytoplasmic at steady state, but 
accumulates rapidly in the nucleus on inhibition of nuclear export. 
 
Depletion of USPL1 and USP1 respectively increased and decreased the 
abundance of FOXO3-EGFP, which was assessed by both fluorescence 
microscopy and immunoblotting. However, as endogenous FOXO3 was not 
detectable in these cells, the findings may reflect regulation of the tagged 
protein only, and not reflect that of endogenous untagged protein. To 
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address this, further validation would involve investigating the effects of 
depletion of both DUBs in cell lines with relatively high FOXO3 expression, 
examples of which include non-small cell lung cancer cell lines such as 
H1299, H1650 [427], or CORL23 (section 3.9). In addition, further work will 
include determining whether depletion of these DUBs alters FOXO3-EGFP 
synthesis, or its degradation. Depletion of either USPL1 or USP1 also 
appeared to alter nuclear localisation of FOXO3-EGFP, however 
interpretation of this data was difficult in view of the considerable differences 
in FOXO3-EGFP abundance in these DUB depletions compared to the 
controls. 
 
USPL1 has been shown to be a specific SUMO isopeptidase and to lack 
activity against ubiquitin [428], however no functional roles have been 
described. SUMOylation, unlike ubiquitylation is not a degradative signal per 
se, but like ubiquitin may influence activity, localisation or stability of its 
substrate [429]. SUMOylation and ubiquitylation are known to cross talk, and 
in certain instances the same residue may be either SUMOylated or 
ubiquitylated (an example being PCNA which may be either ubiquitylated or 
SUMOylated at position K164 [56]). It is therefore feasible that depletion of 
USPL1 could lead to increased SUMOylation of FOXO3, thus preventing  
degradative ubiquitylation, and leading to FOXO3 stabilisation. However, 
SUMOylation of FOXO factors has not yet been reported in the literature and 
analysis of the FOXO3 sequence using the SUMOylation prediction 
programme SUMOplot, identified only motifs with low probability for 
SUMOylation. 
 
Several USPL1 interactors have been identified including ANKFY1 (ankyrin 
repeat and FYVE domain-containing protein 1) [415], which in turn interacts 
with the PtdIns3-K class II catalytic subunit PIK3C2A (p170) [430]. While 
knockdown of USPL1 did not significantly alter p170 protein level in my 
screen (section 3.7), this clearly does not preclude a role for USPL1 in its 
regulation. 
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USP1 is known to deubiquitylate FANCD2 [384] and PCNA [431] and is 
implicated in the DNA damage response. USP1 has also recently been 
shown to regulate the phosphorylation status of Akt by altering the stability of 
PHLPP1 [432]. In a separate study, a small molecule inhibitor of USP1 was 
shown to reverse cisplatin resistance and decrease proliferation in a non-
small cell cancer cell line [214]. This small molecule inhibitor may be useful in 
determining the effects of USP1 on FOXO3 in future. Notably, USP1 
depletion resulted in a decrease in cell number of both cell lines used in this 
thesis. In this chapter I show reduced cell number after a 48 hour knockdown 
of USP1 in FKHRL1-U2OS cells (section 4.4.1), while in section 3.2 I 
described a visual assessment of toxicity, which correlated with a greater 
than 50% reduction in protein yield, following a 72 hour depletion of USP1 in 
A549 (non-small cell lung cancer) cells.  
 
In previous studies, USP7 was shown to be involved in the regulation of 
FOXO subcellular localization [205]. Oxidative stress resulted in the mono-
ubiquitylation of FOXO4 (and FOXO3), leading to its nuclear localisation, and 
this was reversed by USP7 in 293T cells [205]. However, USP7 was not 
identified as a regulator of FOXO3 localisation in the current screen. This 
may indicate that USP7 involvement is limited to oxidative stress response, 
that it is cell type dependent, or it may represent a false negative result from 
the screen. Interestingly though, USP7 depletion did alter FOXO3-EGFP 
abundance in the immunoblotting screen (fig 4.14), although this finding has 
not been confirmed by deconvolution. 
 
In summary, I have described the identification of several DUBs whose 
knockdown either modulates FOXO3-EGFP nuclear accumulation in 
response to inhibition of PtdIns3-K or alters FOXO3-EGFP abundance. While 
further validation is required, these findings suggest a vital role for several 
new deubiquitylases in regulating the PtdIns3-K pathway.        
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Chapter 5 
 
Depletion of USP8 sensitises to PI-103 induced cell death 
 
5.1 Introduction 
 
Synthetic lethality refers to the interaction of two or more mutations, each of 
which is not in itself lethal, but which in combination cause cell death. First 
described in Drosophila over 60 years ago [433, 434], synthetic lethality has 
been extensively investigated in yeast [435] and other model systems. The 
term is now also used when one of the mutations is replaced by loss of gene 
function through RNAi or pharmaceutical inhibition. The latter has provided 
novel therapeutic opportunities, and potentially allows the targeting of 
malignancies in which tumour suppressors are inactivated. The best-
established example is the use of PARP (poly ADP ribose polymerase) 
inhibitors in BRCA mutant breast cancers, where the homozygous loss of 
BRCA (1 or 2) in the cancer bestows sensitivity to PARP inhibitors [436].  
 
Synthetic lethality screens have now become established as valuable tools in 
drug discovery, and provide insights into the mechanisms of drug action and 
resistance [437]. While the FOXO3-EGFP translocation screen described in 
chapter 4 was not designed as a synthetic lethal screen, it provided the 
opportunity to observe synthetic effects between DUB depletion and 
treatment with the PtdIns3-K (and mTOR) inhibitor PI-103.  The depletion of 
three DUBs was observed to potentiate cell death on addition of PI-103, and 
initial validation for one of these candidates, USP8, is described here. 
 
5.2 Depletion of USP8, OTUD4 or DUB4 increases PI-103 
dependent cell death 
 
The screen for regulators of PI-103 dependent nuclear translocation of 
FOXO3 (FKHRL1)-EGFP is described in section 4.2. In brief, FKHRL1-U2OS  
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Fig 5.1. Knockdown of USP8, DUB4 and OTUD4 leads to 
increased cell death on PI-103 treatment. Data shown here are from 
one of three screens performed as described in fig 4.3. Following a 48-hour 
siRNA knockdown in FKHRL1-U2OS cells, cells were imaged at baseline 
and then every 5-minutes following addition of 100nM PI-103. i. 
Representative cropped images for cells transfected with USP8, DUB4, 
OTUD4 and non-targeting (siC) siRNA oligonucleotides. Merged FOXO3-
EGFP (green) and DRAQ5 (red) images are shown. Time after addition of 
100nM PI-103 (minutes) is shown in the bottom left-hand corner. In the top 
three panels an example of a cell undergoing cell death is indicated by an 
arrowhead. ii. Magnified view of inset from DUB4 panel, with separate 
FOXO3-EGFP and DRAQ5 channels. (scale bar represents 25µm).  
 
 
cells were transfected with a DUB siRNA library, incubated for 48 hours and 
imaged every 5 minutes following the addition of 100nM PI-103. While a low 
level of cell death was observed over the time course of the screen in all 
conditions, this was most pronounced and reproducible following depletion of 
USP8, DUB4 or OTUD4. Approximately 40 to 50 minutes after the addition of 
PI-103, a proportion of cells began to round up and progressively exhibit an 
increased intensity of GFP and DRAQ5 fluorescence (fig 5.1i,ii). In addition, 
the cellular margins became irregular, and finally there was evidence of 
nuclear fragmentation (fig 5.1ii). 
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These data suggested that depletion of USP8, DUB4 or OTUD4, sensitises 
FKHRL1-U2OS cells to death following treatment with PI-103. In order to 
confirm this observation, a 48-hour knockdown of these three DUBs was 
performed in FKHRL1-U2OS cells, which were then imaged at baseline and 
hourly following the addition of 100nM PI-103 (fig 5.2). The media conditions 
employed in the original translocation screen were retained, however vehicle 
(DMSO) treatment was included as a control. In addition to a mock-
transfected control, three other members of the DUB library, which had not 
caused increased cell death in the screens (USP9X, DUB3 and PARP11), 
were included as controls. These were contiguous to USP8, DUB4 and 
OTUD4 respectively in the DUB library plate, and were selected in this 
manner to reduce bias. An estimate of cell death was obtained by counting 
cells with increased EGFP and DRAQ5 fluorescence intensity (section 2.4.3), 
and this was expressed as a percentage of total cells.  
 
Basal cell death, prior to the addition of PI-103 or DMSO, provided an 
estimate of the toxicity that could be directly ascribed to a given DUB 
depletion in this assay. Of the three DUBs identified in the screen, only DUB4 
depletion led to an increase in basal toxicity, compared to the mock control. 
 
An assessment of cell death was made at 1 and 2 hours following addition of 
PI-103 or DMSO. Treatment of mock-transfected cells with vehicle alone did 
not result in any quantifiable cell death over the course of the experiment, 
while treatment with PI-103 resulted in less than 5% cell death after 2 hours 
(fig 5.2). Depletion of two of the three DUBs randomly selected from the DUB 
library (USP9X and PARP11) did not induce cell death compared to the 
mock-transfected cells. DUB3 depletion on the other hand did increase PI-
103 induced cell death, albeit to a lesser degree than the DUBs identified in 
the screen, and this only became evident at the two-hour time point. 
 
Similarly to observations made during the screen, depletion of USP8, DUB4 
or OTUD4 increased PI-103 induced cell death (fig 5.2). In DUB4 depleted 
cells, greater than 60% cell death was observed 2 hours after adding PI-103  
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Figure 5.2 (continued overleaf) 
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Fig 5.2. Loss of USP8, DUB4 or OTUD4 increases PI-103 
induced cell death. FKHRL1-U2OS cells were transfected in a 96 well 
plate with siRNA oligonucleotide pools directed at the indicated genes, or 
mock transfected. Following a 48-hour incubation, the cells were stained with 
DRAQ5, and then the media changed to serum-free Hanks Buffered Saline 
Solution (HBSS) containing either 100nM PI-103 or vehicle (DMSO). Imaging 
was performed hourly by automated microscopy. i. Representative grey-
scale FOXO3-EGFP fluorescence images of cells at baseline and an hour 
after addition of PI-103 or DMSO. (scale bar represents 100µm) ii. An 
estimate of cell death was obtained by counting the number of cells with both 
high intensity GFP and DRAQ5 fluorescence using Volocity (PerkinElmer) 
software. The number of dead cells is expressed as a percentage of total 
cells at baseline. A median of 156 (range 62-365) cells were imaged in each 
well (one position) at baseline. Three replicates were performed per condition 
and the mean of the three is reported.  
 
(fig 5.2ii). While basal cell death was increased to about 15% of cells, no 
further cell death was observed after 2 hours of DMSO treatment (fig 5.2ii). 
 
On the other hand, USP8 or OTUD4 depletion did not increase baseline cell 
death (fig 5.2), but was associated with increased cell death after 1 or 2 
hours of PI-103 treatment (fig 5.2B). Depletion of either USP8 or OTUD4 also 
increased cell death following treatment with DMSO, though to a lesser 
extent. The differential in cell death between PI-103 and DMSO treated cells 
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was more marked following depletion of USP8, where cell death of 
approximately 60% and 10% respectively was observed. 
 
These results support the observations made in the screen, and indicate that 
all three DUBs are worthy of further study in the context of interaction with PI-
103 inhibition. However, the most convincing of these was USP8, whose 
depletion did not cause direct toxicity, but increased sensitivity to PI-103 
significantly more than to vehicle. Previous studies have also linked USP8 to 
the PtdIns3-K pathway (discussed in section 5.8), supporting its study in this 
context. Additionally, USP8 has been the subject of other projects in the host 
laboratory, and reagents (including an antibody and inhibitors) were therefore 
available. For these reasons, investigation of USP8 was prioritised over the 
other candidates. 
 
5.3 Assessment of cell death using DRAQ7 provides further 
evidence for a role for USP8 depletion in PI-103 sensitivity.  
 
The first validation step undertaken was deconvolution of the USP8 pool (figs 
5.3 and 5.4). This utilised an alternative assay to measure cell death. In the 
previous section, cell death was estimated based on morphological changes 
that led to an increase in the intensity of EGFP and DRAQ5. This was, 
however, open to observer bias (section 2.4.3). Furthermore, the small 
proportion of cells undergoing mitosis exhibited a similar appearance to 
those scored as undergoing cell death. I therefore designed an assay with 
which to specifically follow cell death during live cell imaging (fig 5.3). This 
employed DRAQ7 (Biostatus), a nuclear dye that is only taken up by dead 
cells, and is non-toxic to live cells [438]. DRAQ7 has previously been 
employed in flow cytometry to count the proportion of dead cells [439], 
however to my knowledge no publications have previously reported the use 
of DRAQ7 in microscopy time lapse assessment of cell death in monolayer 
culture.  
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Fig 5.3. DRAQ7 staining enables the identification of cell death 
during live cell imaging. FKHRL1-U2OS cells were transfected in a 96 
well plate with the indicated siRNA oligonucleotides against USP8, or non-
targeting siRNA control (siC). Following a 48-hour incubation, the media was 
changed to serum-free HBSS, containing 3µM DRAQ7 and either 100nM PI-
103 (PI), 1µM MK2206 (MK) or vehicle (DMSO), and imaging was performed 
hourly by automated microscopy for 13 hours after which DRAQ5 was added 
to a concentration of 5µM, cells were incubated a further 20 minutes and a 
final image taken. i. Representative cropped images (FOXO3-EGFP, 
DRAQ7 and merge) from baseline and first 6 hours following treatment with 
100nM PI-103. Right-hand panel contains final images (FOXO3-EGFP, 
DRAQ5 and merge 2). ii-iii. Timelines for merged (FOXO3-EGFP and 
DRAQ7) cropped images, the final panel was stained with DRAQ5. (Merge 2: 
FOXO3-EGFP and DRAQ5, scale bar represents 25µm, the arrowhead 
indicates mitotic cells)  
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Fig 5.4. USP8 depletion sensitises FKHRL1-U2OS cells to 
PtdIns3-K inhibition. FKHRL1-U2OS cells were transfected with siRNA 
oligonucleotides against USP8 (A-D), mock transfected or transfected with 
non-targeting siRNA (siC), incubated for 48 hours and treated with 100nM PI-
103 (PI), 1µM MK2206 (MK) or vehicle (DMSO) as described in fig 5.3. Cells 
taking up DRAQ7 were counted using Volocity (PerkinElmer) and expressed 
as a percentage of total cells, which were counted following staining with 
DRAQ5, which was performed after the last timepoint. A single position was 
imaged per well and a median of 105 (range 19-256) cells were imaged per 
condition. 
 
 
In fig 5.3, representative images of cells following a 48-hour transfection with 
USP8 siRNA (using oligonucleotides A and B) or control siRNA are shown. 
Cells undergoing the changes scored previously as indicative of cell death  
 (rounding up, increased EGFP intensity), also took up DRAQ7 (fig 5.3i,ii), 
while the remainder of cells were not stained by DRAQ7 (fig 5.3i-iii). Cells 
transfected with control siRNA showed no evidence of DRAQ7 uptake (and 
thus cell death), and indeed continued to divide (fig 5.3iii). Depletion of USP8 
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using either oligonucleotide resulted in the death of a proportion of cells, this 
being most marked with USP8_A (fig 5.3i-iii).  
 
At the end of the experiment, the cells were stained with DRAQ5 to allow a 
total cell count, and DRAQ7 positive (dead) cells at each timepoint were then 
expressed as a percentage of total cells (Fig 5.4i-vi). Minimal cell death was 
observed in either the mock-transfected or non-targeting siRNA controls (fig 
5.4i,ii). On the other hand, depletion of USP8 by all 4 siRNA oligonucleotides 
resulted in increased cell death following treatment with either PI-103 or 
MK2206 (fig 5.4iii-vi). Overall cell death was most marked following depletion 
of USP8 with oligonucleotide A, however for this oligonucleotide, significant 
cell death was also seen on treatment with vehicle alone (fig 5.4iii). Depletion 
of USP8 with the other three oligonucleotides in all cases resulted in 
substantially more cell death following treatment with either PI-103 or 
MK2206, over vehicle alone. 
 
In this experiment, the findings of the original screen, in which USP8 
depletion sensitised cells to PI-103 dependent cell death, were successfully 
validated by deconvolution of the oligonucleotide pool. In addition, inhibition 
of Akt using MK2206 resulted in very similar effects to PI-103 treatment, 
indicating that depletion of USP8 may generally sensitise cells to inhibition of 
the PtdIns3-K pathway. 
 
5.4 The USP8 inhibitors HBX 90,397 and HBX 90,659 increase 
sensitivity to PI-103 treatment. 
 
Two USP8 inhibitors developed by Hybrigenics [440] were available in the 
host laboratory following a previous collaboration. Table 5.1 summarises 
their activity against a panel of deubiquitylases, and shows their selectivity 
for USP8. These compounds were utilised to further investigate the effects of 
USP8 loss of function on sensitivity to PI-103 in FKHRL1-U2OS cells. 
 
Firstly, FKHRL1-U2OS cells were treated with varying concentrations of 
either USP8 inhibitor in the absence of PI-103 and imaged hourly for 12  
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Inhibitor Designation in 
Colombo et al 
[440] 
IC50 (µM) 
USP8 USP7 USP5 UCHL1 UCHL3 
HBX 90,397 22c 0.559 >100 >100 >100 10 
HBX 90,659 22d 0.850 >100 >100 >100 >100 
 
Table 5.1. USP8 inhibitors used in this work. Adapted from Colombo, 
M et al [440], and Colland, F (unpublished). 
 
hours. Representative images following treatment with HBX 90,659 are 
shown in fig 5.5. At the lowest concentration used (1.25µM), no significant 
changes were observed and there was no evidence of increased cell death 
compared to cells treated with vehicle alone (fig 5.5i). Treatment with 2.5µM 
HBX 90,659 however, resulted in several effects commencing approximately 
5 hours after addition of inhibitor. These included a proportion of cells where 
FOXO3-EGFP translocated to the nucleus (fig 5.5i,ii). However, more 
apparent was a tightly localized accumulation of FOXO3-EGFP within the 
nucleus forming a brightly fluorescent spot, which was observed in most 
cells. In addition, the cytoplasm appeared more granular, with dendritic like 
extensions, and a proportion (<10%) became permeabilised to DRAQ7, 
indicating cell death (fig 5.5i,ii). 
 
At the highest concentration of HBX 90,659 (5µM), marked nuclear 
translocation of FOXO3-EGFP was observed (fig 5.5i,iii). This commenced 
approximately 3 hours after addition of inhibitor, and by six hours of 
treatment, essentially all cells showed a predominantly nuclear localization of 
FOXO3-EGFP. Nuclear translocation was generally preceded by a localised 
accumulation within the nucleus (data not shown), as described above for 
cells treated with 2.5µM inhibitor. The cells also developed small vacuoles in 
the perinuclear region, and dendritic-like cytoplasmic extensions. 
Interestingly, cell death was not apparently increased, with no evidence of 
DRAQ7 staining. 
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Fig 5.5. HBX 90,659 promotes nuclear localisation of FOXO3-
EGFP. FKHRL1-U2OS cells were seeded in a 96 well plate and incubated 
overnight. The following day, media was changed to HBSS containing 3µM 
DRAQ7 and the indicated concentrations of HBX 90,659, and hourly imaging 
performed by automated fluorescence microscopy. i. Representative 
FOXO3-EGFP images after 6 or 12 hours are shown in the first 2 panels, 
while the final panel shows merged EGFP/DRAQ7 images from the 12-hour 
timepoint. (scale bar-100µm) ii,iii. Cropped images of cells treated for 12 
hours with 2.5µM or 5µM HBX90,659 respectively. (scale bar 25µm). 
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Fig 5.6. The USP8 inhibitors HBX 90,397 and 90,659 sensitise 
cells to PI-103 induced cell death. FKHRL1-U2OS cells were seeded 
in a 96 well plate, allowed to attach overnight and treated with the indicated 
inhibitors in HBSS containing 3µM DRAQ7. The cells were imaged hourly by 
automated microscopy (Nikon), and after 13 hours, DRAQ5 was added, cells 
were incubated a further 20 minutes and final imaging performed. Dead and 
total cells were counted using the DRAQ7 and DRAQ5 images respectively 
using Volocity (PerkinElmer) software. i,ii Percentage dead cells following 
12 hour treatment with indicated inhibitors. The results represent the mean of 
two experiments. One well, and a median (range) of 190 (103-354) cells 
were imaged per condition. 
 
 
Inhibition of USP8 with the second USP8 inhibitor (HBX 90,397) resulted in 
similar effects (data not shown). Both inhibitors therefore promoted the 
nuclear translocation of FOXO3-EGFP, particularly at the highest 
concentration of inhibitor. However, this translocation was less rapid than 
that following direct inhibition of the PtdIns3-K pathway with LY294002 or PI-
103, which was essentially complete within 45-50 minutes. The nuclear 
translocation was also frequently preceded by a focal accumulation of 
FOXO3-EGFP within the nucleus, which was not seen following direct 
PtdIns3-K inhibition, indicating that it is unlikely to be due to a direct effect on 
the PtdIns3-K pathway. While USP7 depletion has been shown to promote 
the nuclear accumulation of FOXO4, the concentration of either inhibitor in 
the experiment was substantially lower than the IC50 for USP7 (table 5.1), 
suggesting this is not the mechanism.  
 
I next quantitatively investigated the effects of combining USP8 inhibition with 
PI-103 treatment (fig 5.6). Treatment with of U2OS-FKHRL1 cells with PI-103 
alone did not result in increased cell death over the timecourse of the 
experiment, even at the highest concentration (400nM) (fig 5.6). Treatment 
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with either USP8 inhibitor alone resulted in minimal cell death at either the 
lowest (1.25µM) or the highest concentration (5µM), although slightly more 
cell death was observed with HBX 90,397. However, at the intermediate 
concentration of 2.5µM, both USP8 inhibitors increased cell death by three to 
four fold, compared to DMSO treatment (fig 5.6).  
 
In the presence of either USP8 inhibitor at a concentration of 1.25µM, co-
treatment with PI-103 exhibited a dose-dependent effect on cell viability. This 
was more striking in the presence of 2.5µM of the USP8 inhibitors. In view of 
the lack of sensitivity of the cells to PI-103 alone, this supports the findings of 
the USP8 depletion experiments, indicating that inhibition of USP8 sensitises 
these cells to PI-103 induced toxicity.  
 
Interestingly, the highest dose of both USP8 inhibitors (5µM) resulted in less 
cell death. Only HBX 90,397 induced dose-dependent cell death following PI-
103 treatment at this dose. One plausible explanation is that a quiescent or 
senescent state may be induced at this concentration, and is discussed 
further in section 5.7. 
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5.5 The effects of USP8 depletion are partially dependent on 
media conditions 
 
The experiments described so far in this chapter were all performed in 
Hank’s buffered saline solution (HBSS), which had initially been chosen to 
optimize imaging conditions. The HBSS contained glucose, and was 
supplemented with glutamate, pyruvate and HEPES, but did not contain 
essential amino acids or serum. I therefore repeated the experiment 
described in Fig 5.4, in serum-free DMEM (fig 5.7). This experiment 
employed new batches of the siRNA oligonucleotides against USP8, which 
were purchased to replace those from the library. As discussed in appendix 
B, oligonucleotides 2, 5, 1 and 3 appear to correspond to the library 
oligonucleotides A, B, C and D respectively. This experiment also titrated the 
PI-103 concentration.  
 
Significantly more toxicity was observed following transfection with the mock 
and non-targeting siRNA controls when FKHRL1-U2OS cells were grown in 
serum-free DMEM (fig 5.7i,ii), than in the previous experiment in which the 
cells were grown in HBSS (fig 5.4i,ii). PI-103 again increased cell death 
compared to that seen with vehicle alone, however a differential cell kill was 
only clearly apparent after approximately 6 hours of treatment.  
 
Depletion of USP8 by all four oligonucleotides resulted in increased cell 
death, compared to the controls (fig 5.7), however this was less marked than 
that observed in HBSS  (fig 5.3). Furthermore in DMEM the difference in cell 
death in USP8 depleted cells between PI-103 treated and DMSO treated 
cells was less pronounced, and for one of the four oligonucleotides (USP8_1) 
was only apparent at higher PI-103 concentrations (200 and 400nM). 
 
I next employed immunoblotting for cleaved PARP, which is upregulated in 
apoptosis, to investigate the cause of cell death, and to compare the effects 
of PI-103 treatment in HBSS and serum free DMEM. A 48-hour depletion of 
USP8 was followed by a 12-hour treatment with 200nM PI-103 or vehicle 
alone (fig 5.8). Only two USP8 siRNA oligonucleotides (USP8_1 and  
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Fig 5.7. Culture in serum free DMEM reduces sensitisation to 
PtdIns3-K inhibition following USP8 depletion. i-vi.  FKHRL1-U2OS 
cells were transfected in a 96 well plate with the indicated siRNA 
oligonucleotides against USP8 (1,2,3,5), non-targeting siRNA (siC) or mock 
transfected. The letters in parentheses refer to the numbering of the original 
(library) siRNA oligonucleotides. Following a 48-hour incubation, the media 
was changed to serum free DMEM (HEPES buffered, with no phenol red), 
containing vehicle (DMSO) or varying concentrations of PI-103 (legend, top 
right), and 3µM DRAQ7. Imaging was performed hourly by automated 
microscopy for 12 hours after which DRAQ5 was added to a concentration of 
5µM, cells were incubated a further 20 minutes and a final image taken. Cells 
taking up DRAQ7 were counted using Volocity (PerkinElmer) and expressed 
as a percentage of total cells, which were counted using DRAQ5 on 
completion of experiment. A single well and position were imaged per 
condition, with a median (range) of 144 (50-298) cells imaged. 
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Fig 5.8. USP8 depletion does not increase PI-103 dependent 
apoptosis in serum free DMEM. FKHRL1-U2OS cells were transfected 
with the indicated USP8 siRNA and incubated for 48 hours, following which 
they were treated with 200nM PI-103 or DMSO in either HBSS or serum free 
DMEM for 12 hours i. The cells were lysed with NP40, and equal volumes of 
lysate were run on NuPAGE 4-12% gels and immunoblotted for PARP p85, 
USP8 and Actin. ii. Quantification of bands was performed using Odyssey 
(LiCor), and the cleaved PARP p85 was normalized to actin. (siC- non-
targeting siRNA control, n=1). 
 
 
USP8_5) were employed, due to the excessive toxicity observed with the 
other two oligonucleotides.  
 
Cells transfected with non-targeting siRNA and cultured in HBSS, exhibited 
little evidence of apoptosis on treatment with DMSO and this was only 
marginally increased by treatment with PI-103 (fig 5.8i,ii). However in USP8 
depleted cells, PI-103 treatment resulted in substantially more PARP 
cleavage than following DMSO treatment (fig 5.8i,ii), indicating USP8 
depletion leads to increased sensitivity to PI-103 induced apoptosis.  
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Control cells cultured in serum free DMEM exhibited significantly more PARP 
cleavage than those cultured in HBSS, and this was increased by 
approximately 50% on PI-103 treatment over vehicle only (fig 5.8i,ii). USP8 
depleted cells responded similarly to PI-103 treatment, and there was no 
evidence of sensitization to PI-103 induced cell death (fig 5.8i,ii). 
 
These results indicate that FKHRL1-U2OS cells undergo more apoptosis 
when cultured in serum free DMEM, than those cultured in HBSS. This is in 
accordance with the previous live cell experiments, where more cell death 
was observed in the controls when the experiment was performed in serum 
free DMEM (fig 5.7) than when it was performed in HBSS (fig 5.4).  
 
However, the differential induction of PARP cleavage in USP8 depleted cells 
treated with PI-103 or DMSO was less reflective of the results from the live 
cell experiments. Depletion of USP8 did not significantly increase apoptosis 
over controls, and PI-103 induced PARP cleavage was not significantly 
different between USP8 depleted and control cells (fig 5.8). In the live cell 
experiments in serum free DMEM however, some differential in cell death 
between USP8 depleted cells and controls was observed, and PI-103 
induced cell death was also increased in USP8 depleted cells (fig 5.7). The 
latter was however less marked at later timepoints, where PI-103 induced 
cell death was also observed in controls. Lysing cells at earlier timepoints 
may therefore better reflect the findings of the live cell experiments. The 
differences in the results from the two methodologies may also partly reflect 
the contribution of non-apoptotic cell death, which would not be detected 
using immunoblotting for PARP cleavage.  
 
Akt dependent phosphorylation of USP8 has previously been shown to 
increase its stability in 293T cells [441], while in a second study, which was 
performed in glioblastoma cell lines, activation of Akt decreased USP8 
protein level [442]. No changes to USP8 protein level following PtdIns3-K 
inhibition were seen in my experiments (fig 5.8). This may indicate cell line 
specific differences or reflect time dependent changes, as only a single 
timepoint was assessed here. Interestingly however, the USP8 protein level 
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did appear to be altered by media conditions with less USP8 seen in the 
DMEM cultured cells, than in those cultured in HBSS. 
 
Overall, these findings indicate that the effects of USP8 depletion on PI-103 
induced cell death are at least partly dependent on specific media conditions. 
Further investigation into this would include the identification of specific 
media conditions that promote the sensitisation of cell death by USP8 
depletion, however this has not been performed due to time constraints. 
 
5.6 USP8 depletion affects PI-103 sensitivity in U2OS parental 
cells. 
 
All the experiments reported above were performed in U2OS cells stably 
transfected with FOXO3-EGFP. FOXO3 is pro-apoptotic, and its 
overexpression would be expected to increase sensitivity to apoptotic cell 
death. I therefore investigated whether the effects of USP8 depletion on 
sensitizing cells to PI-103 depletion were restricted to cells expressing 
FOXO3-EGFP. In this experiment, parental U2OS cells were transfected with 
USP8 siRNA, incubated for 48 hours and then treated with PI-103 or vehicle 
(fig 5.9 and 5.10). This experiment was performed under the same media 
conditions to the original screen. 
 
The use of DRAQ7 enabled cell death to be followed in label-free cells (fig 
5.9). As previously, DRAQ7 positive cells were counted at each timepoint 
and divided by the number of DRAQ5 cells at the final timepoint to give the 
percentage of dead cells (fig 5.10). Overall, less cell death occurred in this 
experiment (fig 5.10), compared to the same experiment performed with 
FKHRL1-U2OS cells (fig 5.4). The non-targeting siRNA, and mock-
transfected cells did not show an increase in cellular death following PI-103 
treatment over the course of the experiment (fig 5.10i,ii). On the other hand, 
depletion with three of the four USP8 siRNA oligonucleotides resulted in 
increased sensitivity to PI-103 treatment (fig 5.10iii,iv,vi), and this was 
partially dose-dependent. The fourth oligonucleotide, USP8_1 (fig 5.8F) was 
an exception, in which DMSO treatment resulted in similar cell death to cells  
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Fig 5.9. USP8 depletion sensitizes parental U2OS cells to PI-103 
induced cell death (1). U2OS cells were transfected in a 96 well plate 
with siRNA oligonucleotides against USP8, non-targeting siRNA (siC) or 
mock transfected. Following a 48-hour incubation, the media was changed to 
HBSS, containing vehicle (DMSO) or varying concentrations of PI-103, and 
3µM DRAQ7. Imaging was performed hourly by automated microscopy for 12 
hours after which DRAQ5 was added to a concentration of 5µM, cells were 
incubated a further 20 minutes and a final image taken. Representative 
cropped images following 100nM PI-103 treatment of cells transfected with 
USP8_3 siRNA, or mock-transfected are shown here. The panels show a 
merge of DRAQ7 (red) and light microscopic images, with the exception of 
merge 2 (far right panel) in which the red represents DRAQ5 stained cells.  
(scale bar- 25µM).  
 
treated with the highest concentration of PI-103. However, treatment at the 
other dose levels resulted in cell death that was dose dependent, indicating 
possible aberrant results from the DMSO treated well. This experiment 
suggests that interaction between USP8 depletion and PI-103 treatment is 
not limited to cells overexpressing FOXO3. However increased cellular levels 
of FOXO3 may potentiate the effects of their cross-talk. 
 
  156 
 
 
 
Fig 5.10. USP8 depletion sensitizes parental U2OS cells to PI-
103 induced cell death (2). U2OS cells were transfected with the 
indicated siRNA oligonucleotides against USP8 (1,2,3,5), non-targeting 
siRNA (siC) or mock transfected, incubated for 48 hours, treated with varying 
concentrations of PI-103 (legend top right) and imaged as described in fig 
5.9. The letters in parentheses refer to the numbering of the original (library) 
siRNA oligonucleotides. Cells taking up DRAQ7 were counted using Volocity 
(PerkinElmer) and expressed as a percentage of total cells, which were 
counted following staining with DRAQ5 on completion of the experiment. A 
single position, and median (range) of 206 (62-397) cells were imaged per 
condition (n=1).  
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5.7 Discussion 
 
In the screen described in chapter 4, I set out to investigate the effects of 
DUB depletion on PtdIns3-K dependent translocation of an EGFP tagged 
FOXO3 fusion protein. This provided the additional, and originally 
unanticipated, opportunity to observe synthetic effects between depletion of 
DUBs and treatment with the PtdIns3-K inhibitor (PI-103), which I have 
described here.  
 
The depletion of three DUBs (namely DUB4, OTUD4 and USP8) was 
observed to increase cell death on treatment with PI-103. As described in 
section 5.2, several factors led to the prioritization of USP8 for further 
investigation, including the presence of local expertise and reagents, and 
established links between USP8 and PtdIns3-K signaling. USP8 is known to 
be involved in the downregulation of several receptors, including EGFR 
[443], ErbB2 [444], ErbB3 [441], which lie upstream of the PtdIns3-K 
pathway, and is itself phosphorylated by Akt [441]. In the latter study, Akt 
dependent phosphorylation led to USP8 stabilisation in 293T cells [441]. 
However, in a different study, which utilised a glioblastoma multiforme cell 
line, the USP8 protein level was decreased by Akt activation [442]. This 
suggests the effects of Akt on USP8 may be cell line or context dependent, 
and in the work presented in this chapter, PtdIns3-K inhibition did not cause 
obvious alterations to USP8 protein level. The second study also showed 
that USP8 promotes TRAIL-induced apoptosis [442]. These studies taken 
together indicate that USP8 both influences, and is influenced by, PtdIns3-K 
signaling, and may be involved in apoptotic pathways. 
 
Initial validation of USP8 synthetic lethality with PI-103 was performed by 
deconvolution of the oligonucleotide pool. Knockdown with the four 
oligonucleotides resulted in markedly different degrees of cell death in the 
absence of PI-103; this is likely to represent a combination of off-target 
effects as well as differing knockdown efficiencies and dynamics. However all 
four increased sensitivity to PI-103 induced cell death. In addition to 
sensitising the cells to PI-103 induced cell death, USP8 depletion also 
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increased cell death in response to the Akt inhibitor MK2206. While this 
supports a general interaction between USP8 depletion and inhibition of the 
PtdIns3-K pathway, it is feasible that USP8 depletion increases sensitivity to 
stress, rather than specific PtdIns3-K inhibition. This would be partly 
supported by the cell death seen in USP8 depleted cells treated with DMSO 
only. However, as the cells in these experiments were serum-starved, they 
would be anticipated to have decreased signalling through the PtdIns3-K 
pathway, and thus in effect partial PtdIns3-K inhibition. Further (non PtdIns3-
K) inhibitors could be assessed in future to determine if the effects on cell 
death are PtdIns3-K dependent.  
 
Further validation of the interaction between USP8 and PI-103 was obtained 
through the use of two USP8 inhibitors. Hybrigenics had identified USP8 as a 
potential drug target on the basis of a screen for USPs whose depletion 
altered cell viability or proliferation [445] and its known key involvement in the 
regulation of receptor endocytosis and trafficking [443], and had previously 
collaborated with the host laboratory in investigating the activity of two USP8 
inhibitors. Both of these compounds increased sensitivity to PI-103 induced 
cell death (fig 5.6). 
 
Interestingly, while both the inhibitors increased cell death at a concentration 
of 2.5µM, this was less apparent at the highest concentration used (5µM). At 
this concentration, profound nuclear localisation of FOXO3-EGFP was 
observed, even in the absence of PtdIns3-K inhibition, clearly linking their 
effect to this pathway. The FOXO family of transcription factors are known to 
induce both apoptosis and cellular senescence [446], and it is feasible that 
the high levels of nuclear translocation of FOXO3-EGFP seen at the highest 
dose of the USP8 inhibitors led to the senescence rather than apoptosis. In 
future this could be tested by the use of a senescence assay, an example 
being a β-galactosidase assay [447].   
 
Neither inhibitor has been exhaustively investigated, and it is also feasible 
that at higher concentrations, they inhibit other factors that may prevent the 
activation of apoptotic pathways. Interestingly, a recent study has shown that 
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β-catenin translocation to the nucleus can confer resistance to PtdIns3-K 
inhibitors and can subvert FOXO3a to promote metastasis rather than to act 
as a tumour suppressor [448]. It is possible that the USP8 inhibitors used in 
my study promote nuclear translocation of β-catenin in these cells, in addition 
to FOXO3-EGFP, although this has not been assessed. 
 
The mechanism driving nuclear translocation of FOXO3-EGFP on treatment 
with the USP8 inhibitors is unknown. While USP7 depletion has been shown 
to promote FOXO4 and FOXO3 translocation into the nucleus, the 
concentrations of both inhibitors used were over an order of magnitude lower 
then the IC50 for USP7 [440]. Inhibition of USP8 itself may lead to FOXO 
translocation. While this is not supported by the experiments in which USP8 
was depleted using siRNA, it is feasible that this is due to differing effects of 
the acute or chronic loss of USP8 function obtained with inhibitors or siRNA 
transfection respectively. Alternatively, sufficient residual USP8 may remain 
after siRNA dependent depletion to influence FOXO3 translocation. While 
specificity against a limited panel of DUBs has been checked, wider effects 
on other DUBs (or indeed other enzymes) have not been established, and it 
is therefore possible that their effects here may have been mediated through 
inhibition of other targets.  
 
Immunoblotting experiments supported the live cell imaging experiments and 
indicated that the synthetic lethality between loss of USP8 activity and PI-103 
was at least partially due to apoptosis. However, all the above experiments 
were conducted in HBSS, which had originally been used to optimize 
fluorescence imaging. Repeating the USP8 knockdown in serum free DMEM 
resulted in increased cell death in the controls using live cell imaging, and 
increased overall apoptosis measured by immunoblotting for cleaved PARP. 
Under these media conditions, the effects of USP8 depletion on PI-103 
sensitivity were less apparent on live cell imaging and absent on 
immunoblotting. 
 
In both media conditions, the cells were serum starved. FKHRL1-U2OS cells 
grew well in full serum DMEM, suggesting the cell death in serum free 
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DMEM was due to serum starvation. However, cells grown in HBSS 
appeared to have been relatively protected from serum starvation. While the 
role of different media components have not been fully elucidated, two likely 
possibilities are the presence of amino acids and pH. The HBSS was not 
supplemented with amino acids, which may have been protective, potentially 
through the induction of autophagy. Secondly the pH of the HBSS was 
approximately 7- 7.2, and fell to 6.8- 6.9 at the end of a 12-hour incubation, 
and it is possible that this altered pH (compared to 7.4 in DMEM) may have 
altered response to PtdIns3-K inhibition. Interestingly, the lower pH observed 
in cells cultured in HBSS may be more reflective of the pH within tumours, 
which are frequently acidotic [449], and these findings may therefore prove to 
have clinical relevance. Further experiments to dissect out the relevant 
constituents are yet to be performed.  
 
The other two DUBs that induced PI-103 dependent cell death may also be 
worthy of further investigation. The first of these, DUB4 is a member of the 
USP17 subfamily of DUBs, which consists of multiple, closely related 
members that arose through ancestral gene duplication and several of which 
exist within a tandemly repeated block on chromosome 4 [83]. While neither 
a substrate nor function has been ascribed to DUB4, the closely related 
USP17 has been shown to be involved in Ras signalling [450, 451], and 
regulation of HDAC activity [452]. Moreover, another member of the family, 
DUB3, has been shown to rescue cdc25A from proteasomal degradation, 
and promote growth on soft agar; its depletion retarded growth of tumour 
xenografts in mice [453]. Interestingly, DUB3 was not identified in the screen, 
but it was noted to cause increased cell death at a later time point in the 
follow-up experiment, where it had been included as a control (fig 6.2). The 
final DUB that exhibited synthetic lethality with PI103 was OTUD4. 
Substrates for OTUD4 have not been described as yet, although it has been 
implicated in BMP signalling during Zebrafish development [454]. Several 
interactors have been identified including the autophagy protein ATG12 
[455]. 
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The findings in this chapter are both exploratory and preliminary. However, 
they are potentially of significant scientific and clinical interest. Further 
investigation into the interaction between depletion of the three DUBs and PI-
103 induced cell death may provide valuable insights into the cellular roles of 
these DUBs, while the combinatorial inhibition of one or other of these DUBs 
with inhibition of the PtdIns3-K pathway may prove a useful therapeutic 
strategy.                                         
  162 
Chapter 6 
 
USP20, ATXN3, ATXN3L and JOSD1 regulate PTEN protein level 
 
6.1 Introduction 
 
Ubiquitylation has been shown to influence both the stability [335, 359, 360, 
456] and subcellular localization [57, 359] of the tumour suppressor PTEN 
(section 1.5.4). The deubiquitylase USP7 may reverse the 
monoubiquitylation of PTEN, and promote its nuclear exclusion [203]. 
However, no DUBs regulating the stability of PTEN have yet been identified.  
 
In chapter 3, I described the identification of five deubiquitylases whose 
knockdown influenced PTEN protein level. These were USP20, depletion of 
which downregulated PTEN, and USP7, ATXN3, ATXN3L and JOSD1 for 
which depletion upregulated PTEN. All five were successfully validated by 
deconvolution, by the criterion that at least two individual oligonucleotides 
recapitulated the effects of the pool. However, USP7 depletion only modestly 
increased PTEN levels. In addition, USP7 has previously been shown to 
regulate monoubiquitylation of PTEN [203], and it was therefore not followed 
up further in this study. Here I will describe initial investigations into the 
mechanisms by which the other four DUBs may regulate PTEN cellular 
abundance. 
 
6.2  USP20 depletion alters PTEN protein level 
 
In the original siRNA screen, depletion of USP20 using a pool of siRNA 
oligonucleotides resulted in a reduction in the PTEN protein level (figs 3.6 
and 3.7). The effects of the pool were recapitulated by two of the four siRNA 
oligonucleotides that made up the original pool (figs 6.1i and 3.8). However, 
USP20 depletion by the other two oligonucleotides did not have the same 
effect on PTEN, and USP20_D actually led to an increase in PTEN level (Fig 
6.1i).  
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Fig 6.1. The effects of USP20 depletion on PTEN protein level 
inversely correlate with USP33 induction. i,ii. A549 cells were 
transfected with siRNA, incubated for 72 hours and lysed in NP40 buffer. 
Equal amounts of each lysate were immunoblotted as indicated. iii,iv. PTEN 
and USP33 bands were quantified, normalized to actin and then compared to 
the mock control. Imaging and quantification were performed using an 
infrared scanner and associated software [Odyssey, LiCor]. (A-D: individual 
USP20 siRNA oligonucleotides, P: pooled oligonucleotides, USP20/33: dual 
depletion with USP20 and USP33 pools, ‘LB’: lower molecular weight band. 
n=1) 
 
I first set out to investigate if these differences in phenotypic effect on PTEN 
correlated with knockdown efficiency using immunoblotting for USP20 (fig 
6.1i).  For this, I initially employed a polyclonal antibody from Bethyl (A301-
189A), which was raised against an epitope mapping to a region between 
amino acids 863 and 913 of human USP20 (fig 6.3iii). In this region, USP20 
shares extensive sequence homology with its paralogue USP33, with a 
sequence identity of 57% (appendix B), and the A301-189A antibody thus 
detects both USP20 and USP33. As shown in figures 6.1i and iii, at least two 
bands of approximately 120-140kDa are depleted by all USP20 
oligonucleotides, and a band of slightly lower molecular weight (~110-
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120kDa) is depleted by USP33 siRNA. The three reference sequences for 
the USP20 transcript differ only in their untranslated regions and encode a 
protein with a predicted molecular weight of 102kDa (fig 6.3). It is feasible 
that unmodified USP20 is obscured by the USP33 band, although this ran at 
a higher molecular weight than 102kDa (fig 6.1i,ii). The USP20 bands that 
were depleted run at a higher molecular weight to that predicted, suggesting 
these may be modified forms of USP20. Due to the lack of specificity of this 
antibody, quantitative assessment of USP20 knockdown efficiency was not 
attempted for this experiment. 
 
As discussed previously (section 3.3), depletion of USP20 is known to lead to 
upregulation of USP33, this representing an example of paralogue 
compensation [390]. This was again shown here, and interestingly there also 
appeared to be an inverse correlation between the effects of the USP20 
siRNA oligonucleotides on PTEN protein level, and the degree of 
upregulation of USP33 (figs 6.1i,iii). This could suggest that USP20 depletion 
leads to USP33 upregulation, and this in turn leads to a reduction in PTEN 
protein level. In order to test this, I performed a dual knockdown of both 
USP20 and USP33 using pooled siRNA oligonucleotides in each case (fig 
6.1ii,iv). The dual knockdown failed to abolish the effects of USP20 depletion 
on PTEN, indicating that upregulation of USP33 is not required for USP20 
depletion to upregulate PTEN. 
 
I speculated that the degree of USP33 upregulation may be acting as a 
surrogate marker for USP20 knockdown efficiency, which I had not been able 
to assess quantitatively with the Bethyl antibody. I therefore sought to better 
assess USP20 levels with a second commercially available antibody (Aviva, 
ARP59314), which is raised against an internal epitope of USP20 that shares 
limited homology with USP33 (sequence identity of 24%, appendix B). While 
a strong band was detected at just over 100kDa (fig 6.2i), which would be in 
keeping with unmodified USP20, this was not depleted by USP20 
knockdown, and more closely resembled the band structure seen on blotting 
for USP33 (fig 6.2ii). While this band did not colocalise with the  
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Fig 6.2. Antibody ARP59314 does not detect endogenous 
USP20. A549 cells were transfected with the indicated USP20 siRNA, non-
targeting siRNA (siC) or mock transfected. Following a 72-hour incubation 
the cells were lysed in NP40 buffer. Equal amounts of each lysate were 
immunoblotted with the indicated antibodies. i. Immunoblotting for USP20 
was performed using ARP59314 (Aviva-A) and A301-189A (Bethyl-B) 
sequentially (first two panels from the top). Both antibodies were raised in 
rabbits, and the second panel therefore represents a composite of the 
immunoreactive bands for both the antibodies. A merge of images 
immunoblotted with ARP59314 (green channel) and both antibodies (false 
coloured red channel) is shown in the third panel. ii. Immunoblotting was 
also performed for USP33, and a merge of the USP20 (Aviva in green) and 
USP33 signal (in red) is shown in the third panel from the top. 
 
USP33 antibody (fig 6.2ii), it may still represent a splice variant of USP33 
that is not recognized by the USP33 antibody.  
 
None of the other bands detected by this antibody (ARP59314) were 
depleted by USP20 siRNA, and it does not appear to recognise the higher 
molecular weight USP20 bands detected by the Bethyl antibody, that were 
clearly depleted by the USP20 siRNA oligonucleotides (fig 6.2i). This 
suggests antibody ARP59314 does not detect endogenous USP20, and it 
has not been possible thus far to quantitatively assess USP20 depletion 
using immunoblotting.  
 
The difference in effects of the different USP20 oligonucleotides on PTEN 
levels could also reflect differential effects on USP20 splice variants. 
Interestingly, a lower molecular weight band (‘LB’) of approximately 75kDa 
detected with the Bethyl USP20 antibody appeared to directly correlate with 
PTEN level (fig 6.1i). This was supported by an independent experiment, 
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Fig 6.3. The effect of USP20 siRNA oligonucleotides on PTEN 
correlates with location on transcript. i,ii. A549 cells were transfected 
with the indicated USP20 siRNA, incubated for 72 hours and lysed in NP40 
buffer. Equal amounts of each lysate were immunoblotted as indicated. 
PTEN, USP33, and a lower molecular weight band detected with the USP20 
antibody ‘LB’, were quantified, normalized to actin and then compared to the 
mock control. Imaging and quantification were performed using an infrared 
scanner and associated software [Odyssey, LiCor]. (1- 4: individual USP20 
siRNA oligonucleotides, P: pooled oligonucleotides.) iii. Schematic of USP20 
protein and splice variants (named in right hand column). Location of USP20 
siRNA oligonucleotides and QPCR primers is also shown. Bethyl Ab and 
Aviva Ab respectively refer to the epitopes detected by USP20 antibodies 
A301-189A (Bethyl) and ARP59314 (Aviva). (UBP-ZnF: UBP type Zinc 
Finger, DUSP: Domain of Ubiquitin Specific Protease. USP20 
oligonucleotides 1, 2, 3 and 4 correspond to plates C, A, D and B 
respectively from the DUB siRNA library- see Appendix A.) The position of 
the QPCR amplicon is highlighted in red. 
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which employed four USP20 siRNA oligonucleotides that were purchased to 
replenish those in the original DUB siRNA library (fig 6.3i, ii). Both USP20 
siRNA oligonucleotides which downregulated PTEN protein levels (and the 
75kDa immunoreactive band detected using the USP20 antibody) were 
located at the 3’ end of the USP20 transcript within the 3’UTR (untranslated 
region), while the other two sequences map internally within the coding 
region of the transcript (fig 6.3iii). This would suggest that oligonucleotides 1 
and 2 may differentially affect alternative USP20 splice variants compared to 
oligonucleotides 3 and 4, providing a possible explanation for the effects 
these four USP20 oligonucleotides have on the 75kDa band.  
 
However a search of multiple databases (ASD, ECgene, DOTS, Ensembl 
and Aceview), failed to identify any USP20 splice variants that would give 
rise to an alternative 75kDa isoform. Moreover this immunoreactive band 
also appears to be partially depleted by USP33 knockdown (fig 6.1ii). As this 
USP20 antibody also detects USP33, the band could represent an alternative 
splice variant of USP33, rather than USP20. While the band was not 
detected using the USP33 antibody (fig 6.3i), this does not rule out the 
possibility that the lower band represents a USP33 splice variant, as it could 
lack the epitope which is detected by the USP33 antibody. 
 
As I had been unsuccessful in the assessment of USP20 knockdown 
efficiency using immunoblotting, I turned to QPCR instead (fig 6.4). This 
showed the knockdown efficiency of the four individual oligonucleotides and 
the pool ranged from approximately 65% - 85% (fig 6.4i). There was no 
evidence of correlation between the knockdown efficiency of the USP20 
oligonucleotides and their effects on PTEN protein level  (fig 6.4ii). This 
suggests that variation in USP20 siRNA oligonucleotide knockdown 
efficiency was not responsible for their differences in effect on PTEN protein.  
 
In addition, this experiment allowed me to assess the effect of USP20 
knockdown on PTEN mRNA levels (fig 6.4i). Depletion of USP20 using 
oligonucleotide USP20_1 or the USP20 siRNA pool led to a reduction in 
PTEN mRNA. On the other hand, USP20_3 led to an increase in PTEN  
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Fig 6.4. USP20 knockdown efficiency does not correlate with 
PTEN protein levels. i. A549 cells were transfected with the indicated 
USP20 siRNA, non-targeting siRNA or mock transfected, and incubated for 
48 hours prior to preparation of total RNA. QPCR was performed for USP20 
and PTEN using an IQ5 real time PCR detection system and SYBR green 
supermix (BioRad). Actin was employed as the reference gene and results 
were further normalized to the mock control. ii, iii. Scatterplots of the relative 
USP20 or PTEN mRNA levels compared to the PTEN protein levels 
observed in the experiment described in fig 6.3. The coefficient of correlation 
(R2) is shown in the top right hand corner in both graphs. Controls are shown 
in red. (P: pooled siRNA oligonucleotide. 1,2,3 and 4: individual USP20 
oligonucleotides. siC: Non-targeting siRNA control. The experiment was 
performed once.) 
 
mRNA. Interestingly the effects of USP20 oligonucleotides on PTEN mRNA 
partly correlate with their effects on PTEN protein (fig 6.4iii), as assessed by 
immunoblotting in fig 6.3. These findings suggest that the effects of USP20 
on PTEN may at least partly occur through regulation of its transcript level.  
 
The experiments described in this section support the findings of the screen, 
and suggest depletion of USP20 can alter PTEN protein level. While 
  169 
individual USP20 siRNA oligonucleotides had differential effects on PTEN, 
the most reproducible finding was a reduction in PTEN protein level with two 
out of the four oligonucleotides. The data do not provide a clear explanation 
for the differential effects of the siRNA oligonucleotides on PTEN, however 
one possibility is that they represent differential effects on USP20 splice 
variants. Further investigation into the potential role of USP20 splice variants 
was not prioritized, as the DUB screen also identified three DUBs whose 
depletion upregulated PTEN, and which may therefore represent potential 
drug targets (section 6.9). 
 
6.3 Both ATXN3 and ATXN3L upregulate PTEN protein level 
 
Depletion of ATXN3, ATXN3L or JOSD1 led to increased PTEN protein 
levels in the screen (figs 3.6 and 3.7). Interestingly all three are members of 
the Josephin family of deubiquitylases and share extensive sequence 
homology (fig 6.5). Only one member of the family, JOSD2, was not 
identified in the PTEN immunoblot screen. Although TAF1D (also known as 
JOSD3) is sometimes included in this DUB family [415], neither the catalytic 
Cys nor His are conserved ([415] and S Urbé, personal communication). 
Initial validation has focused on ATXN3 and ATXN3L, which share the 
greatest homology, and for which additional reagents were locally available.  
 
Depletion of ATXN3 by any of the four siRNA oligonucleotides from the DUB 
library resulted in an increase in PTEN level (fig 3.8). Similar results were 
obtained with siRNA oligonucleotides purchased to replace the original 
library oligonucleotides (fig 6.6). A correlation between effects on PTEN level 
and ATXN3 knockdown efficiency is also noted (fig 6.6i,ii). Knockdown 
efficiency was in excess of 95% for three out of four oligonucleotides, each of 
which increased the PTEN protein level to at least 150% of control. 
Transfection with the fourth oligonucleotide (ATXN3_1) only depleted ATXN3 
by 60%, and had marginal effects on PTEN level. 
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Fig 6.5 The Josephin family of deubiquitylases. i. A phylogenetic 
tree was constructed using the maximum likelihood method as described in 
figure 1.3. JOSD3 (TAF1D) lacks both the catalytic Cys and His and was not 
included in the DUB library. ii. A representation of the domain structure of 
the four Josephins that were included in this study. The domains of each 
protein are drawn to scale with the catalytic domains of each protein depicted 
in orange, the ubiquitin-interacting motif’s (UIM) in green and polyglutamine 
tracts (polyQ) in yellow. Ab represents the binding site of the ATXN3 
antibody (650401, BioLegend). 
 
As discussed in section 6.2, depletion of USP20 (using pooled siRNA 
oligonucleotides) led to a reduction in PTEN protein level, thus regulating 
PTEN in the opposite direction to ATXN3. While these effects are most likely  
to be independent of each other (fig 6.6iii), two alternative models may be 
hypothesized in which one of the two deubiquitylases exerts its effects on 
PTEN through regulation of the other (fig 6.6iv,v). I therefore performed a 
dual knockdown of ATXN3 and USP20 to determine if depletion of either had 
a dominant effect on PTEN protein level (fig 6.6vi). This resulted in an 
intermediate PTEN protein level, which most likely indicates that the two 
deubiquitylases act independently (6.6iii). 
 
Similarly to ATXN3, ATXN3L depletion also upregulated the PTEN protein 
level (fig 3.6 and 3.7). This effect of ATXN3L was also successfully 
deconvoluted, with all four siRNA oligonucleotides leading to an increase in 
PTEN protein level (fig 6.7i). ATXN3L is closely related to ATXN3 (fig 6.5) 
with which it shares an overall sequence identity of 72%, including 85%  
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Fig 6.6. ATXN3 depletion upregulates PTEN protein level. i,vi. 
A549 cells were transfected with the indicated siRNA oligonucleotides, 
incubated for 72 hours and lysed in NP40 buffer. Equal amounts of each 
lysate were immunoblotted as indicated. ii. PTEN and ATXN3 were 
quantified, normalized to actin and then compared to the mock control. Mean 
data for three (ATXN3) or four (PTEN) experiments are shown. Students’ t-
tests compared PTEN or ATXN3 abundance in response to each siRNA to 
that with siC, *P<0.05, **P<0.001. Error bars show standard deviation.  
iii,iv,v.  Models of interaction between USP20, ATXN3 and PTEN. vii. 
Quantification of dual USP20/ATXN3 depletion was performed, as described 
in ii, from a single experiment. (1, 3, 4, 5: individual ATXN3 siRNA 
oligonucleotides, P and P2: pooled ATXN3 oligonucleotides from the DUB 
siRNA library and replacement oligonucleotides respectively. DUAL: 
combined knockdown of ATXN3 and USP20 using pooled siRNA for both. 
Imaging and quantification were performed using an infrared scanner and 
software [Odyssey, LiCor]. n=1)  
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Fig 6.7. ATXN3L upregulates PTEN in an ATXN3-independent 
manner. i. Depletion of ATXN3L was performed as described in fig 3.8. 
Lysates were immunoblotted for ATXN3 and actin as shown in the first two 
panels; immunoblots for PTEN and actin from fig 3.8 are shown for 
comparison. ii. Scatterplot of ATXN3 and PTEN quantification normalized to 
actin and mock control. The coefficient of determination (R2) is shown. iii. 
A549 cells were transfected with the indicated siRNA, incubated for 72 hours 
and lysed in NP40 buffer. Equal amounts of each lysate were immunoblotted 
as indicated. iv.  PTEN was quantified, normalized to actin and then 
compared to the mock control. (A- D: individual ATXN3L siRNA 
oligonucleotides, P: pooled oligonucleotides, D1-D4 ATXN3L 
oligonucleotides (Dharmacon), ATXN3/3L: combined depletion of ATXN3 
and ATXN3L. Imaging and quantification were performed using an infrared 
scanner and associated software [Odyssey, LiCor].)  
 
homology in the catalytic domain [457]. Although the ATXN3L siRNA 
oligonucleotides were designed to be specific for ATXN3L and were not 
predicted to cross-react with ATXN3, this could not be ruled out. I therefore  
assessed the effects of ATXN3L siRNA on ATXN3 protein level (fig 6.7i). 
There was no evidence of ATXN3 depletion following knockdown of ATXN3L, 
and the ATXN3 level did not correlate with the PTEN protein level in this 
experiment (fig 6.7i,ii). It is therefore unlikely that the effects of the ATXN3L 
siRNA oligonucleotides on PTEN were mediated through off-target depletion 
of ATXN3. The lack of correlation between ATXN3 and PTEN protein levels 
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in the absence of direct ATXN3 depletion, is also in keeping with the findings 
in fig 6.6i, where partial depletion of ATXN3 with ATXN3_1 did not have 
significant effects on PTEN protein. This indicates that a profound loss of 
ATXN3 is required in order to upregulate PTEN. 
 
The effects of ATXN3L depletion on PTEN levels in both the screen and 
deconvolution were further supported by depletion using another four 
independent siRNA oligonucleotides (Dharmacon), which had previously 
been used in our lab (fig 6.7iii,iv). All four of these siRNA oligonucleotides 
resulted in increased PTEN protein levels, albeit to a more modest degree for 
all oligonucleotides bar ATXN3L_D3. No ATXN3L antibody was available to 
assess ATXN3L depletion in this experiment, and the differences in effect on 
PTEN level may therefore reflect differing knockdown efficiencies.  
 
In view of the similarity between ATXN3 and ATXN3L, I also sought to 
investigate the effects of a dual depletion of both (fig 6.7iii,iv). In this 
experiment, depleting both ATXN3 and ATXN3L did not appear to have 
additive effects on PTEN protein level (fig 6.7ii,iv). This suggests that both 
may have functions within the same pathway, such that depletion of either 
leads to disruption of the pathway and produces a similar phenotype.  
 
6.4 USP20 or ATXN3 depletion alter overall PTEN protein levels  
 
In addition to negatively regulating the PtdIns3-K pathway, PTEN has well 
established nuclear roles including the regulation of the APC-CDH1 complex 
[458]. PTEN nuclear shuttling is regulated by ubiquitylation [57], which may 
be reversed by USP7 [203]. I therefore set out to investigate whether 
depleting either USP20 or ATXN3 led to alterations in the distribution of 
PTEN rather than the overall protein levels. A549 cells were lysed with a 
series of buffers to crudely fractionate proteins into cytosolic (NP40), nuclear 
(Dignam C) and chromatin bound (Laemmli) fractions (fig 6.8). PTEN was 
only detected in the NP40 fraction, despite loading a relatively high 
proportion of nuclear to cytosolic lysate (fig 6.8). This may indicate either that  
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Fig 6.8. USP20 and ATXN3 regulate overall PTEN protein level. 
A549 cells were transfected with the indicated siRNA, incubated for 72 hours 
and lysed sequentially with NP40, Dignam C and Laemmli buffers to obtain 
crude cytoplasmic, nuclear and chromatin bound fractions. Lysates were 
immunoblotted for PTEN and actin as indicated. 15µg of NP40 and 5µg of 
Dignam C and Laemmli lysates were loaded respectively. This represents a 
higher proportion of protein from either Dignam C or Laemmli fractions than 
was extracted (approximately ten times as much protein was extracted with 
NP40 than with Dignam C or Laemmli). Imaging was performed using an 
infrared scanner [Odyssey, LiCor]. 
 
PTEN was almost exclusively localized to the cytoplasm, or that nuclear 
PTEN was being extracted in the NP40 fraction. Discrimination between the 
two would require fluorescence microscopy and/or the use of alternative lysis 
buffers [203], neither of which have been performed. However, in the 
absence of any detectable PTEN in the other cellular fractions, the changes 
in PTEN level in the NP40 fraction do reflect changes in total cellular PTEN. 
While the effects of ATXN3L and JOSD1 depletion on PTEN level in other 
cellular fractions were not assessed, depletion of either DUB led to an 
increase in PTEN in the NP40 fraction and, in view of the absence of PTEN 
detected in the nuclear fraction here (fig 6.8), this most likely also reflects an 
increase in overall cellular PTEN protein levels. 
 
6.5 ATXN3 depletion does not alter the rate of PTEN degradation 
 
Here, I investigated the effects of ATXN3 and USP20 depletion on turnover 
of PTEN protein. Cells were lysed at successive timepoints following 
treatment with cycloheximide, which was employed to inhibit translation of 
new protein (fig 6.9). As previously, USP20 and ATXN3 depletion  
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Fig 6.9. USP20 depletion stabilizes ATXN3 and USP33. A549 cells 
were transfected with the indicated siRNA oligonucleotides or mock 
transfected. Cells were incubated for a total of 72 hours, and prior to lysis 
were treated for the indicated duration with 100µg/ml cycloheximide (CHX). 
Cells were lysed with NP40 and equal volumes of lysate were immunoblotted 
as indicated. Imaging and quantification were performed on an infrared 
scanner and associated software (Odyssey, LiCor). i. Immunoblots. ii. 
Quantification prior to CHX addition. iii-vii. Each protein was quantified, 
normalized to actin and baseline level, and plotted as shown. USP20_2, 
ATXN3_5, siC (non-targeting siRNA) and Mock are represented in blue, 
green, purple and red respectively. The half-life is indicated by a dotted line. 
(n=1).  
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respectively decreased and increased the PTEN protein level prior to 
cycloheximide addition (fig 6.9i,ii). However PTEN was relatively stable, 
exhibiting a half-life in excess of 20 hours (fig 6.9iii). Previous studies have 
reported a wide range for PTEN’s half-life, ranging from 10 to more than 72 
hours in different cell lines [364, 459, 460]. 
 
ATXN3 depletion did not affect the rate of PTEN protein degradation (fig 
6.9iii). Interestingly, while USP20 depletion had decreased PTEN protein 
level by approximately 60% at baseline, the degradation rate of the residual 
PTEN in the presence of cycloheximide was slowed (fig 6.9iii). This indicates 
that USP20 may have two effects on PTEN, potentially altering both its 
transcription and degradation.  
 
I wondered whether USP20 may have broader effects on protein 
degradation. The effects of USP20 depletion on rates of degradation of 
ATXN3, USP33 and USP7 (fig 6.9iv,vi) were also assessed. In all three 
cases, USP20 depletion stabilized the protein and decreased the rate of 
degradation, although this was less apparent for USP7.  
 
While this may represent a specific effect on a subset of deubiquitylases, it 
could alternatively reflect more general effects on protein degradation. I 
therefore assessed the effects of USP20 depletion on β-catenin degradation, 
as an example of an unrelated protein, which is degraded by the proteasome 
(fig 6.9vii). The rate of β-catenin degradation was not influenced by USP20 
depletion. However I did not assay the effects of USP20 depletion on the 
degradation of a wider range of proteins, and it remains feasible that USP20 
has a generic role in protein degradation. 
 
6.6 Crosstalk between ATXN3, ATXN3L and USP20  
 
No commercial antibodies were available for ATXN3L or JOSD1, and as 
discussed in section 6.2, depletion of USP20 was impossible to quantitatively 
assess using either of the available antibodies. I therefore employed  
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Fig 6.10 ATXN3, ATXN3L and JOSD1 transcriptionally regulate 
PTEN i.ii A549 cells were transfected with pooled siRNA oligonucleotides 
against the indicated targets and incubated for 72 hours prior to lysis, after 
which RNA was extracted and cDNA prepared by reverse transcription. 
QPCR was performed for ATXN3, ATXN3L, JOSD1, USP20, PTEN and 
PTENP1 using an IQ5 real time PCR detection system and SYBR green 
supermix (BioRad). Actin was employed as a reference gene and results 
were further normalized to the mock control. The arrowheads indicate direct 
effects of siRNA on their respective targets. (n=1). 
 
 
quantitative RT-PCR (QPCR) to assess knockdown efficiency of these DUBs 
(fig 6.10i). Pooled siRNA oligonucleotides from the DUB library were used. A 
knockdown efficiency at the transcript level of 95% or greater was obtained 
for ATXN3 and JOSD1, while that for USP20 and ATXN3L was 
approximately 65% and 50% respectively. For ATXN3, this mirrors estimation 
of ATXN3 depletion by immunoblotting (fig 6.6). The relatively poor 
knockdown efficiency for USP20 however, did not appear to be reflected on 
immunoblotting (fig 6.1 and 6.2). This may be due to the presence of USP20 
species that were not visualized due to lack of antibody specificity (section 
6.2). In addition, the USP20 mRNA) knockdown efficiency was better when 
assessed after a 48-hour transfection (fig 6.4), and it is possible that at 72 
hours the effects of the USP20 siRNA were beginning to decline.  
 
ATXN3L knockdown efficiency at the transcript level was only approximately 
50% (fig 6.10i). However I have not been able to assess this by 
immunoblotting, and have also not assessed either the differential effects of 
individual ATXN3L siRNA oligonucleotides or earlier experimental timepoints. 
Interestingly, the ATXN3L transcript was also much less abundant than that 
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for ATXN3, taking on average an additional eight cycles of amplification to 
cross the cycle threshold (Ct). This suggests that the ATXN3L transcript is 
approximately 250 fold less abundant than that of ATXN3. 
 
Intriguingly, there were several indications of interplay between the four 
DUBs at the transcript level (fig 6.10i). USP20 depletion reduced ATXN3L 
transcripts to a similar degree to that which occurred following ATXN3L 
depletion. However, USP20 depletion had the opposite effect on ATXN3 
transcripts, which it upregulated (fig 6.10i). On the other hand depletion of 
ATXN3L led to upregulation of the USP20 transcript (fig 6.10i). These 
findings could represent either feedback mechanisms. However, the 
experiment has only been performed once and these findings will firstly 
require confirmation in independent experiments.  
 
6.7 ATXN3 regulates PTEN transcriptionally  
 
As discussed in section 3.1, DUBs may have effects on protein level through 
multiple mechanisms. These include regulation of transcription, which was 
assessed here using QPCR. Depletion of ATXN3, ATXN3L or JOSD1 all 
increased PTEN mRNA transcript levels (fig 6.10ii). This was most marked 
for ATXN3 for which depletion resulted in an almost three fold increase in 
PTEN transcripts (6.10ii), while ATXN3L and JOSD1 depletion resulted in an 
approximately 2-fold increase in transcript levels. Depletion of USP20 using 
pooled oligonucleotide did not alter PTEN transcription (fig 6.10ii). However 
the earlier experiment described in figure 6.4 had shown a correlation 
between PTEN mRNA and protein levels. Further parallel experiments will be 
required to confirm this finding.  
 
PTENP1 (PTEN pseudogene 1) is a pseudogene that has been shown to be 
involved in regulating PTEN level by acting as a decoy for miRNAs targeting 
PTEN [375]. I therefore also assessed transcript levels for PTENP1 (fig 
6.10ii). This supported co-regulation of PTEN and PTENP1 transcription by 
ATXN3. While ATXN3L and JOSD1 depletion also upregulated the PTENP1 
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transcript level, this was to a more modest degree, and similar levels were 
seen with a non-targeting siRNA.  
 
The data were most supportive for a role of ATXN3 at the PTEN and/or 
PTENP1 transcript level, and were in keeping with the experiment described 
in fig 6.9 in which ATXN3 depletion failed to alter PTEN protein degradation. 
This transcript level regulation of PTEN by ATXN3 was further supported by 
a correlation between PTEN protein and mRNA levels which were assessed 
in parallel (fig 6.11).  The latter experiment utilized a 48-hour incubation to 
avoid cellular toxicity, which was observed with ATXN3 depletion at longer 
timepoints. Although induction of PTEN protein levels after 48 hours by 
ATXN3 depletion was less marked than by 72 hours, this clearly correlated 
with PTEN transcript levels (fig 6.11).  
 
We next sought to determine if ATXN3 depletion leads to increased PTEN 
transcript levels through increasing transcription or by reducing transcript 
degradation. For this purpose, actinomycin D was used to inhibit de novo 
transcription, thus enabling determination of the half-life of relevant 
transcripts. mRNA half-lives were 1.9, 4.4 and >6 hours for PTENP1, PTEN 
and ATXN3 respectively (fig 6.12i). The relatively short half-life for PTENP1 
transcript compared to that of PTEN is in keeping with its function as a decoy 
for miRNA directed at PTEN [375].  
 
Depletion of ATXN3 led to an increase in the level but a decrease in the half-
lives of both PTEN and PTENP1 transcripts. The half lifes of PTEN and 
PTENP1 were decreased from 4.1 to 1.7, and 1.7 to 0.7 hours respectively in 
ATXN3 depleted cells (fig 6.12ii).  
 
Interestingly, degradation of PTEN mRNA was delayed and only began to 
occur after about half an hour, at which time PTENP1 levels had already 
decreased significantly; in the case of ATXN3 depleted cells by almost half. 
Between 30 and 90 min PTEN mRNA degradation was substantially 
accelerated in ATXN3 depleted cells while the rate of degradation at later 
time points was similar to that of the control (fig 6.12ii). The reduction in the  
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Fig 6.11. ATXN3 depletion regulates PTEN abundance by 
increasing the level of the PTEN and PTENP1 transcripts. i,ii. 
A549 cells were transfected with the indicated siRNA oligonucleotides for 
48hrs prior to lysis. i. Total RNA was extracted and expression of ATXN3, 
PTEN and PTENP1 transcripts relative to actin were determined by QPCR. 
Mean values are shown normalised to mock transfected cells for three 
independent experiments, error bars show standard deviation.  Student’s t-
test compares each siRNA with siC, *P<0.05, n=3. ii. In parallel, cells were 
lysed using NP40 and equal amounts of each lysate were immunoblotted. A 
representative blot is shown. PTEN protein levels were quantified relative to 
actin and normalised to the mock control (n=3). iii. A scatter plot correlating 
PTEN mRNA and protein expression for each ATXN3 siRNA. (error bars 
show standard deviation, R2=0.797). 
 
half-life of both PTEN and PTENP1 does not explain their increase in 
abundance following ATXN3 depletion, and most likely reflects a  
compensatory mechanism that is attempting to counteract increased 
expression. This experiment therefore indicates that ATXN3 depletion 
increases PTEN and/or PTENP1 transcription, rather than the degradation of 
these transcripts. 
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Fig 6.12.  Depletion of ATXN3 does not enhance stability of the 
PTEN or PTENP1 transcripts. i. A549 cells were treated with 
actinomycin D for the indicated times prior to preparation of total RNA.  
Levels of the ATXN3, PTEN and PTENP1 transcripts were determined 
relative to that of actin by QPCR.  Mean values, normalised to the expression 
level of each gene prior to addition of actinomycin D, are shown from three 
independent experiments.  Error bars show standard deviation and the half-
life is indicated by a dotted line.  ii. A549 cells were transfected with a single 
siRNA targeting ATXN3 or with no oligonucleotide for a total of 48hrs; cells 
were treated with actinomycin D for the indicated times immediately prior to 
preparation of total RNA.  The levels of ATXN3, PTEN and PTENP1 
transcripts were determined relative to that of actin by QPCR.  Mean values, 
normalised to the expression level of each gene in mock-transfected cells 
prior to addition of actinomycin D, are shown from two independent 
experiments.  The half-life of each transcript following ATXN3 depletion is 
indicated by a fine dotted line. The half-life of PTEN in mock-transfected cells 
is similarly shown. PTENP1s half-life in mock-transfected cells is obscured 
by that of PTEN in ATXN3 depleted cells, and is similarly 1.7hrs. 
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6.8 ATXN3 depletion and HDAC inhibition have additive effects 
on PTEN transcript levels 
 
ATXN3 is known to be involved in transcriptional repression through the 
modulation of histone acetylation status [378, 461], which suggested a 
possible mechanism by which ATXN3 could regulate PTEN. We therefore 
assessed the effects of the histone deacetylase inhibitor vorinostat, on 
PTEN, PTENP1 and ATXN3 transcript levels (fig 6.13). While PTEN 
transcript levels were increased by vorinostat, this was to a much lesser 
extent than that seen for the positive control SCG3 (fig 6.13i) which is known 
to be highly repressed in A549 cells [373], through an HDAC dependent 
mechanism (J. Coulson, unpublished data). SCG3 transcript levels increased 
linearly with increasing vorinostat concentrations (fig 6.13i). In contrast, 
maximum PTEN induction (3-fold) occurred in cells treated with 2µM 
vorinostat, while at higher drug concentrations PTEN levels declined to a 
plateau of approximately 2-fold induction. PTENP1 also exhibited an 
increase in transcript levels in cells treated with 2µM vorinostat, however this 
was less marked, representing an increase of only 50%, and at higher 
concentrations of vorinostat, PTENP1 transcript levels were similar to those 
in untreated cells (fig 6.13i). The ATXN3 transcript level was unaffected by 
vorinostat. 
 
We next investigated the effect of combining ATXN3 depletion and vorinostat 
treatment (fig 6.13ii). In this experiment, depletion of either ATXN3 or 
vorinostat treatment resulted in an approximately 2.5-fold increase in PTEN 
transcript level, while combination of the two resulted in a 5-fold increase in 
transcript level. This represents an additive effect of the two interventions 
and suggests that ATXN3 depletion alters PTEN transcription independently 
of its previously reported role in modification of histone acetylation status.  
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Fig 6.13. ATXN3 depletion and HDAC inhibition additively 
increase PTEN transcript levels. i. A549 cells were treated with the 
indicated concentrations of vorinostat for 16 hours prior to preparation of total 
RNA.  Levels of the ATXN3, PTEN and PTENP1 transcripts were determined 
relative to that of actin by QPCR. ii. A549 cells were transfected with a single 
siRNA targeting ATXN3 or with no oligonucleotide for a total of 48hrs. For the 
last 16 hours, cells were treated with 2µM vorinostat. Total RNA was 
extracted and the levels of ATXN3, PTEN and PTENP1 transcripts were 
determined relative to that of actin by QPCR. (n=1)  
 
 
The effects on PTENP1 transcripts were less clear, as vorinostat treatment 
did not affect PTENP1, while ATXN3 depletion and combined treatment 
resulted in 1.5-fold and 2.5-fold induction respectively. However, this 
experiment has only been performed once, and confirmation of these 
findings in an independent experiment will be required. 
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6.9 Discussion 
  
In this chapter I have presented further confirmation that USP20, ATXN3, 
ATXN3L and JOSD1 are involved in the regulation of PTEN, and described 
preliminary investigations into the mechanisms by which this occurs.  
 
USP20 has previously been shown to be involved in multiple cellular 
processes, including regulation of type II deiodinase [89, 90], β2 adrenergic 
receptor recycling [91], VHL stability [92], and downregulation of NFκB 
signaling through deubiquitylation of TRAF6 and TAX [93]. Here I provide 
evidence suggesting USP20 is also involved in regulation of PTEN. The 
effects of USP20 depletion on PTEN protein level were however 
oligonucleotide dependent, with two siRNAs directed at the 3’-end of the 
transcript leading to a reduction in PTEN level, and the other two (which map 
internally on the transcript) leading if anything to a slight increase in PTEN 
level.  
 
USP33 is a paralogue of USP20, and is upregulated on depletion of USP20 
[390]. Intriguingly, the effects on PTEN inversely correlated with the extent of 
USP33 upregulation in response to USP20 depletion, though dual 
knockdown of USP33 and USP20 indicated that the upregulation of USP33 is 
not required for the effects of USP20 depletion on PTEN. This may indicate 
instead that upregulation of USP33 acts as a marker for the extent of 
depletion of USP20, which was otherwise difficult to assess. Quantitative 
assessment of knockdown efficiency at the protein level was unfortunately 
hampered by the absence of a specific antibody, and it is possible that subtle 
differences in residual USP20 may explain the differential effects on PTEN. 
This was not however supported by QPCR data, which showed similar 
knockdown efficiency between the four oligonucleotides.  
 
Interestingly, a lower molecular weight protein was also detected with the 
USP20 antibody, and levels of this directly correlated with effects on PTEN. 
This may represent a splice variant or truncated version of either USP20 or 
USP33, however further investigation will be required establish its identity. 
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Following treatment with cycloheximide, PTEN appeared to be stabilized by 
USP20 depletion. This is contrary to the effects of USP20 depletion on 
steady-state PTEN protein levels, and may indicate two distinct effects of 
USP20 on PTEN. Alternatively this may suggest a separate role for USP20 in 
protein degradation in general. Indeed, USP20 depletion also stabilized 
ATXN3, USP33 and USP7 protein levels in the absence of ongoing 
translation. Although USP20 depletion failed to impact on stability of beta-
catenin, a more general role for USP20 in protein degradation cannot be 
ruled out. Interestingly, in a proteomic screen for DUB interactors, Sowa et al 
identified several components of the 19S proteasome as USP20 interactors 
[415]. This suggests that USP20 may be involved in regulation of the 
proteasome and thus protein degradation. However this needs further 
investigation, particularly as the cycloheximide experiment was carried out 
with a single oligonucleotide that reduced PTEN levels and has not been 
performed using one of the other oligonucleotides that, if anything, increased 
the protein level of PTEN.  
 
ATXN3 depletion upregulated PTEN protein level but did not affect its protein 
stability. This is consistent with the QPCR findings, which suggest ATXN3 
influences PTEN transcription.  Interestingly, ATXN3 depletion upregulates 
transcripts of both PTEN and its pseudogene PTENP1. Upregulation of the 
latter could augment effects on PTEN by acting as a decoy for miRNA 
against PTEN [375], thus protecting PTEN mRNA against degradation. 
However, degradation of PTEN transcripts was actually increased following 
ATXN3 depletion, which likely reflects a feedback mechanism to increased 
PTEN levels.  
 
ATXN3 was first identified due to its role in Machado-Joseph disease. 
Subsequently it has been shown to have several functions, including 
regulation of retrotranslocation of substrate in endoplasmic reticulum 
associated protein degradation (ERAD) [407]. Recently, increased longevity 
was described in C. elegans worms deficient in ATXN3 and p97 [408], and 
this appears to be mediated through IGF signalling [408].  Another potential 
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link between ATXN3 and PtdIns3-K signalling is suggested by a proteomic 
study of the EGF induced ubiquitin network, in which ATXN3 was identified 
[409].  
 
ATXN3 has previously been shown to modulate histone acetylation and to 
repress gene expression [378, 461].  In addition, PTEN transcript levels may 
be upregulated by histone deacetylase (HDAC) inhibition [347-349]. 
Upregulation of PTEN transcript levels by the HDAC inhibitor vorinostat was 
also seen in our study. Combining HDAC inhibition and ATXN3 depletion 
resulted in additive increases in PTEN transcript level. This suggests that 
ATXN3’s effects on PTEN are not dependent on histone modulation, and that 
depletion or inactivation of ATXN3 may prove to be useful therapeutic 
intervention leading to upregulation of PTEN expression.  
 
Depletion of the closely related ATXN3L similarly increased the PTEN protein 
level. This appears to be at least partly due to effects on PTEN transcription. 
Post-translational effects on protein degradation have not been examined, 
and it remains feasible that effects on PTEN protein level may be mediated 
through multiple mechanisms. Little is known of the cellular role for ATXN3L. 
However, in a study in A549 cells, ATXN3L depletion led to a decrease in 
HGF-dependent scattering as well as a decrease in wound healing [385], 
indicating a potential role in cell signaling. Crystallographic and enzymatic 
studies have shown ATXN3L is a more efficient enzyme than ATXN3 [457]. 
This is of interest as QPCR indicates very low ATXN3L expression as 
assessed at the mRNA level, which may result in a low cellular abundance of 
ATXN3L protein. 
 
JOSD1, the third DUB which upregulated PTEN is also a member of the MJD 
family of deubiquitylases. While QPCR indicates some transcriptional 
regulation, investigation of effects on protein degradation have not yet been 
undertaken. JOSD1 was also identified in the study of the EGF induced 
ubiquitin network which included ATXN3 [409].  
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Interestingly JOSD3, which is a more distant relative of the Josephins (fig 
6.5) and which was not included in the screen as it is an inactive DUB, is a 
bona fide transcriptional regulator [462]. This provides support to the findings 
of my study, which identified three Josephins that appear to transcriptionally 
regulate PTEN.  
 
While the data presented in this chapter require further elaboration, they 
support a key role for deubiquitylases in the regulation of PTEN. In addition 
to providing insights into the regulation of a core tumour suppressor, these 
data have clear therapeutic implications. As discussed in section 1.5.3, 
PTEN is frequently silenced in cancer through non-genetic mechanisms. Its 
reactivation in these tumours would potentially lead to a reduction in 
activation of the PtdIns3-K signaling pathway, leading in turn to a reduction in 
cancer cell survival. Reactivation of PTEN could potentially be achieved 
through several mechanisms (section 1.5.3). However, research into this field 
is at a relatively early stage, and the identification here of three DUBs whose 
depletion leads to upregulation of PTEN, may provide new targets for 
pharmaceutical development.                       
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Chapter 7 
 
Final Discussion 
 
The deubiquitylases are increasingly recognised as vital regulators of 
multiple cellular processes germane to cancer [9, 111], and are moreover 
attractive drug targets (section 1.4.7). Previous studies have shown that 
ubiquitylation plays a vital role in regulating PtdIns3-K signaling (section 
1.5.4), which is a crucial survival pathway that is frequently dysregulated in 
malignancy (1.5.3). Several DUBs that regulate components of the PtdIns3-K 
pathway have been identified (1.5.4), however this had not been previously 
approached in systematic manner. In this thesis, I have described a series of 
siRNA screens, which were employed to identify previously undescribed 
DUB regulators of the PtdIns3-K pathway. Here I will summarise the main 
findings of this work and discuss their implications, as well as potential future 
work. 
 
7.1 The PtdIns3-K pathway is extensively regulated by DUBs 
 
The project was designed to approach the role of DUBs in this pathway 
systematically, and I therefore utilised two complementary screening 
strategies to maximise the chances of success. This involved assessing the 
effects of DUB depletion on both the protein level of PtdIns3-K components 
(chapter 3), and downstream activity of the pathway (chapter 4). The 
methodology employed a DUB siRNA library that had previously been 
designed by the host laboratory in collaboration with Qiagen. The library is 
comprehensive, consisting of siRNA oligonucleotides against 92 DUBs and 
covering all but one of the currently known, transcribed, DUBs (section 2.1).  
 
The screens performed in this work led to the identification of candidate 
DUBs that regulate the protein level of nine PtdIns3-K components (p110α, 
p110β, p110γ, p85α, p170, PTEN, PDK1, Akt and mTOR), as well as DUBs 
that modulate the translocation of GFP-tagged FOXO3 in response to 
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PtdIns3-K inhibition. The planned assessment of the effects of DUB depletion 
on endogenous FOXO1, FOXO3 and FOXO4 transcription factors was not 
feasible due to low-level expression in A549 cells. However, the second 
screening approach, which utilised cells stably expressing an EGFP tagged 
form of FOXO3, allowed the identification of several DUBs that altered 
protein levels of this overexpressed form of FOXO3. 
 
As discussed in sections 3.2 and 3.10, several measures were undertaken to 
minimise the false positive and negative rates in these screens. The main 
method for eliminating false positives involved deconvolution of the 
oligonucleotide pool, which was employed as a first validation step (section 
3.2). Initial refining of candidates using deconvolution was performed for the 
translocation screen and two of the immunoblotting screens (PTEN and 
PDK1). More than half of all candidates subject to deconvolution were 
validated according to the criteria described (sections 3.2 and 4.3.2). The 
remainder of the immunoblotting screens were not subject to deconvolution 
due to time constraints.  
 
Surprisingly, the screens failed in the main to identify DUBs previously known 
to be involved in regulating the PtdIns3-K pathway (1.5.4). A partial exception 
is USP7, depletion of which increased PTEN and FOXO3-EGFP protein 
levels (sections 2.4 and 4.4.2). Although in previous studies USP7 regulated 
PTEN and FOXO localisation rather than stability [203, 205] it is feasible that 
USP7 depletion may also influence their stability (discussed in sections 3.10 
and 4.5).  
 
Several factors may explain the lack of overlap between the results of my 
screens and published data. Firstly, the findings may be context specific. For 
example USP7 was shown to regulate FOXO4 (and FOXO3) 
monoubiquitylation under conditions of oxidative stress [205] rather than in 
response to PtdIns3-K modulation as was investigated here. Similarly, the 
role of UCHL1 in the regulation of Akt was described in the context of 
mechanical stress induced vascular injury ([353], section 3.7). Secondly, 
DUBs may have differential effects in different cell lines. The work 
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establishing a role for USP7 regulation of PTEN monoubiquitylation for 
example, was predominantly performed in a promyelocytic cell line [203]. 
Additionally, DUBs may have redundant effects, such that depletion of a 
single DUB is compensated for by other DUBs. For example, while 
overexpression of USP4 was recently shown to reduce monoubiquitylation of 
PDK1, its depletion did not impact on PDK1 ubiquitylation, suggesting that 
other DUBs may also be able to deubiquitylate PDK1 [358]. Similarly both 
USP1 and USP46 have been implicated in altering the stability of the Akt 
phosphatase PHLPP1 [356, 357] and it is feasible that depletion of either 
would be insufficient to alter signalling.  
 
However the lack of overlap may also partly represent experimental false 
negatives, which are an inherent risk in siRNA screens (section 3.10). 
Several factors influence the false negative rate; experimental noise and the 
quality of the RNAi reagents being of particular importance [387, 463]. The 
former was clearly a concern in this project, as demonstrated by the degree 
of variation between replicates. However, the selection of a relatively large 
proportion (approximately 10%) of the DUB library from each screen for 
further investigation is likely to have minimised the chances of missing a 
candidate DUB whose depletion significantly altered the parameter under 
investigation. The second point, relating to the quality of RNAi reagents, may 
be partly assessed by knockdown efficiency. While this was greater than 
70% for the four DUBs that were assessed in the DUB lysate library (section 
3.3), USP20 and ATXN3L knockdown efficiency, as assessed by QPCR, was 
respectively only 60% and 50% (section 6.x). In addition, the degree of 
depletion required to produce a loss of function phenotype is likely to vary 
significantly between different proteins.  
 
There was also limited overlap between DUBs identified in the 
immunoblotting and translocation screens. This likely results from similar 
factors to those described above. In addition, the translocation screen 
assayed the effects of DUB depletion on downstream PtdIns3-K signalling, 
and therefore reflects a synthesis of effects for all upstream components. 
This would be of relevance if a DUB has effects on more than one 
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component, which could antagonise each other. Notably the two screens 
were performed in different cell types (A549 and U2OS respectively). A549 
cells in particular contain both homozygous K-Ras mutations and are LKB1 
null [464], which would be expected to increase signalling through the 
PtdIns3-K axis. Interestingly, despite these mutations, A549 cells show 
minimal activation of K-Ras effectors (Akt and extracellular signal regulated 
kinase 1/2 [ERK1/2]) under non-stimulated conditions, and respond to EGF 
stimulation [465]. However, it is likely that PtdIns3-K signalling would be 
subtly different from that in U2OS cells, which do not contain these 
mutations.  
 
Despite the above caveats, this study has significantly expanded the number 
of DUBs implicated in the regulation of the PtdIns3-K pathway. Several of 
these have been subject to initial validation, and examples of particular 
scientific and therapeutic potential are discussed further in sections 7.2-7.4.  
 
7.2 PTEN is transcriptionally regulated by three members of the 
Josephin family of deubiquitylases 
 
The immunoblot screen for regulators of the tumour suppressor PTEN 
identified four DUBs whose depletion upregulated its protein levels (section 
3.4). USP7, which has previously been shown to alter monoubiquitylation of 
PTEN [203], was not followed up further. The remaining three (ATXN3, 
ATXN3L and JOSD1) were all members of the Josephin family of DUBs, 
which contains only two other members (fig 6.3). In view of the similarity 
between these proteins, I used QPCR to show that the siRNA 
oligonucleotides against ATXN3, ATXN3L and JOSD1 were not cross-
reactive. In the case of ATXN3 for which I had an antibody, I was additionally 
able to show that ATXN3L depletion did not affect ATXN3 protein levels.  
 
Depletion of all three DUBs increased the transcript levels of PTEN and its 
pseudogene PTENP1. ATXN3 depletion was additionally shown to have no 
effect on PTEN protein or transcript stability, supporting a role in the 
transcriptional regulation of PTEN. Previous studies have shown that ATXN3 
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interacts with modifiers of histone acetylation [378, 461]. However, in this 
study, depletion of ATXN3 and the use of histone deacetylase inhibitors 
resulted in an additive increase in PTEN protein levels suggesting that the 
role of ATXN3 in PTEN regulation is independent of histone modification.   
 
PTEN is a key negative regulator of PtdIns3-K signaling and one of the most 
commonly mutated tumour suppressors in cancer (section 1.5). Studies in 
human cancers and model systems have shown that PTEN is a 
haploinsufficient tumour suppressor, with loss of a single PTEN allele being 
sufficient to promote cancer development ([319, 466], section 1.5.3). This is 
supported by work in mouse models, which showed that reducing PTEN 
expression by only 25% is sufficient to increase cancer risk [467].  
 
PTEN is often silenced in tumours through non-genetic mechanisms, both at 
transcriptional and post-transcriptional levels ([197], section 1.5.3). In these 
tumours, development of drugs that lead to reactivation of PTEN may prove 
a valuable therapeutic strategy [197]. This could potentially be achieved in 
several different ways, for example inhibiting E3 ligases (XIAP, NEDD4.1, 
WWP2) that promote PTEN degradation, increasing the enzymatic activity of 
PTEN, or increasing PTEN transcription. However all of these strategies are 
at a relatively early stage, and the identification here of three DUBs whose 
depletion leads to an increase in PTEN level is therefore of potential clinical 
significance. 
 
Several lines of investigation will be required to determine if one or other of 
these DUBs are indeed potential drug targets. Identification of the 
mechanism(s) by which these DUBs regulate PTEN level is not only of 
scientific interest, but would also enable a better understanding of the likely 
wider effects of their loss of function. In addition it would be important to 
determine if the mechanism is dependent on the catalytic activity of the 
DUBs as this may potentially be targeted through the use of small molecule 
inhibitors. Assessing the functional effects of their depletion on PtdIns3-K 
downstream signaling and viability/proliferation of different cell types would 
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also be vital in determining if the upregulation of PTEN is likely to translate 
into clinical effect. 
 
7.3 Promoting FOXO3 nuclear translocation and/or stability 
 
Similarly to the screen for regulators of PTEN, the translocation screen 
described in chapter 4 identified DUBs whose depletion could potentially be 
used to increase tumour suppressor function. The FOXO family of 
transcription factors are tumour suppressors that are often functionally 
silenced in cancer [468, 469]. This may occur through several different 
mechanism63s, including deletion [470], repression of expression by 
miRNAs [471, 472], proteasomal degradation [473] and Akt-dependent 
nuclear exclusion [297]. In this study, depletion of USP45 enhanced FOXO3-
EGFP nuclear translocation in response to PtdIns3-K inhibition. Several 
DUBs were also identified whose depletion increased FOXO3-EGFP protein 
levels. These included USPL1, which was validated by deconvolution using 
both imaging and immunoblotting. Depletion of either USP45 or USPL1 may 
therefore potentially lead to increased FOXO3 function, the former through 
increased nuclear localisation and the latter through an increase in 
abundance. However, as discussed in section 4.5, several steps are required 
to validate these findings, which would firstly involve demonstrating that 
these DUBs also regulate endogenous FOXO.  
 
7.4 DUBs, PI-103 and synthetic lethality 
 
Intriguingly, the translocation screen identified three DUBs (USP8, OTUD4 
and DUB4) whose depletion was synthetically lethal with PI-103 treatment 
(chapter 6). Validation was confined to USP8, which showed the most 
convincing effect, and for which reagents were available. The effects of 
USP8 depletion on sensitisation to PI-103 induced cell death were confirmed 
on deconvolution of the siRNA pool, and were also replicated in parental 
U2OS cells and with an Akt inhibitor. In addition, similar results were 
obtained using immunoblotting for cleaved PARP p85 as a readout for cell 
death. Furthermore, two USP8 inhibitors similarly sensitised cells to PI-103 
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induced cell death. However, all these findings were observed when cells 
were cultured in HBSS, and the differential in cell death was less marked in 
DMEM. The reason for this difference has not been deciphered but may 
relate to either the absence of amino acids or the lower pH in the HBSS 
(section 5.8). If the latter is the case, the findings here may remain clinically 
relevant, as tumours are frequently acidotic [449]. In addition, the interaction 
between USP8 depletion and PtdIns3-K inhibition may also provide an 
opportunity to identify novel functions for USP8.  
 
7.5 Concluding remarks 
 
The work described in this thesis led to the identification of several, 
previously undescribed, DUB modulators of the PtdIns3-K pathway. In this 
chapter, I have focused on candidates for which initial validation has been 
performed, and which, subject to further mechanistic and functional studies, 
may increase the options available for targeting this vital pathway in 
malignancy. However, in addition to these, several other screens identified 
interesting lead candidates for future investigation. These include the screen 
for DUB regulators of PDK1 stability, which identified a number of candidates 
that have been partly validated, and screens for DUB regulators of p110 
isoforms.                    
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Appendix A: DUB library siRNA sequences 
The DUB library used in my project was obtained from Qiagen (Crawley, UK) and contains four siRNA oligonucleotides against 
each of 92 DUB targets. These had been arrayed on storage plates and lyophilised prior to being shipped to us. The 
oligonucleotides were arrayed in two different ways. In the first, the four oligonucleotides against each DUB were pooled prior to 
being arrayed; these plates were used for the initial screening phase. In the second, the library was arrayed on four storage plates, 
such that each plate contained an individual oligonucleotide targeting each of 92 DUBs. These plates were used for the 
deconvolution phase. The siRNA sequences for all of the oligonucleotides included in the library are shown in table A1 below. 
 
Entrez 
Gene Id 
NCBI gene 
symbol 
First siRNA Sequence (C) 
  
 Second siRNA sequence (A) 
  
 
Third siRNA sequence (D) 
  
Fourth siRNA sequence (B) 
7345 UCHL1 Hs_UCHL1_1 CACGCAGTGGCCAATAATCAA Hs_UCHL1_2 CTCCGCGAAGATGCAGCTCAA Hs_UCHL1_4 CAGCCACACCCAGGCACTTAA Hs_UCHL1_5 AACGTGGATGGCCACCTCTAT 
7347 UCHL3 Hs_UCHL3_2 CAGGGACAAGATGTTACATCA Hs_UCHL3_3 TAGAAGTTTGCAAGAAGTTTA Hs_UCHL3_4 CTGGCAATTCGTTGATGTATA Hs_UCHL3_5 CCCGAGGTCACCAACCAGTTT 
51377 UCHL5 Hs_UCHL5_2 TCGATTTAATTTAATGGCCAT Hs_UCHL5_5 ATGGATACAGATCAAGGTAAT Hs_UCHL5_6 CAGCAGTTAATACCACTAGTA Hs_UCHL5_7 TCAGATGTGATTCGACAAGTA 
8314 BAP1 Hs_BAP1_1 CAGCAGCTGATAAGAGTAACA Hs_BAP1_2 CTCAATTCCTCTGTCCATCAA Hs_BAP1_3 CCCGCTGGTGCTGGAAGCAAA Hs_BAP1_5 AAGGTGAACCGTCAGACAGTA 
7398 USP1 Hs_USP1_6 ATGTGGCAGAATTACCTACTA Hs_USP1_9 CTGGGACCCATGAATCTGATA Hs_USP1_10 ACAGGCATTAATATTAGTGGA Hs_USP1_11 AACCCTATGTATGAAGGATAT 
9099 USP2 Hs_USP2_5 CAGATTGTGGTTACTGTTCTA Hs_USP2_6 CAGGAGAATGGCACACTTTCA Hs_USP2_4 CCGCGCTTTGTTGGCTATAAT Hs_USP2_7 CCCTAAGAGACCTGGACTTAA 
9960 USP3 Hs_USP3_2 AGCGCTCTAAGAATCAAGAAA Hs_USP3_3 CTGGATCGGATAAACTTTAAT Hs_USP3_4 CAGAAGTAAGCGCTCTAAGAA Hs_USP3_5 CAGGGCGGTTTCAACGGTGTT 
7375 USP4 Hs_USP4_1 ACCGAGGCGTGGAATAAACTA Hs_USP4_3 TAGATGAATTAAGACGGTTAA Hs_USP4_6 CAGGCAGACCTTGCAGTCAAA Hs_USP4_7 CACCTACGAGCAGTTGAGCAA 
8078 USP5 Hs_USP5_1 ACCGACGATCCGGGTCCCTAA Hs_USP5_2 TACGTCTGCCACATCAAGAAA Hs_USP5_3 AGCGAGGAGAAGTTTGAATTA Hs_USP5_5 CCCAGCGAGTTGACTACATCA 
9098 USP6 Hs_USP6_2 CCCAGGATCGTGATAACTGTA Hs_USP6_3 TGCGGAGAGGTTCACAACAAA Hs_USP6_5 GCGGAAGGACATACTTATGAA Hs_USP6_6 AAGCACAGTAGCAAACTCATA 
7874 USP7 Hs_USP7_1 CGGGCCGACACCAGTACATAA Hs_USP7_2 ATGGAGTTGCGTGGGATTCAA Hs_USP7_3 CCCAAATTATTCCGCGGCAAA Hs_USP7_5 AAGCGTCCCTTTAGCATTACA 
9101 USP8 Hs_USP8_1 CAGGGTCAATTCAAATCTACA Hs_USP8_2 AAGGCTCGTATTCATGCAGAA Hs_USP8_3 CAGGTTCAGGCAAGCCATTTA Hs_USP8_5 GAGGATACAGACGATACCGAA 
8239 USP9X Hs_USP9X_1 CCGCCAGATAGCACAACGATA Hs_USP9X_3 CAGCTAGTATTTAGCCCAAAT Hs_USP9X_4 CCGCCTGCAGTGGAAAGTGTA Hs_USP9X_5 GACGATGTATTCTCAATCGTA 
8287 USP9Y Hs_USP9Y_1 ATGACTGGTCCTAATCTGTAA Hs_USP9Y_2 AACCGATTGCAATATAGTTTA Hs_USP9Y_3 CACTAAGGTCTTATAGTCCAA Hs_USP9Y_5 CAGCGTTGGATGCACTTAGTA 
9100 USP10 Hs_USP10_5 AACACAGCTTCTGTTGACTCT Hs_USP10_1 TCGCTTTGGATGGAAGTTCTA Hs_USP10_3 AAGGGAACTGGTGCTACATTA Hs_USP10_4 CAGCTTTGTTCGGCTAATGAA 
8237 USP11 Hs_USP11_6 ACCGATTCTATTGGCCTAGTA Hs_USP11_5 CTGCGTCGGGTACGTGATGAA Hs_USP11_3 AAGGTCGAAGTGTACCCAGTA Hs_USP11_4 CCCATTGAACGCAAGGTCATA 
219333 USP12 Hs_USP12_5 CCGATCATGGTAGTTGATTTA Hs_USP12_1 AAGAAGTTCATCACAAGATTA Hs_USP12_3 ATGGATCAACTTCATCGATAT Hs_USP12_4 TCACAAGATTACGGAAAGAAA 
8975 USP13 Hs_USP13_1 TCGCTTATGAACTAACGAGAA Hs_USP13_2 AGCGACGATTATGAATATGAA Hs_USP13_5 CACTACGAGCAACGAATAATA Hs_USP13_6 CCACCCGGAATTCTCCTCTAA 
9097 USP14 Hs_USP14_1 CAGAGTTGAAATGCCTTTCAA Hs_USP14_2 CCCATCCTTTGCCTTATCTAA Hs_USP14_3 CCGCTCTACTCCGTTACTGTA Hs_USP14_4 TGGCTTCAGCGCAGTATATTA 
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Entrez 
Gene Id 
NCBI gene 
symbol 
First siRNA Sequence (C) 
  
 Second siRNA sequence (A) 
  
 
Third siRNA sequence (D)  
  
Fourth siRNA sequence (B) 
9958 USP15 Hs_USP15_1 ATGAATAATGTTGTAACTCGA Hs_USP15_2 TATGTCGGAATTCTTAATTAA Hs_USP15_3 AAGATGATACCAGGCATATAA Hs_USP15_5 CAGTCGATACATGAGAGACAA 
10600 USP16 Hs_USP16_7 ACCCGTAATGAGAAACTTCGA Hs_USP16_8 CCAGTGCTTAGAGAACTACTA Hs_USP16_9 CAAGGGTACTCTATTCCTTAT Hs_USP16_10 TTGGGTCAAGTGGTTGATTAT 
391627 USP17 Hs_USP17_1 TGGAAATTCCTTCAAGAGCAA Hs_USP17_2 CCCGACGTACTTGTGATTCAT Hs_USP17_3 ATGAAGAACCATCATCCTGAA Hs_USP17_4 CACAGGCAACAAGATTGCCAA 
391622 DUB4 Hs_DUB4_1 GCCCTTGGCTCTGAAGACTAA Hs_DUB4_2 AGCAGGTAGATCATCACTCTA Hs_DUB4_3 TGGGAAATACCTGCTACGTGA Hs_DUB4_4 CGCCGGCCTCCAAGACGTTAA 
377630 DUB3 Hs_DUB3_4 GACGTACTTGTGATTCATCAA Hs_DUB3_5 AAGCCTGAGTTCAACGTCAGA Hs_DUB3_9 CGCCGGCCTCCAAGACGTTAA Hs_DUB3_10 AGCAGGTAGATCATCACTCTA 
11274 USP18 Hs_USP18_1 TAAGCGCTTCCTGGAAGTGAA Hs_USP18_2 AAGATGGAGTGCTAATGGAAA Hs_USP18_6 TTCGCTTTCCATTCAGTGGAA Hs_USP18_7 CTGGATCTACGGAGTCTTCTA 
10869 USP19 Hs_USP19_1 TTCAGTGGTGGTGCACGTGTA Hs_USP19_2 AACGTGTTCTATCCTCTGGTA Hs_USP19_3 CACGAGGACCTGAATCGCATT Hs_USP19_4 CTGGCGTGACAAGATCAATGA 
10868 USP20 Hs_USP20_1 CCGGATGATGAAACAGGGATA Hs_USP20_2 CAGGCTTGTTGAAACGACCAA Hs_USP20_3 ACCGTCGTACGTGCTCAAGAA Hs_USP20_4 TCGAGTGACACGGATGAGAAA 
27005 USP21 Hs_USP21_2 CAACCTAATGTGGAAACGTTA Hs_USP21_3 GCGGCTACACCTTGAAATCAA Hs_USP21_5 CAGTACAAAGATTCCCTCGAA Hs_USP21_6 CCGAGCTGTCTTCCAGAAATA 
23326 USP22 Hs_USP22_8 CTGAGTTTATACAGAAATTTA Hs_USP22_7 AAGGTGAATTTCATAAATGTA Hs_USP22_1 AAGAAGCATATTCACGAGCAT Hs_USP22_2 CAGGACTACATCTATGACAAA 
23358 USP24 Hs_USP24_5 AAGAGCAATCAGGAAGCAGTA Hs_USP24_6 ACCACAGAGTAATGTCTCTAA Hs_USP24_7 CACCGTGTATATTATACGCTT Hs_USP24_8 CTAATGAAACATCAACTGGAA 
29761 USP25 Hs_USP25_5 CAAGAGGAGTTTAATAAAGAA Hs_USP25_6 CTGGCAATGATAGATACATCA Hs_USP25_7 ACCTCACGGTATTACAACAAA Hs_USP25_8 TTCATCGAGATCAGTAATACA 
83844 USP26 Hs_USP26_5 TACGATGATATGCGGGTGTTA Hs_USP26_6 CAGCTTAATAGCAAGGAGGTA Hs_USP26_7 AAGATTATCAATAATCGGAGA Hs_USP26_8 AACCGTTAGCTCACTTAATGA 
389856 USP27X Hs_LOC389856_1 ACGGAGGTATATACTGCTTTA Hs_LOC389856_2 GCCGTTTATGGCCTCAAGTAA Hs_LOC389856_3 CAGAATGAATGGACAATTGCA Hs_LOC389856_4 CAGTCTGATGTCACCTGTCAA 
57646 USP28 Hs_USP28_5 AAGGATTAGGTGGGCACATAA Hs_USP28_6 CTACAAGAGATTAGAAATATA Hs_USP28_7 ATGAAGGTGGCTCAAGCGAAA Hs_USP28_8 CCGTGATTGCTTTATACCGAA 
57663 USP29 Hs_USP29_5 AAGAATAACGAGCAAGTTTAT Hs_USP29_6 CAGCTAGGGACTGATTAGAAA Hs_USP29_7 CTCAAGGTAGAACCTAATAAT Hs_USP29_8 GGAGATGATTTCTGAGATCAA 
84749 USP30 Hs_USP30_2 CACACCAGTATTTATCCTTAA Hs_USP30_5 AACAAATTACCTGCCGCACAA Hs_USP30_6 CTCCGATGACACTGTCCGCAA Hs_USP30_7 CTCACGAATTATTCCATGTCA 
57478 USP31 Hs_USP31_1 CCCGAAATATTTAGGCCTGAA Hs_USP31_2 CCGAGTTCATGAAGACCTCAA Hs_USP31_3 GAGCGTCATCATCAGCCTCAA Hs_USP31_5 CACCGAGCTCTTCGCCGAGTA 
84669 USP32 Hs_USP32_5 TTCACGAATATCTATCTCAAA Hs_USP32_6 TTGAAGTTCGCAACAAAGATA Hs_USP32_7 AGGCTGCGCATTAAAGAGGAA Hs_USP32_8 CAGGATGAACAACACCTGGTA 
23032 USP33 Hs_USP33_2 CTGCAAGTAGTGGACACTATA Hs_USP33_3 AAGAATTCCTTCGATGTTTAA Hs_USP33_4 AAGAAGATCCGCAAACCATAA Hs_USP33_5 TTCGAGTATGGTGTTATGCTT 
9736 USP34 Hs_USP34_2 CTGGATTGAGTCAGATAACAA Hs_USP34_4 AAGCCTAGATCTTGCATTTAA Hs_USP34_5 AGCAGTGATAATAGCGATACA Hs_USP34_6 GTGGATTGAACTGTTGACGAA 
57558 USP35 Hs_USP35_2 CCCTTCTAACTTCTAACCGAA Hs_USP35_5 TTCCTTCGAATCTGTCAGCAA Hs_USP35_6 CAAGGACTTGATGGAAGCCAT Hs_USP35_7 CTGCTCGGAGTATCTGAAGTA 
57602 USP36 Hs_USP36_1 TCCGTATATGTCCCAGAATAA Hs_USP36_2 CCCGAGTGTGATTCCAGATCA Hs_USP36_3 CAAGAGCGTCTCGGACACCTA Hs_USP36_4 CCGCATCGAGATGCCATGCAT 
57695 USP37 Hs_USP37_5 AAGGATTTACTCAAGAAGGTT Hs_USP37_6 ATGGTCCTATCAGAATTCGAA Hs_USP37_7 CTCGGACGATTCCTTCTTTGA Hs_USP37_8 ATCCGGGTAGAGGATCGATTA 
84640 USP38 Hs_USP38_1 CAGCATAGTACTAATGGTTTA Hs_USP38_2 CAGGAAGTAGCTAGTAAAGCA Hs_USP38_3 ATGGGTAATTGCACTCCTGAA Hs_USP38_4 CTGGTCTTATTAACCTAGGAA 
10713 USP39 Hs_USP39_5 ACCAAGTTGCCTCCATATCTA Hs_USP39_6 CCCGTACCTGGACACCATTAA Hs_USP39_7 CAGGCTCTATCTAATGTTCCT Hs_USP39_8 CTGGAACCCTCGAAATTTCAA 
55230 USP40 Hs_USP40_5 AAGGTTCGAATCATCCCTTTA Hs_USP40_6 ATGGTGTTTGATATTCGAATT Hs_USP40_7 AAAGTCGGCCAAATTACGTAA Hs_USP40_8 CTGAAGCTCGAGCTAATCCAA 
373856 USP41 Hs_USP41_5 CAAACTCTGGAACCTGATTAA Hs_USP41_7 CTGCCTTAACTCCTTGATTCA Hs_USP41_8 TCGCCAGGATATTGAAGAGGA Hs_USP41_6 CCGGATGAAGGACTCCTTGAT 
84132 USP42 Hs_USP42_2 TTGGAGGATACCTAAGATCTA Hs_USP42_5 ATCTTGATATTCGGCCATATA Hs_USP42_6 CACTATCCATAGATCCTCTAA Hs_USP42_7 CAGCTTCAAAGAGGTTCACTA 
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Third siRNA sequence (D) 
  
Fourth siRNA sequence (B) 
124739 USP43 Hs_USP43_2 CACCTTTCAGAGAGTCAAATA Hs_USP43_5 ACGGTGGAACCGCTTCGAGAA Hs_USP43_6 CCCGCTGGACTTCCTGTACGA Hs_USP43_7 CTCCGTCGAGTTGGTGGAGTA 
84101 USP44 Hs_USP44_2 TTGCATGTGACAACAAATCAA Hs_USP44_3 ACGGCAGGAATTGGAGTATCA Hs_USP44_5 CTCGCTCAGTCGACCATAATA Hs_USP44_6 TACGACGTACATTAAGTGCCA 
85015 USP45 Hs_USP45_5 CAGGAAATTATCGGAACATAA Hs_USP45_6 CGGGTGAAAGATCCAACTAAA Hs_USP45_9 CACATGGATTATATGGTGTTA Hs_USP45_10 CAGCTAGTACTTACTTCTGAT 
64854 USP46 Hs_USP46_5 TAGGGAAATGTTTGTACTATA Hs_USP46_4 CAGCACGGCATTGTTCCTTAT Hs_USP46_7 CAGGGAACGCTTACCAATGAA Hs_USP46_10 CAGGTTGTCAATTACACGGAT 
55031 USP47 Hs_USP47_4 CAGGATGCTCATAGCTTAATA Hs_USP47_5 AGGATTAAACTGAATGATCGA Hs_USP47_6 TGGCGTCAAGTCAACATATAT Hs_USP47_7 TGGATCGGCATGCAAATACAA 
84196 USP48 Hs_USP48_5 ACCAGATGCGTTGGTCCATAA Hs_USP48_1 ATGGCTGAGATGCGTAAGCAA Hs_USP48_2 CACAGTCTGGTGAATGGTATA Hs_USP48_6 AGGCGATACATTGATCCATCA 
25862 USP49 Hs_MGC20741_4 TCCAGTCAATATCCCACTTAA Hs_USP49_7 CTGGAATTCCCTGAACGCTAT Hs_USP49_8 CCGAGTCATGTGGTCCGGGAA Hs_USP49_9 TACGTGCTCAATGATAACCCA 
373509 USP50 Hs_USP50_1 CAGCTCAATTATAGCATCGTA Hs_USP50_2 CCCGGAGAAGATCATATGAGA Hs_USP50_5 CAGGAAGTGGATTACCACTGA Hs_USP50_6 TGCAGATGACTTCGATATCTA 
158880 USP51 Hs_USP51_2 GAGGACTTACTCTACAGTGAA Hs_USP51_3 CCAGAGACTAGGAAACGTAAA Hs_USP51_4 AGGCCTGAGAGGGCTAATCAA Hs_USP51_5 CTCAAGCGGTTTGAGCATGTA 
9924 PAN2 Hs_USP52_5 AAGGTGCTCAAGGGTCTTTAT Hs_USP52_6 AGCCGATATCTTTCATGTGAA Hs_USP52_7 CATCGTCATCATGAACTTTGA Hs_USP52_8 CAGCCCTTCAGCTGTACCGAA 
54532 USP53 Hs_USP53_5 TTGTACTATGCTGGTAAACTA Hs_USP53_6 CAGATTACGACAAGCAACCTA Hs_USP53_7 ACCGAGGTTGGAAACCTATGA Hs_USP53_8 CTTCGTCCTGTTAAAGATAAA 
159195 USP54 Hs_USP54_2 CAGGGTGCAATCCTCAACTAA Hs_USP54_6 CAGCAGAGCCCTAGTCGATAA Hs_USP54_7 AAGGGATGTTTGCACCTCGAA Hs_USP54_8 AAGGAGTTAGAGGCAGCGAAA 
1540 CYLD Hs_CYLD_2 AAGGGTAGAACCTTTGCTAAA Hs_CYLD_3 AAAGAACGATGTAGAATATTA Hs_CYLD_4 AAGGTTCATCCAGTCATAATA Hs_CYLD_5 CACCAAGATGCCCAATACCAA 
10208 USPL1 Hs_USPL1_1 CAAGACCAATTTGTGGACATA Hs_USPL1_2 CCAGGGACTGATATAGGGATA Hs_USPL1_3 AAGGTATAAACCAGAAGGCCA Hs_USPL1_4 ATGCCTGCGTTAGAACATTAA 
55611 OTUB1 Hs_OTUB1_1 CAGCAGGACCGAATTCAGCAA Hs_OTUB1_3 CACTACGATATCCTCTACAAA Hs_OTUB1_4 CTGCCAGGCGCTAGACATGTA Hs_OTUB1_5 CTCCGACTACCTTGTGGTCTA 
78990 OTUB2 Hs_OTUB2_6 CAGGGAGATCTTCAAGTTCAA Hs_OTUB2_2 CAGCCGATAAACATTGATTAA Hs_OTUB2_7 AAGGTTCACCGCCATCCGCAA Hs_OTUB2_8 TTCCGTTTACCTGCTCTATAA 
56957 OTUD7B Hs_ZA20D1_2 CAGGATGACATCGTTCAAGAA Hs_OTUD7B_1 AACCCATCCCTTGGAACGTAA Hs_OTUD7B_2 ATCCGTTTGTTTAGATGGGAA Hs_OTUD7B_3 ACCGAGTGGCTGATTCCTATA 
161725 OTUD7A Hs_OTUD7A_1 CACGCCGTCGCCCACAGACAA Hs_OTUD7A_2 CCACGTGGCAAGTGAATGCAA Hs_OTUD7A_3 CGGGACCTGGTGTTACGGAAA Hs_OTUD7A_4 CCGCGATTCGGTGTGCAGCAA 
54726 OTUD4 Hs_OTUD4_1 AAAGATAAGAATATTCTTCGA Hs_OTUD4_2 CAGAGAGAAATTTGAAGCGTT Hs_OTUD4_3 CAGGCGGAGAATGGATACAGA Hs_OTUD4_4 CACGTTGGAAGTAGCTGATGA 
57097 PARP11 Hs_PARP11_3 ATGGATCGCAACCGAATTAAA Hs_PARP11_6 TTGATTGGAGAATAAATGGTA Hs_PARP11_7 CTCAACTAATGTGGTCATTGA Hs_PARP11_8 CAGCGGCATCTGTTTAGAACA 
54764 ZRANB1 Hs_ZRANB1_1 CAGATCTGTAATGACCCTAAA Hs_ZRANB1_2 CAAGGGTGAAATCTTCGTATA Hs_ZRANB1_3 CACATATTCTTAGACGACCAA Hs_ZRANB1_4 TAGGATAATTCAATGTCGAAA 
80124 VCPIP1 Hs_VCIP135_3 CCCGATGATTATACTCCTGTA Hs_VCPIP1_1 TACCAGAAGCTTTCCCTATTA Hs_VCPIP1_2 CAGGGACAGACTTTAGTAATA Hs_VCPIP1_3 CAGCTCCGGTAGAAACCATTA 
55432 YOD1 Hs_YOD1_2 ATAAGCTATGGTAACCCTAAA Hs_YOD1_4 GACCGTCAAATTAGAGCTTTA Hs_YOD1_5 CAGCGTAACTTCCCTGATCCA Hs_YOD1_6 AAACTGGTATAGGCTATGTAA 
7128 TNFAIP3 Hs_TNFAIP3_1 CCGAGCTGTTCCACTTGTTAA Hs_TNFAIP3_3 CAGATGTATGGCTAACCGGAA Hs_TNFAIP3_4 CTCGGCTATGACAGCCATCAT Hs_TNFAIP3_5 CAGCCTTTACTCATACTATTA 
51633 OTUD6B Hs_CGI-77_3 AGGGTCATTGATAGCAAGTAA Hs_OTUD6B_2 TTCGGTTACACGGTTGGTAAA Hs_OTUD6B_3 AAGGAGCGAGAAGAACGGATA Hs_OTUD6B_4 CAGACCGCTGAGTATATGCAA 
139562 OTUD6A Hs_HSHIN6_1 CAAGACGACAGTAGCATTGAA Hs_OTUD6A_1 CTACGACGACTTCATGATCTA Hs_OTUD6A_2 AGGCCCAGATCCGGAGCTTAA Hs_OTUD6A_3 AAGAGTGAACAGCAGCGCATA 
55593 OTUD5 Hs_DKFZp761A052_1 CAGGCCGGCTTGGACAATGAA Hs_OTUD5_1 TACCACCTACATTAACAGGAA Hs_OTUD5_2 TGCCGACTACTTCTCCAACTA Hs_OTUD5_3 CCCATTCGTGTTAGCTACCAT 
220213 OTUD1 Hs_OTUD1_1 CTGAATGTGAATATCCATTTA Hs_OTUD1_2 CACGGTGTCTACCATGATTCA Hs_OTUD1_3 AACGGACACTATGATGCTGTA Hs_OTUD1_4 ACGAAGAACTTGCCAAATCTA 
79184 BRCC3 Hs_CXorf53_1 TACGATGTTGATTATAACATT Hs_CXorf53_2 CAGATTGAGATGAATTTGCAA Hs_CXorf53_3 CAGCATTTGCAGGAATTACAA Hs_BRCC3_1 TACGACGTTCTGATAAGAGGA 
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Table A1. DUB siRNA library. The siRNA sequences for all of the oligonucleotides included in the Qiagen DUB si RNA library are 
shown. For three of the DUBs, highlighted in red, siRNAs were re-purchased separately to replenish depleted oligonucleotides in 
the library (USP8, USP20 and ATXN3). DUB screens were performed with pools of oligonucleotides that were made up of all four 
oligonucleotides against each target which were arrayed on a single 96-well plate. Columns 3 to 7 each contain a set of siRNA 
oligonucleotides targeting all the DUBs in the library, and these were also arrayed on separate plates for the purposes of 
deconvolution experiments. However, as discussed below, these were mislabelled, and the designation of each set of siRNA 
oligonucleotides (C, A, D and B) in columns 3-7 is explained below.  
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First siRNA Sequence (C) 
  
 Second siRNA sequence (A) 
  
 
Third siRNA sequence (D) 
  
Fourth siRNA sequence (B) 
10987 COPS5 Hs_COPS5_3 TAGGACATACCCAAAGGGCTA Hs_COPS5_5 AAGAACAATATCCGCAGGGAA Hs_COPS5_6 ATGCAATCGGGTGGTATCATA Hs_COPS5_7 CTGGACTAAGGATCACCATTA 
10980 COPS6 Hs_COPS6_1 CCCAACCTTATAAACATGATA Hs_COPS6_4 CCCGGTGCTCAGCACAGACAA Hs_COPS6_5 CCGCGTCAAGCTCATCTTGGA Hs_COPS6_6 CTCGGACATCCACGTCCATAA 
8667 EIF3H Hs_EIF3S3_1 GCGGAGCCTTCGCCATGTAAA Hs_EIF3S3_5 CCCAAGGATCTCTCTCACTAA Hs_EIF3S3_8 CAGATAGATGGCCTTGTGGTA Hs_EIF3S3_9 CTCGGGAGATTCAGCCGTGAA 
8665 EIF3F Hs_EIF3S5_1 TACGCGTACTACGACACTGAA Hs_EIF3S5_3 CACAATGAGTCAGAAGATGAA Hs_EIF3S5_5 AACGGCCGCATGAGCATCAAA Hs_EIF3S5_6 CGCCTCCTTCTTTCTCGACAA 
5713 PSMD7 Hs_PSMD7_5 AAGAATAGTTGGCTGGTACCA Hs_PSMD7_1 CCGAATCGGCAAGGTTGGAAA Hs_PSMD7_3 TTCCGTATTGGTCATCATTGA Hs_PSMD7_6 CACGTGACCAGTGAAATTGGA 
10213 PSMD14 Hs_PSMD14_1 CAGGCATTAATTCATGGACTA Hs_PSMD14_3 TTGGATACTGTCGTATTTAAA Hs_PSMD14_4 ACAGACATTATTACTCCATTA Hs_PSMD14_5 CTGGGTCACTTAAACAAGCCA 
10594 PRPF8 Hs_PRPF8_2 ACGGGCATGTATCGATACAAA Hs_PRPF8_3 ATGGCTTGTCATCCTGAATAA Hs_PRPF8_4 CAACGTCGTCATCAACTATAA Hs_PRPF8_5 CTCATCGTGGACCACAACATA 
10617 STAMBP Hs_STAMBP_5 AAGGAGATTGCATTTCCCAAA Hs_STAMBP_6 ACAGAGGGTAGCACAACAGAA Hs_STAMBP_7 ATCACGCTCTTTATTGAGAAA Hs_STAMBP_8 CCGCTCTGGAGTTGAGATTAT 
84954 MPND Hs_FLJ14981_5 TCAGGTAATAAAGAAACGGAA Hs_FLJ14981_6 CCGGATGGGCTCAGGTAATAA Hs_FLJ14981_2 ACGGAGTGAGGTCGTGGGTTA Hs_FLJ14981_3 CACCTACCTCGACAAGCTTAA 
57559 STAMBPL1 Hs_AMSH-LP_1 CAGGCTGTTCAGTATATGCAA Hs_AMSH-LP_2 CCCAAATACTATGGCCAGATA Hs_AMSH-LP_3 AACCATCGAGATTACCAGCAA Hs_AMSH-LP_4 ACCGTCAACATCAGACACCTA 
114803 MYSM1 Hs_MYSM1_3 TATAATCGAAATAATCCCTTA Hs_MYSM1_4 AAGACCGGCCATAATCTTCAA Hs_MYSM1_5 TGGGATGATTGTTAGTCCCTA Hs_MYSM1_6 GAGGCGGATGTGGATATCGAA 
4287 ATXN3 Hs_ATXN3_1 TACGATGGGATCATTATTTCA Hs_ATXN3_3 TCGGAAGAGACGAGAAGCCTA Hs_ATXN3_4 TGCGTCGGTTGTAGGACTAAA Hs_ATXN3_5 CAGGGCTATTCAGCTAAGTAT 
92552 ATXN3L Hs_ATXN3L_5 AACAAGTTCGAGAGCAATTGA Hs_ATXN3L_6 CAACACTGGTTTACTATTAGA Hs_ATXN3L_7 CACAGTTCATACCTACACGAA Hs_ATXN3L_8 CTCGGCATTGATCCTATAAAT 
9929 JOSD1 Hs_KIAA0063_2 CAACCTCGACTCCAAACTCAA Hs_KIAA0063_3 CACAATTCAGTAGACACTCTA Hs_KIAA0063_4 TAGCCATCTCTGGAACCTAAA Hs_JOSD1_1 CTGGTGGTACCAGAAGAGGTA 
126119 JOSD2 Hs_SBBI54_1 CTGCCGCTGCTGCCTCAATAA Hs_SBBI54_2 CTGGGAAAGGCCAGCACTTCA Hs_SBBI54_3 ACCGGCAACTATGATGTCAAT Hs_JOSD2_1 CCAGGTGGACGGTGTCTACTA 
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Fig A1. Correlation between re-purchased siRNA 
oligonucleotides and the original DUB library. A 72 hour 
depletion of ATXN3 was performed in A549 cells with either a set of 
oligonucleotides purchased individually from Qiagen (1, 2, 3 and 5), 
or the same oligonucleotides, which had previously been arrayed on 
four individual 96 well plates (A, B, C, and D). Immunoblotting was 
performed for PTEN (X), ATXN3 and actin. The phenotypic effects 
observed were reproducible in at least 3 experiments in each case. 
The arrows indicate the probable identity of the oligonucleotides on 
the plates based on their phenotypic effects, and results from similar 
experiments contrasting the re-purchased oligonucleotides with the 
library oligonucleotides (data not shown). (mck: mock transfected, 
siC: non-targeting siRNA control). 
 
Three siRNA oligonucleotides from the library (USP8, USP102 and 
ATXN3) were used extensively and were therefore repurchased. 
Experiments performed using these oligonucleotides showed the 
same range of phenotypic effects as seen using the original library 
oligonucleotides, however the results indicated that the original 
plates had been correctly arrayed but systematically mislabelled. A 
comparison of depletion of ATXN3 using the library and replacement 
siRNA is given in fig A1 as an example; similar findings were 
obtained with USP20, USP8 and by colleagues using other 
oligonucleotides from the library. Based on these experiments, the 
most likely designation of each plate is given in the table A1 above. 
Confirmation of this will involve mass spectroscopy but is yet to be 
carried out. 
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Appendix C:  USP20 and USP33 sequence alignments 
 
Reference sequences for USP20 and USP33 were obtained from Uniprot (www.uniprot.org/), while alignments were performed 
using Clustal W (www.ebi.ac.uk/Tools/msa/clustalw2/).  
 
The positions of the Bethyl (A301-189A) and Aviva (ARP59314) antigens are depicted in green and red respectively.  
 
sp|Q9Y2K6|UBP20_HUMAN      -------------------------------MGDSRDLCPHLDSIGEVTK 19 
sp|Q8TEY7|UBP33_HUMAN      MTGSNSHITILTLKVLPHFESLGKQEKIPNKMSAFRNHCPHLDSVGEITK 50 
                                                          *.  *: ******:**:** 
 
sp|Q9Y2K6|UBP20_HUMAN      EDLLLKSKGTCQSCGVTGPNLWACLQVACPYVGCGESFADHSTIHAQAKK 69 
sp|Q8TEY7|UBP33_HUMAN      EDLIQKSLGTCQDCKVQGPNLWACLENRCSYVGCGESQVDHSTIHSQETK 100 
                           ***: ** ****.* * ********:  *.******* .******:* .* 
 
sp|Q9Y2K6|UBP20_HUMAN      HNLTVNLTTFRLWCYACEKEVFLEQRL----AAPLLGSSSKFSE---QDS 112 
sp|Q8TEY7|UBP33_HUMAN      HYLTVNLTTLRVWCYACSKEVFLDRKLGTQPSLPHVRQPHQIQENSVQDF 150 
                           * *******:*:*****.*****:::*    : * : .. ::.*   **  
 
sp|Q9Y2K6|UBP20_HUMAN      PPPS-HPLKAVPIAVADEGESES-EDDDLKPRGLTGMKNLGNSCYMNAAL 160 
sp|Q8TEY7|UBP33_HUMAN      KIPSNTTLKTPLVAVFDDLDIEADEEDELRARGLTGLKNIGNTCYMNAAL 200 
                             **  .**:  :** *: : *: *:*:*:.*****:**:**:******* 
 
sp|Q9Y2K6|UBP20_HUMAN      QALSNCPPLTQFFLECGGLVRTDKKPALCKSYQKLVSEVWHKKRPSYVVP 210 
sp|Q8TEY7|UBP33_HUMAN      QALSNCPPLTQFFLDCGGLARTDKKPAICKSYLKLMTELWHKSRPGSVVP 250 
                           **************:****.*******:**** **::*:***.**. *** 
 
 
sp|Q9Y2K6|UBP20_HUMAN      TSLSHGIKLVNPMFRGYAQQDTQEFLRCLMDQLHEELKEPVVATVALTEA 260 
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sp|Q8TEY7|UBP33_HUMAN      TTLFQGIKTVNPTFRGYSQQDAQEFLRCLMDLLHEELKEQVMEVE----- 295 
                           *:* :*** *** ****:***:********* ******* *: .       
 
sp|Q9Y2K6|UBP20_HUMAN      RDSDSSDTDEKREGDRSPSEDEFLSCD--SSSDRGEGDGQGRGGGSSQAE 308 
sp|Q8TEY7|UBP33_HUMAN      EDPQTITTEETMEEDKSQSDVDFQSCESCSNSDRAENENGSRCFSEDNNE 345 
                           .*.::  *:*. * *:* *: :* **:  *.***.*.:. .*  ...: * 
 
sp|Q9Y2K6|UBP20_HUMAN      TELLIPDEAGRAISEKERMKDRKFSWGQQRTNSE-QVDEDADVDTAMAAL 357 
sp|Q8TEY7|UBP33_HUMAN      TTMLIQDDENNSEMSKDWQKE-KMCNKINKVNSEGEFDKDRDSISETVDL 394 
                           * :** *: ..:  .*:  *: *:.   ::.*** :.*:* *  :  . * 
 
sp|Q9Y2K6|UBP20_HUMAN      DDQPAEAQPPSPRSSSPCRTPEPDNDAHLRSSSRPCSPVHHHEGHAKLSS 407 
sp|Q8TEY7|UBP33_HUMAN      NNQETVKVQIHSRAS------EYITDVHSNDLSTPQILPSNEGVNPRLSA 438 
                           ::* :      .*:*      *  .*.* .. * *     :.  :.:**: 
                                              Sequence identity 24% 
 
sp|Q9Y2K6|UBP20_HUMAN      SPPRASPVRMAPSYVLKKAQVLSAGSRRRKEQRYRSVISDIFDGSILSLV 457 
sp|Q8TEY7|UBP33_HUMAN      SPPKSGNLWPGLAPPHKKAQSASP-KRKKQHKKYRSVISDIFDGTIISSV 487 
                           ***::. :  . :   ****  *. .*:::.::***********:*:* * 
 
sp|Q9Y2K6|UBP20_HUMAN      QCLTCDRVSTTVETFQDLSLPIPGKEDLAKLHSAIYQNVPAKPGACGDSY 507 
sp|Q8TEY7|UBP33_HUMAN      QCLTCDRVSVTLETFQDLSLPIPGKEDLAKLHSSSHPTSIVKAGSCGEAY 537 
                           *********.*:*********************: : .  .*.*:**::* 
 
sp|Q9Y2K6|UBP20_HUMAN      AAQGWLAFIVEYIRRFVVSCTPSWFWGPVVTLEDCLAAFFAADELKGDNM 557 
sp|Q8TEY7|UBP33_HUMAN      APQGWIAFFMEYVKRFVVSCVPSWFWGPVVTLQDCLAAFFARDELKGDNM 587 
                           *.***:**::**::******.***********:******** ******** 
 
sp|Q9Y2K6|UBP20_HUMAN      YSCERCKKLRNGVKYCKVLRLPEILCIHLKRFRHEVMYSFKINSHVSFPL 607 
sp|Q8TEY7|UBP33_HUMAN      YSCEKCKKLRNGVKFCKVQNFPEILCIHLKRFRHELMFSTKISTHVSFPL 637 
                           ****:*********:*** .:**************:*:* **.:****** 
  236 
 
sp|Q9Y2K6|UBP20_HUMAN      EGLDLRPFLAKECTSQITTYDLLSVICHHGTAGSGHYIAYCQNVINGQWY 657 
sp|Q8TEY7|UBP33_HUMAN      EGLDLQPFLAKDSPAQIVTYDLLSVICHHGTASSGHYIAYCRNNLNNLWY 687 
                           *****:*****:..:**.**************.********:* :*. ** 
 
sp|Q9Y2K6|UBP20_HUMAN      EFDDQYVTEVHETVVQNAEGYVLFYRKSSEEAMRERQQVVSLAAMREPSL 707 
sp|Q8TEY7|UBP33_HUMAN      EFDDQSVTEVSESTVQNAEAYVLFYRKSSEEAQKERRRISNLLNIMEPSL 737 
                           ***** **** *:.*****.************ :**::: .*  : **** 
 
sp|Q9Y2K6|UBP20_HUMAN      LRFYVSREWLNKFNTFAEPGPITNQTFLCSHGGIPPHKYHYIDDLVVILP 757 
sp|Q8TEY7|UBP33_HUMAN      LQFYISRQWLNKFKTFAEPGPISNNDFLCIHGGVPPRKAGYIEDLVLMLP 787 
                           *:**:**:*****:********:*: *** ***:**:*  **:***::** 
 
sp|Q9Y2K6|UBP20_HUMAN      QNVWEHLYNRFGGGPAVNHLYVCSICQVEIEALAKRRRIEIDTFIKLNKA 807 
sp|Q8TEY7|UBP33_HUMAN      QNIWDNLYSRYGGGPAVNHLYICHTCQIEAEKIEKRRKTELEIFIRLNRA 837 
                           **:*::**.*:**********:*  **:* * : ***: *:: **:**:* 
 
sp|Q9Y2K6|UBP20_HUMAN      FQAEESPGVIYCISMQWFREWEAFVKGKDNEPPGPIDNSRIAQVKGSGHV 857 
sp|Q8TEY7|UBP33_HUMAN      FQKEDSPATFYCISMQWFREWESFVKGKDGDPPGPIDNTKIAVTK-CGNV 886 
                           ** *:**..:************:******.:*******::** .* .*:* 
 
sp|Q9Y2K6|UBP20_HUMAN      QLKQGADYGQISEETWTYLNSLYGGGPEIAIRQSVAQPLGPENLHGEQKI 907 
sp|Q8TEY7|UBP33_HUMAN      MLRQGADSGQISEETWNFLQSIYGGGPEVILRPPVVH-VDPDILQAEEKI 935 
                            *:**** ********.:*:*:******: :* .*.: :.*: *:.*:** 
 
                                            Sequence identity 57% 
 
sp|Q9Y2K6|UBP20_HUMAN      EAETRAV 914 
sp|Q8TEY7|UBP33_HUMAN      EVETRSL 942 
                           *.***:: 
